Podcasts about Jeanny

Play Episode Listen Later May 25, 2024 26:04

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss promising combination therapies and other compelling advances in genitourinary cancers in advance of the 2024 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I'm the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to be joined by Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical program director of genitourinary cancers at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing some key abstracts in GU oncology that will be featured at the 2024 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode. Jeanny, it's great to have you on the podcast. Dr. Jeanny Aragon-Ching: Thank you so much, Dr. Agarwal. It's a pleasure to be here. Dr. Neeraj Agarwal: So, Jeanny, let's start with some bladder cancer abstracts. Could you tell us about the Abstract 4509 titled, “Characterization of Complete Responders to Nivolumab plus Gemcitabine Cisplatin versus Gemcitabine Cisplatin Alone in Patients with Lymph Node Only Metastatic Urothelial Carcinoma from the CheckMate 901 Trial.” Dr. Jeanny Aragon-Ching: Of course, Neeraj, I would be delighted to. First, I would like to remind our listeners that the CheckMate 901 trial was a randomized, open-label, phase 3 study, in which this particular sub-study looked at cisplatin-eligible patients with previously untreated, unresectable, or metastatic urothelial carcinoma who were assigned to receive the combination of gemcitabine and cisplatin, followed by up to 2 years of nivolumab or placebo. Based on the data presented at ESMO 2023 and subsequently published in the New England Journal of Medicine, which shows significantly improved progression-free survival and overall survival in patients receiving the combination of gemcitabine, cisplatin, and nivolumab, this regimen was approved in March 2024 as a first-line therapy for patients with unresectable or metastatic urothelial carcinoma. In the abstract that will be featured at ASCO this year, Dr. Matt Galsky and colleagues present a post-hoc analysis that aims to characterize a subset of patients with complete response as well as those with lymph node-only metastatic disease. In patients receiving the experimental treatment, 21.7% achieved a complete response, while 11.8% of the patients in the control arm achieved a complete response. Among these complete responders, around 52% had lymph- node-only disease in both arms. Furthermore, when characterizing the subgroup of patients with lymph-node-only disease, those receiving the combination of gemcitabine-cisplatin plus nivolumab had a 62% reduction in the risk of progression or death and a 42% reduction in the risk of death compared to those treated with gemcitabine-cisplatin alone. The median overall survival in the experimental arm in this subgroup was around 46.3 months, while it was only 24.9 months in the control arm. The ORR in patients with lymph-node-only disease receiving gem-cis plus nivo was about 81.5% compared to 64.3% in those treated with gem-cis alone. Dr. Neeraj Agarwal: Thank you, Jeanny, for the excellent summary of this abstract. We can say that nivolumab plus gemcitabine-cisplatin induced durable disease control and clinically meaningful improvements in OS and PFS compared to gem-cis alone in patients with lymph- node-only metastasis, and deserves to be considered as one of the options for these patients. In a similar first-line metastatic urothelial carcinoma setting, Abstract 4502, also reported data on a recently approved combination of enfortumab vedotin and pembrolizumab. Can you tell us more about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Sure, Neeraj. So, as quick reminder to our audience, this regimen was tested in the EV-302 phase 3 trial, where patients with previously untreated, locally advanced or metastatic urothelial carcinoma were randomized to receive enfortumab vedotin, plus pembrolizumab or gemcitabine plus either cisplatin or carboplatin. These data were also first presented at ESMO 2023 and subsequently published in the New England Journal of Medicine. They showed that this immune based combination significantly improved both progression free survival and overall survival, which were the primary endpoints compared to chemotherapy. In this abstract, Dr. Shilpa Gupta from the Cleveland Clinic and colleagues present the results of patient reported outcomes based on quality-of-life questionnaires in this trial. Time to pain progression and time to confirm deterioration were numerically longer in patients treated with EV plus pembro, and patients with moderate to severe pain at baseline receiving this combination had a meaningful improvement in the Brief Pain Inventory Short-Form worst pain from week 3 through 26. Dr. Neeraj Agarwal: Thank you, Jeanny. This means that patients treated with EV plus pembro did not only have improved survival compared with platinum-based chemotherapy, but also improvement in their quality-of-life and functioning, further supporting the value of this combination for patients with locally advanced or metastatic urothelial carcinoma. This is terrific news for all of our patients. Before we wrap up the bladder cancer section, would you like to tell our listeners about Abstract 4565, which provides the data on the efficacy of trastuzumab deruxtecan in patients with bladder cancer? Dr. Jeanny Aragon-Ching: Yes, Neeraj; this is timely given the recent FDA approval, which we will talk about. The abstract is titled, “Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2 Expressing Solid Tumors: Results from the Bladder Cohort of the DESTINY-PanTumor02 Study.” And as a quick reminder, the DESTINY-PanTumor02 was a phase 2 open-label study where trastuzumab deruxtecan, an antibody-drug conjugate targeting HER2 expression on cancer cells, was evaluated in patients with HER2-expressing locally advanced or metastatic disease who previously received systemic treatment or who had no other treatment options. The expression of HER2 was evaluated on immunohistochemistry by local or central testing. The primary endpoint was confirmed objective response rate by investigator assessment. Secondary endpoints included duration of response, progression free survival, disease control rate, and safety. The primary analysis, which was published in the Journal of Clinical Oncology, showed an ORR of 37.1% and responses across all cohorts and the median duration of response was 11.3 months. Based on these results, fam-trastuzumab deruxtecan-nxki was just granted accelerated FDA approval for unresectable or metastatic HER2-positive solid tumors in April 2024. So, back to this abstract; Dr. Wysocki and colleagues report the results of the bladder cancer cohort. This study included 41 patients with urothelial cancer and at a median follow up of around 12.6 months, the objective response rate among these patients was 39%, the median PFS was 7 months, and the duration of response median was 8.7 months. The disease control rate at 12 weeks was around 71%. Regarding the safety profile, 41.5% of patients experienced grade ≥3 drug related adverse events and interstitial lung disease or pneumonitis did occur in about 4 patients. Although there was no statistical comparison between different groups, the ORR was numerically highest among the HER2 3+ group with 56.3%. Dr. Neeraj Agarwal: Thank you, Jeanny. So, these data support consideration of trastuzumab deruxtecan as a salvage therapy option for pre-treated patients with HER2 expressing urothelial cancers and show that we are extending our treatment options to include therapies with novel mechanisms of action. This is definitely exciting news for patients with bladder cancer. Dr. Jeanny Aragon-Ching: Yes, absolutely, Neeraj. Now, let's switch gears a bit to prostate cancer. Could you tell us about Abstract 5005 which is titled, “EMBARK Post Hoc Analysis of Impact of Treatment Suspension on Health Quality-of-Life?” Dr. Neeraj Agarwal: Of course, I'd be happy to. So, enzalutamide was recently granted FDA approval for the treatment of patients with non-metastatic castration-sensitive prostate cancer with biochemical recurrence at high-risk of metastasis, based on the results of the EMBARK trial, which was a phase 3 study where patients with high-risk biochemical recurrence were randomized to receive either enzalutamide with leuprolide, enzalutamide monotherapy, or placebo plus leuprolide. The primary endpoint was metastasis-free survival with secondary endpoints including overall survival and safety. Results showed that patients receiving enzalutamide alone or enzalutamide plus leuprolide had significantly improved metastasis-free survival compared to those treated with leuprolide alone while preserving health-related quality-of-life. One important aspect in the design of the trial was that patients who achieved undetectable PSA at week 37 underwent treatment suspension. The treatment was resumed if PSA rose to more than 2 ng/ml for patients who underwent radical proctectomy or when PSA rose to more than 5 ng/ml for those who did not undergo surgery. In this abstract, Dr. Stephen Freedland and colleagues present a post-hoc analysis of health-related quality-of-life outcomes after treatment suspension between weeks 37 and 205. They found that treatment was suspended in 90.9% of patients receiving enzalutamide plus leuprolide, 85.9% of those receiving enzalutamide monotherapy, and 67.8% of those receiving leuprolide monotherapy. Among those patients who stayed on treatment suspension, a trend toward numerical improvement in health-related quality-of-life after week 37 was seen in all 3 arms and this reached clinically meaningful threshold at week 205 in pain questionnaires, physical well-being, urinary and bowel symptoms. For hormonal treatment side effects, all arms reached clinically meaningful improvement at the subsequent assessments of week 49 to week 97. However, patients slowly deteriorated, with clinically meaningful deterioration at week 205 relative to week 37 in patients receiving the combination of enzalutamide and leuprolide and those treated with leuprolide. Concerning sexual activity, a clinically meaningful improvement was reported only in patients receiving enzalutamide plus leuprolide, possibly because sexual function was better preserved prior to suspension in the enzalutamide monotherapy arm and thus there was less opportunity for “improvement” while on suspension. Dr. Jeanny Aragon-Ching: Thank you, Neeraj, for this great summary. This analysis confirms that treatment suspension in good responders might lead to a clinically meaningful improvements in health-related quality-of-life. Now, moving on to patients with metastatic castration-resistant prostate cancer, what can you tell us, about Abstract 5008 titled, “Baseline ctDNA analyses and associations with outcomes in taxane-naive patients with mCRPC treated with 177Lu-PSMA-617 versus change of ARPI in PSMAfore”? Dr. Neeraj Agarwal: Sure, Jeanny. The PSMAfore trial was a phase 3 study that compared the efficacy of 177Lu-PSMA-617 versus an ARPI switch in patients with mCRPC and prior progression on a first ARPI, and not previously exposed to docetaxel chemotherapy. The primary endpoint was rPFS and OS was an important secondary endpoint. The primary analysis presented at ESMO 2023 showed a significantly prolonged rPFS in patients receiving lutetium. In the abstract that will be featured at the 2024 ASCO Annual Meeting, Dr. Johann De Bono and colleagues present an exploratory analysis regarding the associations between baseline circulating tumor DNA and outcomes. ctDNA fraction was evaluated in all samples as well as alterations in key prostate cancer drivers prevalent in more than 10% of participants. The investigators sought to interrogate the association of ctDNA fraction or alterations with rPFS, PSA response, and RECIST response at data cutoff. They showed that median rPFS was significantly shorter in patients with a ctDNA fraction >1% compared to those with a fraction < 1% regardless of the treatment arm. Furthermore, ctDNA fraction >1% was also associated with worst RECIST response and PSA50 response. Regarding prostate cancer drivers, median rPFS was significantly shorter in patients with alterations in the AR, TP53 or PTEN in both treatment arms. There was no significant association between ctDNA alterations and PSA or objective responses. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So, these results show that the presence of a ctDNA fraction >1% or alterations in AR, P53 and PTEN were all associated with worse outcomes regardless of treatment with lutetium or change in the ARPI. These data are definitely important for counseling and prognostication of patients in the clinic and may guide the design of future clinical trials. Let's move on to kidney cancer. Neeraj, do you have any updates for us? Dr. Neeraj Agarwal: Sure. In Abstract 4512 titled, “A Multi-institution Analysis of Outcomes with First-Line Therapy for 99 Patients with Metastatic Chromophobe Renal Cell Carcinoma,” Dr. Sahil Doshi and colleagues present a retrospective, multi-institutional study comparing survival outcomes, including time-to-treatment failure and overall survival, between different first-line treatment options in patients with metastatic chromophobe renal cell carcinoma, where limited clinical trial data exists to guide systemic therapy. They categorized patients into 4 treatment groups: and immune checkpoint inhibitors + targeted therapy doublets (such as ICI VEGF TKI); pure immune checkpoint inhibitor monotherapy and doublets (such as ipilimumab plus nivolumab); targeted therapy doublets (such as lenvatinib plus everolimus), and targeted monotherapy (such as sunitinib). They identified 99 patients, of whom 54 patients received targeted monotherapy, 17 received ICI VEGF-TKI, 14 received targeted doublet, and 14 patients received only ICI therapies. So the patients treated with any doublet containing a targeted agent had a 52% decrease in the risk of treatment failure and a 44% decrease in the risk of death compared to those treated with targeted monotherapy. The median time to treatment failure was 15 months with IO-targeted doublet, and the median overall survival was 56 months. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So, these results show that targeted doublet regimens resulted in a longer time to treatment failure and overall survival compared to any monotherapy in patients with chromophobe metastatic RCC and definitely provides valuable insights on treatment selection, albeit I would say there's still a small number of patients that were included in this retrospective analysis. Dr. Neeraj Agarwal: I completely agree this is a relatively small number of patients, but I decided to highlight the abstract given how rare the cancer is, and it is highly unlikely that we'll see large randomized clinical trials in patients with metastatic chromophobe renal cell carcinoma. So, before we wrap up the podcast, what would you like to tell us about Abstract 5009 which is titled, “A Phase II Trial of Pembrolizumab Platinum Based Chemotherapy as First Line Systemic Therapy in Advanced Penile Cancer: HERCULES (LACOG 0218) Trial.” Dr. Jeanny Aragon-Ching: I'm glad you brought this up, Neeraj. As our listeners may know, advanced penile squamous cell carcinoma has a poor prognosis with limited treatment options. From this perspective, the results of the LACOG 0218 trial are very important. As you mentioned, this was a phase 2 single-arm study evaluating the addition of pembrolizumab to platinum-based chemotherapy as first-line treatment in patients with metastatic or locally advanced penile squamous cell carcinoma not amenable to curative therapy. Patients enrolled received chemotherapy, namely 5-Fluorouracil with cisplatin or carboplatin and pembrolizumab 200 mg IV every 3 weeks for 6 cycles, followed by pembrolizumab 200 mg IV every 3 weeks up to 34 cycles. The primary endpoint was confirmed overall response rate by investigator assessment. In the 33 patients eligible for the efficacy analysis, the confirmed ORR by investigator assessment was 39.4% and included one complete response and 12 partial responses. The confirmed ORR was 75% in patients with high TMB and 55.6% in patients positive for HPV16, making TMB and HPV16 potential predictive biomarkers for efficacy in this study. Concerning the toxicity profile, any grade treatment-related adverse events were reported in around 92% of patients, and grade 3 or more treatment-related adverse events occurred in 51% of patients. 10.8% of patients discontinued treatment due to adverse events. Dr. Neeraj Agarwal: Thank you, Jeanny. I would like to add that HERCULES is the first trial to demonstrate the efficacy of an immune checkpoint inhibitor in advanced penile squamous cell carcinoma with a manageable safety profile. Thus, the combination of ICI with platinum-based chemotherapy is a promising treatment for advanced penile squamous cell carcinoma and warrants further investigation. Dr. Jeanny Aragon-Ching: I agree, Neeraj. Any final remarks before we conclude today's podcast? Dr. Neeraj Agarwal: Jeanny, I really want to thank you for your participation and valuable insights. Your contributions are always appreciated, and I sincerely thank you for taking the time to join us today. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. It was a pleasure. Dr. Neeraj Agarwal: As we bring this podcast to an end, I would like to acknowledge the significant advances happening in the treatment of patients with genitourinary cancers. During our upcoming 2024 ASCO Annual Meeting, there will be an array of different studies featuring practice-changing data presented by researchers and physicians from around the globe. I urge our listeners to not only participate in this event to celebrate these achievements, but to also play a role in sharing these cutting-edge data with healthcare professionals worldwide. Through our collective efforts, we can surely optimize the benefits of patients on a global scale. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Thank you very much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Neeraj Agarwal @neerajaiims Dr. Jeanny Aragon-Ching Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis, Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics.

university time speaker dna medicine cancer safety impact trial journal patients os fda iv results pfizer analysis psa ev outcomes embark gu io secondary astrazeneca hercules bayer abstract ici oncology merck efficacy cleveland clinic prostate cancer janssen checkmate new england journal novartis agarwal sanofi precision medicine asco genentech amgen orr bristol myers squibb takeda characterization rcc her2 pfs clinical oncology nektar abstracts tmb wysocki esmo eisai asco annual meeting pten nivolumab ctdna tp53 emd serono foundation medicine jeanny p53 aveo crispr therapeutics health quality arpi medimmune seattle genetics fluorouracil dendreon neeraj agarwal pharmacyclics recist janssen oncology transcript dr hpv16 mei pharma

S1:E14:The Enemy that Steals Our Confidence and Happiness

confidence happiness meditation yoga shame enemy affirmations preview cycles expecting self sabotage freed teaser steals asians jeanny super early bird

Play Episode Listen Later May 14, 2024 39:57 Transcription Available

In shame-based cultures, when a parent doesn't like something the child is doing, often times they discipline the kid's behavior but the child herself feels like she is a bad girl. She takes on guilt, embarrasment and feels like she has "failed" her family. Unless this is undone, she will carry all the anxiety of just being "herself" into adulthood.This episode connects the dots on why so many Asians have a hard time just being "themselves" and how to stop the cycle of being afraid of others' opinions of us.*Freed to Lead 3 Day VIRTUAL EVENT: June 7, June 8, June 9*Super Early Bird tix through May 19th!*[00:00] Teaser[00:47] Episode 14 Intro[02:00] Expecting the Worst[02:48] What happened to your podcast?[06:23] How Shame Started[08:47] Before Shame Stole Our Joy[11:09] When We Don't Meet Our Own Expectations[13:11] Self-Sabotage[16:19] Yoga and Meditation won't fix it[18:42] BREAK[19:19] Cycles of Shame[22:11] What Does Shame Look Like?[25:48] Jeanny's Journey to Weed Out Old Shame[33:05] Shame Assessement[34:42] Affirmation[39:17] Preview of Season 2Theme Song: Imagine by ZooMid-roll Song: Making Progress by Dan PhillipsonAffirmation Song: Sky High by AKPost-roll Song: Clarity by Zoo*Freed to Lead 3 Day VIRTUAL EVENT: June 7, June 8, June 9

Bonus Episode! Vicki and Shannon in Boca Raton with Special Guest Jeanny!

Bravo Tea With A Stay At Home Mom

Play Episode Listen Later Apr 28, 2024 54:49

My first travel podcast! I join my BFF Jeanny in sunny Boca Raton,Florida to see Vicki and Shannon live! We discuss the show and all things Bravo, and some tea! Instagram: https://www.instagram.com/bravoteawithastayathomemom?igsh=MXgyNjI4NnN6dWpldg%3D%3D&utm_source=qr Spotify: https://open.spotify.com/show/1PsRVdSFI9WAq2qunoO2e5?si=VLSwm1glRR- U7q8SMW_URQ Apple: https://podcasts.apple.com/us/podcast/bravo-tea-with-a-stay-at-home-mom/id1715599754 Tik Tok: https://www.tiktok.com/@bravoteastayathomemom?_t=8jvBP0ibBhm&_r=1 Youtube: www.youtube.com/@Bravoteawithastayathomemom iHeart: https://www.iheart.com/podcast/269-bravo-tea-with-a-stay-at-h-166837955/

bravo boca raton jeanny

Madonna – "Like A Prayer"

SWR1 Meilensteine - Alben die Geschichte machten

Play Episode Listen Later Mar 18, 2024 34:29

Madonna ist die Queen of Pop. Und das spätestens seit ihrem 1989 erschienenen vierten Album und gleichnamigen Megahit "Like A Prayer", mit dem sie auch schon den Sound der 90er-Jahre einläutet hat. Es ist eine der großen Qualitäten von Madonna: ihre Wandlungsfähigkeit! Mit jedem Album schafft es die Queen of Pop, sich neu zu erfinden. Das war auch schon in den 80er-Jahren so, sagt SWR Musikredakteur Niels Berkefeld im Meilensteine Podcast zum Album "Like A Prayer": "Die Madonna von '83 klingt anders, als die von '85, die von '87 klingt anders als die von '89 [...] und diese ständige Entwicklung hat sie ja auch sehr erfolgreich durchgezogen." Sich andauernd zu verändern, bringt aber auch Nachteile mit sich. "Da vergraulst du auch Stammkunden", erklärt Niels Berkefeld weiter. Bei "Like A Prayer" hat Madonna wieder mit dem Sound experimentiert und es gibt auch mehr Soul, Funk und Hip-Hop-Einflüsse zu hören, als bei ihren ersten drei Alben. Auf ihrem vierten Album "Like A Prayer" ist Madonna deutlich erwachsener geworden, sagt SWR1 Musikredakteurin Michelle Habermehl im Podcast. Madonna war auch in einer ganz anderen Lebenssituation als noch beim Album "True Blue". Sie war frisch geschieden und hat auf diesem Album versucht, vieles zu verarbeiten. "Bei "Like A Prayer" stellt sie sich quasi ihren Dämonen aus der Vergangenheit.", erklärt SWR1 Musikredakteurin Michelle Habermehl im Podcast. Dass Madonna mit dem Album erwachsener geworden ist, hört man unter anderem auch daran, dass viel mehr akustische Instrumente auf "Like A Prayer" verwendet worden sind als bei ihren vorherigen Platten, findet SWR1 Musikredakteur Dave Jörg. "Echte Gitarren und ein echtes Schlagzeug waren bis dahin für Madonna eher untypisch", ergänzt er. Das Musikvideo zum Song "Like A Prayer" hat damals einen handfesten Skandal ausgelöst. Der Musiksender MTV hat den Song sogar aus seinem Programm genommen. "Da spielt ein Künstler mit vermeintlichen Tabus, provoziert so ein bisschen einen Skandal, aber am Ende ist es ja auch künstlerische Freiheit", sagt SWR1 Musikredakteur Niels Berkefeld zum Skandal um das Video zu "Like A Prayer". Und so ein bewusst provozierter Skandal bedeutet für Künstlerinnen wie Madonna oder auch Künstler wie Falco und seinen Song "Jeanny" natürlich immer jede Menge Gesprächswert und damit sowas wie Gratiswerbung, wenn der Song dauerhaft im Gespräch ist. Aus heutiger Sicht kann man sich den Skandal Ende der 80er kaum noch vorstellen, findet Niels Berkefeld: "Wenn man sich das Video heute anschaut, denkt man sich: Was ist eigentlich passiert? Es ist ein Video gegen Rassismus, es ist ein tolles Video!" Neben dem Überhit "Like A Prayer" und dem erwähnten skandalträchtigen Video zum Song hat das Album aber noch einiges mehr zu bieten. Zum Beispiel den feministisch-unterstützenden Song "Express Yourself". Insgesamt hat Madonna mit "Like A Prayer" damals einen großen Schritt nach vorne in Richtung Popikone gemacht. Auch, in dem sie ihre eigene Vergangenheit verarbeitet hat und dadurch die Kraft hatte, sich und ihre Position zu nutzen, um sich für andere starkzumachen. Dieses Album ist auf jeden Fall ein wichtiger Baustein in der Festungsmauer, auf den sich Madonnas inoffizieller Titel "Queen of Pop" stützt. __________ Über diese Songs vom Album "Like A Prayer" wird im Podcast gesprochen (03:13) – "Like A Prayer" (15:07) – "Express Yourself" (19:45) – "Oh Father" (22:45) – "Till Death Do Us Part" (28:44) – "Love Song" (31:01) – "Dear Jessie" __________ Über diese Songs wird außerdem im Podcast gesprochen (27:10) – "Don't Cry For Me Argentina" von Madonna (aus Evita) (30:29) – "Hung Up" von Madonna __________ Shownotes Das Musikvideo zu "Like A Prayer": https://www.youtube.com/watch?v=79fzeNUqQbQ Interview mit Madonna-Produzent Patrick Leonard in Billboard: https://web.archive.org/web/20211119200818/https://www.billboard.com/music/pop/madonna-producer-patrick-leonard-talks-like-a-prayer-at-25-5944767/ Buchtipp: "Madonna und wir": https://www.suhrkamp.de/buch/madonna-und-wir-t-9783518459928 ZDF-Dokumentation "The True Story of Madonna": https://www.ardmediathek.de/video/zdfinfo/the-true-story-of-madonna/zdf/Y3JpZDovL3pkZi5kZS9QUk9EMS9TQ01TXzU5ZTg1YzM5LWEzYzktNGU0Yy04NzkzLTE3M2FmNTA1YTlkMQ SWR1 Meilenstein zu Madonnas Album "Ray Of Light": https://www.swr.de/swr1/rp/meilensteine/swr1-meilensteine-ray-of-light-madonna-100.html __________ Ihr wollt mehr Podcasts wie diesen? Abonniert die SWR1 Meilensteine! Fragen, Kritik, Anregungen? Meldet euch gerne per WhatsApp-Sprachnachricht an die (06131) 92 93 94 95 oder schreibt uns an meilensteine@swr.de

Romorantin-Lanthenay : les chantiers et les temps forts de 2024 avec Jeanny Lorgeoux

Ça se passe en Val de Loire

Play Episode Listen Later Feb 5, 2024 1:45

Le maire de Romorantin-Lanthenay et président de la Communauté de communes du Romorantinais et du Monestois passe en revue les dossiers qui vont marquer l'année dans la capitale de la Sologne.

temps forts communaut chantiers jeanny

What's New in Prostate Cancer, RCC, and mUC at GU24

Play Episode Listen Later Jan 22, 2024 25:10

Drs. Neeraj Agarwal and Jeanny Aragon-Ching discuss several key abstracts to be presented at the 2024 ASCO GU Cancers Symposium, including sequencing versus upfront combination therapies for mCRPC in the BRCAAway study, updates on the CheckMate-9ER and CheckMate-214 trials in ccRCC, and a compelling real-world retrospective study in mUC of patients with FGFR2 and FGFR3 mutations. TRANSCRIPT Dr. Neeraj Agarwal: Hello, everyone, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the podcast today. I am the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah's Huntsman Cancer Institute, and editor-in-chief of ASCO Daily News. I am delighted to welcome Dr. Jeanny Aragon-Ching, a genitourinary oncologist and the clinical program director of Genitourinary Cancers at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing key posters and oral abstracts that will be featured at the 2024 ASCO Genitourinary Cancer Symposium, which is celebrating 20 years of evolution in GU oncology this year. You will find our full disclosures in the transcript of this podcast, and disclosures of all guests on the podcast at asco.org/DNpod. Jeanny, it's great to have you on the podcast today to highlight some key abstracts for our listeners ahead of the GU meeting. Dr. Jeanny Aragon-Ching: Thank you so much, Neeraj. It's an honor to be here. Dr. Neeraj Agarwal: Jeanny, as you know, this year we are celebrating the 20th anniversary of the ASCO GU Cancers Symposium, and judging from this year's abstracts, it's clear that this meeting continues to play a major role in advancing GU cancer research. Dr. Jeanny Aragon-Ching: Indeed, Neeraj. This year's abstracts reflect the important strides we have made in GU cancers. So, let's start with the prostate cancer abstracts. What is your takeaway from Abstract 19 on BRCAAway, which will be presented by Dr. Maha Hussein, and of which you are a co-author? As our listeners know, several PARP inhibitor combinations with second-generation androgen receptor pathway inhibitors, or ARPIs, have recently been approved as first-line treatment for patients with metastatic castrate-resistant prostate cancer, or metastatic CRPC, and the question of sequencing PARP inhibitors and ARPIs instead of combining them has emerged. From that perspective, the results of the BRCAAway trial are very important. Can you tell us a little bit more about this abstract, Neeraj? Dr. Neeraj Agarwal: I totally agree with you, Jeanny. The BRCAAway study attempts to answer the crucial questions regarding sequencing versus upfront combination of therapies in the mCRPC setting. It is a phase 2 trial of abiraterone versus olaparib versus abiraterone with olaparib in patients with mCRPC harboring homologous recombination repair mutations. Enrolled patients had mCRPC disease and no prior exposure to PARP inhibitors or ARPIs or chemotherapy in the mCRPC setting and had BRCA1 or BRCA2 or ATM mutations. As previously mentioned, these patients were randomized to 3 arms: abiraterone monotherapy at 1000 milligrams once daily, or olaparib monotherapy at 300 milligrams twice daily, or the combination of abiraterone and olaparib. The primary endpoint was progression-free survival per RECIST 1.1 or Prostate Cancer Working Group 3-based criteria or clinical assessment or death, so, whichever occurred first was deemed to be progression. Secondary endpoints included measurable disease response rates, PSA response rate, and toxicity. This was a relatively small trial with 21 patients in the combination arm, 19 patients in the abiraterone monotherapy arm, and 21 patients in the olaparib monotherapy arm. It should be noted that 26% of patients had received docetaxel chemotherapy in the hormone-sensitive setting, and only 3% of patients had any prior exposure to an ARPI, and these were darolutamide or enzalutamide or in the non-metastatic CRPC setting. The results are very interesting. The median progression-free survival was 39 months in the combination arm, while it was 8.4 months in the abiraterone arm and 14 months in the olaparib arm. An important finding that I would like to highlight is that crossover was also allowed in the monotherapy arms. Of the 19 patients receiving abiraterone, 8 crossed over to receive olaparib, and of the 21 patients receiving olaparib, 8 crossed over to the abiraterone arm. The median PFS from randomization was 16 months in both groups of patients who received abiraterone followed by olaparib or those who received olaparib followed by abiraterone. This is striking when compared to 39 months in patients who started therapy with the combination therapy of abiraterone with olaparib. Dr. Jeanny Aragon-Ching: Thank you so much for that wonderful summary, Neeraj. So the key message from this abstract is that combining olaparib and abiraterone upfront seems to be associated with improvement in PFS compared to just sequencing those agents. Dr. Neeraj Agarwal: Exactly, Jeanny. I would like to add that these results are even more important given that in real-world practice, only half of the patients with mCRPC receive a second-line treatment. Based on these results, upfront intensification with a combination of an ARPI plus a PARP inhibitor in the first-line mCRPC setting seems to have superior efficacy compared to sequencing of these agents. Dr. Jeanny Aragon-Ching: Thank you so much. Now, moving on to a different setting in prostate cancer, there were a couple of abstracts assessing transperineal biopsy compared to the conventional transrectal biopsy for the detection of prostate cancer. So let's start with Abstract 261. Neeraj, can you tell us a little bit more about this abstract? Dr. Neeraj Agarwal: Sure, Jeanny. So, in Abstract 261 titled "Randomized Trial of Transperineal versus Transrectal Prostate Biopsy to Prevent Infection Complications," Dr. Jim Hugh and colleagues led a multicenter randomized trial comparing these 2 approaches, so, transperineal biopsy without antibiotic prophylaxis with transrectal biopsy with targeted prophylaxis in patients with suspected prostate cancer. The primary outcome was post-biopsy infection. Among the 567 participants included in the intention-to-treat analysis, no infection was reported with the transperineal approach, while 4 were detected with the transrectal approach, with a p-value of 0.059. The rates of other complications, such as urinary retention and significant bleeding, were very low and similar in both groups. The investigators also found that detection of clinically significant cancer was similar between the 2 techniques and concluded that the transperineal approach is more likely to reduce the risk of infection without antibiotic prophylaxis. Dr. Jeanny Aragon-Ching: So the key takeaway from this abstract sounds like office-based transperineal biopsy is well-tolerated and does not compromise cancer detection, along with better antibiotic stewardship and health care cost benefits. Moving on to Abstract 273, also comparing these two approaches, what would be your key takeaway message, Neeraj? Dr. Neeraj Agarwal: In this Abstract 273, titled "Difference in High-Risk Prostate Cancer Detection between Transrectal and Transperineal Approaches," Dr. Semko and colleagues found that the transperineal biopsy based on MRI fusion techniques was also characterized by a higher possibility of detecting high-risk prostate cancer and other risk factors as well, such as perineural and lymphovascular invasion or the presence of cribriform pattern, compared to the conventional transrectal method. Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So we can see that the transperineal approach is gaining more importance and could be associated with more benefits compared to the conventional methods. Let's now switch gears to kidney cancer, Neeraj. Dr. Neeraj Agarwal: Sure, Jeanny. Let's start by highlighting Abstract 361, which discusses patient-reported outcomes of the LITESPARK-005 study. So what can you tell us about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Thank you, Neeraj. So as a reminder to our listeners, based on the LITESPARK-005 trial, it was a Phase 3 trial looking at belzutifan, which is an inhibitor of hypoxia inducible factor 2 alpha or I'll just call HIF-2 alpha for short, was very recently approved by the FDA as a second-line treatment option for patients with advanced or metastatic clear cell renal cell carcinoma after prior progression on immune checkpoint and antiangiogenic therapies. The title of Abstract 361 is "Belzutifan versus Everolimus in Patients with Previously Treated Advanced RCC: Patient-Reported Outcomes in the Phase 3 LITESPARK-005 Study," and this will be presented by Dr. Tom Pells at the meeting. At a median follow-up of 25.7 months, the median duration of treatment with belzutifan was 7.6 months, while it was only 3.9 months with everolimus. At the time of data cutoff date for the second interim analysis, 22.6% of patients remained on belzutifan while only 5% remained on everolimus. In the quality of life questionnaires, the time of deterioration to various quality of life scores, as assessed by standardized scales, was significantly longer in patients randomized to the belzutifan arm compared to those in the everolimus arm. Also, patients in the everolimus arm had worse physical functioning scores. Dr. Neeraj Agarwal: Yes, Jeanny. In addition to the improved outcomes associated with belzutifan, patient-reported outcomes indicate better disease-specific symptoms and better quality of life among patients treated with belzutifan compared to everolimus. This is great news for patients with advanced renal cell carcinoma. Now, Jeanny, can you please tell us about the two abstracts that reported longer follow-up of CheckMate 9ER and CheckMate 214 trials in untreated patients with advanced or metastatic renal cell carcinoma? Dr. Jeanny Aragon-Ching: Yes, Neeraj. So you are referring to Abstracts 362 and 363. Let's start with Abstract 362. This abstract reports the results after a median follow-up of 55 months in the CheckMate 9ER trial, comparing the combination of nivolumab and cabozantinib to sunitinib in patients with advanced RCC without any prior treatment, so first-line therapy. The primary endpoint was PFS per RECIST 1.1 as assessed by an independent central review. So there were key secondary outcomes including overall survival (OS), objective response rates, and safety. Consistent with prior analysis at a median follow-up time of 18.1 and 44 months, the combination of nivolumab and cabozantinib at a median follow up of 55.6 months continues to show a significant reduction in the risk of progression or death by 42% and in the risk of death by 23% compared to sunitinib. Dr. Neeraj Agarwal: And Jeanny, what can you tell us about the efficacy results of this combination by IMDC risk categories? Dr. Jeanny Aragon-Ching: Similar to prior results in patients with intermediate to poor risk IMDC risk category, the combination treatment maintained significant efficacy and reduced the risk of progression or death by 44% and the risk of death by 27%. To put it simply, the update now shows a 15-month improvement in overall survival with the cabozantinib-nivolumab combination compared to sunitinib, which is amazing. Also, in patients with favorable IMDC risk group, which represented truly a small number of patients in the trial, there was a strong trend for improvement of outcomes as well. I would like to point out that no new safety concerns were identified. Dr. Neeraj Agarwal: So, it looks like the key message from this abstract is that with longer follow-up, the combination of nivolumab and cabozantinib maintains a meaningful long-term efficacy benefit over sunitinib, supporting its use for newly diagnosed patients with advanced or metastatic renal cell carcinoma. Let's move on to Abstract 363, which compares nivolumab with ipilimumab to sunitinib in first-line advanced renal cell carcinoma. What would you like to tell us about this abstract, Jeanny? Dr. Jeanny Aragon-Ching: Yes, Neeraj. The title of this abstract is "Nivolumab plus Ipilimumab versus Sunitinib for the First-Line Treatment of Advanced RCC: Long-Term Follow-Up Data from the Phase 3 CheckMate 214 Trial." In this abstract, Dr. Tannir and colleagues report outcomes with the longest median follow-up in first-line advanced RCC setting for any clinical trial. So the median follow-up now is about 18 months. The primary endpoints were OS, PFS, and objective response rates, as assessed by an independent review according to RECIST 1.1 criteria in the intermediate to poor risk IMDC risk group, which is the intent-to-treat (ITT) analysis, while secondary outcomes included the same outcomes in the ITT population of patients. Although the progression-free survival was similar in both arms, the combination of nivolumab-ipilimumab reduced the risk of death by 28% compared to sunitinib in the ITT population of patients. When stratifying the results by IMDC risk groups, the combination arm of nivolumab-ipilimumab showed significant improvement in the intermediate to poor risk group, but there was no difference in the favorable risk group. But in the study, no new safety signals were identified. Dr. Neeraj Agarwal: Thank you, Jeanny, for such a comprehensive description of the results of these two studies. I'd like to add that the median overall survival of patients with metastatic renal cell carcinoma in the ITT population in the CheckMate 214 trial has now reached 53 months, which would have been unimaginable just a decade ago. This is wonderful news for our patients. So the key takeaway from these two abstracts would be that immune checkpoint inhibitor-based combinations remain the backbone of first-line advanced renal cell carcinoma treatment. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. This is wonderful news for all of our patients, especially for those who are being treated for first-line therapy. Now, let's move on to the bladder cancer abstracts. We have two exciting abstracts from the UNITE database. What are your insights on Abstract 537, titled "Outcomes in Patients with Advanced Urethral Carcinoma Treated with Enfortumab Vedotin After Switch-Maintenance of Avelumab in the UNITE Study"? Dr. Neeraj Agarwal: As our listeners know, enfortumab vedotin is an antibody-drug conjugate that binds to a protein called Nectin 4 expressed on bladder cancer cells. In this abstract, Dr. Amanda Nizam and colleagues describe outcomes in 49 patients receiving third-line enfortumab vedotin after prior progression on platinum-based therapy and maintenance avelumab. At a median follow-up of 8.5 months, the median progression-free survival was 7 months and the median overall survival was 13.3 months with enfortumab vedotin in this treatment-refractory setting, the objective response rates were 54%. The message of this study is that enfortumab vedotin is an effective salvage therapy regimen for those patients who have already progressed on earlier lines of therapies, including platinum-based and immunotherapy regimens. Dr. Jeanny Aragon-Ching: Thank you, Neeraj, for that comprehensive review. I want to focus on another patient population in the UNITE database, which is the use of fibroblast growth factor receptor (FGFR) alterations. Can you tell us more about the sequencing now of erdafitinib and enfortumab vedotin in these patients with metastatic urothelial cancer, as discussed in Abstract 616? Dr. Neeraj Agarwal: Sure, Jeanny. As a reminder, erdafitinib is a fibroblast growth factor receptor kinase inhibitor approved for patients with locally advanced or metastatic urothelial carcinoma harboring FGFR2 or FGFR3 alterations after progression on platinum-based chemotherapy. However, the optimal sequencing of therapies in these patients is unclear, especially with enfortumab vedotin being approved in the salvage therapy setting and now in the frontline therapy setting. So in this retrospective study, all patients with metastatic urothelial carcinoma had FGFR2 or FGFR3 alterations. Dr. Cindy Jiang and colleagues report outcomes in 24 patients receiving enfortumab vedotin after erdafitinib, 15 patients receiving erdafitinib after enfortumab vedotin, and 55 patients receiving enfortumab vedotin only. This is a multicenter national study. Interestingly, patients receiving both agents had a longer overall survival in a multivariate analysis, regardless of the treatment sequencing, than patients receiving enfortumab vedotin alone or only with a hazard ratio of 0.52. The objective response rate of enfortumab vedotin in the enfortumab vedotin monotherapy arm was 49%. When these agents were sequenced, the objective response with enfortumab vedotin was 32% after erdafitinib and 67% when used before erdafitinib. Dr. Jeanny Aragon-Ching: Thank you so much, Neeraj. I think these are important real-world data results, but I would like to point out that larger and prospective studies are still needed to confirm these findings, especially regarding the outcome of erdafitinib after enfortumab vedotin, particularly when the latter is used in the first-line setting. Dr. Neeraj Agarwal: I totally agree, Jeanny. Now, let's discuss some abstracts related to disparities in the management of patients with genitourinary cancers. Dr. Jeanny Aragon-Ching: Sure, actually, I would like to discuss 2 abstracts related to disparities in patients with prostate cancer. So the first one, Abstract 265, titled "Patient-Provider Rurality and Outcomes in Older Men with Prostate Cancer." In this study, Dr. Stabellini, Dr. Guha and the team used a SEER Medicare-linked database that included more than 75,000 patients with prostate cancer. The primary outcome was all-cause mortality, with secondary outcomes included prostate cancer-specific mortality. The investigators showed that the all-cause mortality risk was 44% higher in patients with prostate cancer from rural areas who had a provider from a non-metropolitan area compared to those who were in a metropolitan area and had a provider also from a metropolitan area. Dr. Neeraj Agarwal: Those are very important data and highlight the healthcare disparities among the rural population with prostate cancer that still exist. So what is your key takeaway from Abstract 267, titled "Rural-Urban Disparities in Prostate Cancer Survival," which is a population-based study? Dr. Jeanny Aragon-Ching: Of course. This abstract discusses, actually, a very similar issue regarding access to healthcare among rural versus urban patients. In this study, Dr. Hu and Hashibe and colleagues and team at the Huntsman Cancer Institute assessed all-cause death and prostate cancer-related death risk in a retrospective study in which patients with prostate cancer based on rural versus urban residencies looked at 18,000 patients diagnosed with prostate cancer between 2004 and 2017. 15% lived in rural counties. Similar to the prior abstract we talked about, patients living in rural areas had about a 19% higher risk of all-cause mortality and a 21% higher risk of prostate cancer-specific mortality in comparison to patients living in urban areas. Dr. Neeraj Agarwal: So Jeanny, we can say that both of these abstracts, led by different groups of investigators, highlight that patients with prostate cancer living in rural areas have inferior survival outcomes compared to those living in urban areas, and it is time to focus on the disparities experienced by the rural population with prostate cancer. Dr. Jeanny Aragon-Ching: Yeah, absolutely Neeraj. I concur with your thoughts. So, any final thoughts before we wrap up the podcast today? Dr. Neeraj Agarwal: Yes, before concluding, Jeanny, I want to express my gratitude for your participation and the valuable insights you have shared today. Your contributions are always appreciated, and I sincerely thank you for taking the time to join us today. As we bring this podcast to a close, I would like to highlight the significant advances happening in the treatment of patients with genitourinary cancers during our upcoming 2024 ASCO GU meeting. Many studies featuring practice-impacting data will be presented by investigators from around the globe. I encourage our listeners to not only participate at this event to celebrate these achievements, but to also play a role in disseminating these cutting-edge findings to practitioners worldwide. By doing so, we can collectively maximize the benefit for patients around the world. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Thank you very much. Disclaimer: The purpose of this podcast is to educate and inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guest speakers express their own opinions, experience, and conclusions. Guest statements on the podcast do not necessarily reflect the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:  Dr. Neeraj Agarwal @neerajaiims Dr. Jeanny Aragon-Ching Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn   Disclosures:  Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas  Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis, Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics.

university moving speaker study utah trial patients os phase fda consistent pfizer similar psa unite outcomes drs gu mri secondary astrazeneca atm bayer abstract oncology merck hu prostate cancer janssen checkmate novartis sanofi precision medicine asco genentech amgen itt bristol myers squibb takeda older men rcc brca1 pfs enrolled parp nektar brca2 crpc abstracts guha randomized trial hif eisai muc huntsman cancer institute nivolumab first line treatment emd serono foundation medicine jeanny aveo ipilimumab crispr therapeutics fgfr arpi medimmune asco gu seattle genetics everolimus sunitinib neeraj agarwal dendreon recist pharmacyclics janssen oncology transcript dr ccrcc mei pharma

Falco - Jeanny

Peters Pop Stories

Play Episode Listen Later Dec 13, 2023 8:14

Zu diesem Song hatte 1985 wirklich jeder eine Meinung. Für die einen war "Jeanny" ein unerträglicher Skandal. Für die anderen ein geniales Lied, das man nicht oft genug hören konnte. Wie der Song, der nicht im Radio gespielt wurde, sich trotzdem Monate lang in den Deutschen Charts halten konnte, verrät Euch Peter in dieser Folge.

film song radio meinung lied lyrics skandal falco 1985 jeanny

S1:E13 Do you know what you want?

asian zoo know what you want jeanny

Play Episode Listen Later Nov 13, 2023 38:45

Asian women experience shame as little girls. We start feeling not good enough all the way into our career. This habit negatively affects us in all aspects of work and personal relationships. We end up knowing what we want. So we don't ask and get what we want. In this episode Jeanny shares examples from her past in she learned she was not good enough. Included in this session is an extra-long affirmation in Part 2 of the Episode for you to gain your confidence back!Jeanny Chai Bio here*Take the FREE ASSESSMENT My Personal Roadblock to Success Book A Free Confidence Igniter Call with Jeanny if you want to overcome stress and imposter sydrome and propel your career forward with confidence and certainty.Theme Song: Imagine by ZooMid-roll Song: Clarity by ZooAffirmation Song: Sky High by AKPost-roll Song: Clarity by Zoo

S1:E11 Overcoming Indecisiveness (Part 3 on Guilt)

Play Episode Listen Later Oct 23, 2023 34:42 Transcription Available

When overthinking causes too much stress and indecisiveness, we need to stop. We were taught to not give others "bad news" but instead to SAVE FACE. These norms in turn make it hard for us to make decisions that make us happy but might have a negative effect on others. We don't want to disappoint others so we make decisions to put up with stress, anxiety, busyness, bad treatment and unfulfillment. There's a better way to make decisions that value yourself, your time and propel your career forward with confidence. See full transcipt at AsiansBreakingCeilings.com in Episode 11.Jeanny Chai Bio here*Take the FREE ASSESSMENT My Personal Roadblock to Success [00:00] Teaser[01:05] Episode 11 Intro[02:32] Are you more comfortable with stress or peace?[04:20] Always expecting the worst[05:19] What causes Overthinking?[07:00] Overthinking causes constant Stress[08:31] You can only be as happy as your most unlucky relative[10:51] Feeling guilty for good fortune[11:14] Feeling guilty to leave your department[14:09] Effects of mean Asian relatives[15:43] When guilt become an addiction[17:14] BREAK[17:52] If it's easy, you're probably LAZY[18:32] Asians getting stuck with the sh*tty projects[19:15] Guilt keeps us in toxic situations[19:58] We are guilted into being responsible, instead of following our dreams[22:54] Stress becomes a way of life[24:57] The Key to Freedom[26:11] Let Yourself be happy[29:35] Create you own pschological safety[30:03] Affirmation to help you gain your power back[33:00] Episode 11 TeaserBook A Free Confidence Igniter Call with Jeanny if you want to overcome stress and imposter sydrome and propel your career forward with confidence and certainty.Theme Song: Imagine by ZooMid-roll Song and Post-roll Song: Clarity by Zoo

success freedom stress song overcoming asian effects guilt affirmations lazy zoo overthinking teaser asians indecisiveness save face jeanny

S1:E10 Hard to Say No? (Part 2 on Guilt)

Play Episode Listen Later Oct 16, 2023 36:04 Transcription Available

Most women have a habit of feeling guilty for saying NO. How is this affecting our careers negatively and more importantly, how to we stop this habit?Here's an actionable first step. Start noticing when you are saying YES when you mean NO.Then give yourself permission to make yourself happy.See full transcipt at AsiansBreakingCeilings.com in Episode 10.Jeanny Chai Bio here*Take the FREE ASSESSMENT My Personal Roadblock to Success [00:00] Teaser[00:48] Episode 10 Intro[02:08] Hard to Say No to Assignments at Work[03:35] Guilt comes from trauma in childhood[06:41] Guilt makes us feel like we have no time[07:25] Feeling like a burden to parents[08:39] I almost became a Mormon[07:39] Guilt steals our joy[08:08] The Age that Guilt starts[08:40] No child is born feeling constantly guilty[09:15] Feeling like a burden to parents[11:42] Guilt causes problems in dating relationships[15:17] Afraid to say no to boss ended up really bad...[17:04] Saving Face can cause a guilt complex[17:30] Always worried about being fired from your job?[20:24] BREAK Book a Confidence Igniter call with Jeanny[21:21] Guilt makes parenting really stressful[21:44] Bad babysitters[25:21] Guilt hurts our careers[26:00] The Key to Freedom[29:03] How to have compassion for yourself[30:22] Affirmation to Say No without Guilt[34:36] Preview of Episode 11 (Guilt, Part 3) Theme Song: Imagine by ZooMid-roll Song: Making Progress by Dan PhillipsonAffirmation Song: Ghost YetiPost-roll Song: Clarity by Zoo

success freedom work afraid guilt affirmations preview say no mormon zoo teaser assignments saving face jeanny

S1:E8 Sorry, Not Sorry

success freedom truth story asian affirmations zoo teaser apologize sorry not sorry din tai fung jeanny

Play Episode Listen Later Oct 2, 2023 40:18 Transcription Available

Asian women tend to apologize unnecessarily. This habit negatively affects us in all aspects of work and personal relationships. In this episode Jeanny shares examples from her past in which an apology was warranted. Included in this session is an extra-long affirmation in Part 2 of the Episode for you to gain your confidence back!See full transcipt at AsiansBreakingCeilings.com in Episode 7.Jeanny Chai Bio here*Take the FREE ASSESSMENT My Personal Roadblock to Success [00:00] Teaser[00:36] Episode 7 Intro[01:59] How To Benefit from this podcast[02:23] The Truth about People who Apologize[04:35] Story 1[07:50] Story 2[09:13] Story 3[11:40] Story 4[14:35] My parent apologized. It was underwhelming.[21:10] BREAK[21:46] Unnecessary Apologizing[23:52] Din Tai Fung[26:28] The Key to Freedom[29:42] Affirmation to help you gain your power back[39:04] Episode 9 TeaserBook A Free Confidence Igniter Call with Jeanny if you want to overcome stress and imposter sydrome and propel your career forward with confidence and certainty.Theme Song: Imagine by ZooMid-roll Song: Making Progress by Dan PhillipsonAffirmation Song: Ghost Piano by Yeti MusicAffirmation Song: No Eye Has Seen by Caden ChaiPost-roll Song: Clarity by Zoo

S1: E1 Top 10 Symptoms of the Bamboo Ceiling

Play Episode Listen Later Aug 28, 2023 29:31 Transcription Available

Do you want to know what thousands of AAPI women in corporate America are really experiencing? In this eye-opening episode, Jeanny reveals the Top 10 trends mid-career professionals are experiencing. Spoiler: it's not pretty.Can you relate? You are not alone. We are in this together.Jeanny Chai Bio here*Take the FREE ASSESSMENT My Personal Roadblock to Success [00:00] Teaser[00:57] Episode 1 Trailer[02:20] Bad Ass Immigrants Sacrifice Too Much[04:33] Trend 10. AAPI woman is sole breadwinner[05:20] Trend 9. AAPI woman does the work of 3 people[05:55] Trend 8. No time for herself[06:46] Trend 7. Underpaid by $30-40K[07:19] Trend 6. Feels Unfulfilled[07:45] Trend 5. Tolerates a Toxic Environment [09:08] Trend 4. Exhausted[09:44] Trend 3. Physically Ill[11:46] Trend 2. Constantly Proving Herself[13:33] Trend 1. Not Getting Promoted[14:19] It's not your fault.[14:38] We need to address clash of cultural norms.[15:52] There is HOPE.Take the "My Personal Roadblock to Success" Assessment here:https://asiansbreakingceilings.com/assessmentLeave a written review for me at Podchaser, thank you![17:03] Data from ASCEND report, executive parity lowest for AAPI women[19:43] Three Biggest Asian Cultural Ceilings to Reframe[20:56] First Ceiling: Self-Criticism[22:28] Second Ceiling: Emotional Restraint[24:21] Third Ceiling: Filial Piety[28:02] Goal of Asians Breaking Ceilings[28:33] Episode 2 PreviewTake the "My Personal Roadblock to Success" Assessment here:https://asiansbreakingceilings.com/assessmentTheme Song: Imagine by ZooMid-roll and Post-roll Song: Clarity by ZooAscend Report: The Diversity Equity Gap in the Fortune 500:Mentioned in this episode:Outtro

america success spoilers data fortune goal trend trailer symptoms teaser ceiling exhausted reframe bamboo aapi ascend podchaser 40k underpaid toxic environment outtro jeanny

Welcome Ceiling Breakers!

amazon netflix founders drawing silicon valley authentic stanford usa today oracle asian americans salesforce hp abc news ceiling kpmg breakers fortune magazine jeanny

Play Episode Listen Later Aug 10, 2023 1:25

Who this podcast if for and why you should listen.Multi-cultural female professionals who want to:ignite your confidenceovercome imposter syndromebreak that career ceilingLearn how to decide, create, and ask for what you want in your career without apology or guilt.Whether you are looking to get promoted, searching for your next perfect role, or thinking about starting your side hustle, this podcast will give you strategies to increase your confidence and start living your leadership potential.Authentic success, without the stress!Who is Jeanny Chai?BambooMyth.com Founder, coach & speaker, Jeanny Chai helps Asian American professionals find their worth from within and “Live Their Leadership Potential” by reframing the cultural priorities that have been given to us. She believes that breaking through the Bamboo Ceiling is an internal quest and only by thinking differently that we can create a new norm. She has been invited to speak at companies including Salesforce, Amazon, Netflix, Oracle, KPMG, HP and has been featured in Fortune Magazine, USA Today, and ABC News.Drawing from powerful personal experiences that include “shaming” her family by not attending medical school after graduating from Stanford, raising four children and becoming known as a successful business development professional in Silicon Valley, Jeanny has devoted herself to helping Asian Americans find their confidence from within.It took Jeanny 3 breast cancer tumors and a divorce to come into the realization of how she could flourish, and she is dedicated to saving other women the pain of having to go through great adversity to reach the point of personal transformation.Read more about Jeanny's impact and work at www.BambooMyth.com

Learning Life lessons with Jeanny Alexandre: Part Two

Fuel For Freedom

Play Episode Listen Later Jul 24, 2023 25:45

I am delighted to have another interview with a very interesting lady, Jeanny Alexandre. I had the opportunity to interview her in December of 2022. Her interview was very interesting and when I asked her if we could follow up she agreed to visit for this second time. You are going to enjoy hearing what she has to say.Connect with Tony:Aim your sights

family health culture society funny personality selfhelp life lessons alexandre life skills wealth building social skills hidden potential learning life jeanny

ASCO23: Novel Approaches in RCC, mUC, and Prostate Cancer

SWR1 Meilensteine - Alben die Geschichte machten

Play Episode Listen Later May 25, 2023 24:49

Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss the CLEAR study in renal cell carcinoma, a new exploratory analysis combining the TheraP and VISION trials in metastatic urothelial cancer, and compelling advances in prostate cancer and across GU oncology in advance of the 2023 ASCO Annual Meeting. TRANSCRIPT Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host for the ASCO Daily News Podcast today. I'm the director of the Genitourinary Oncology Program and a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to welcome Dr. Jeanny Aragon-Ching, a GU medical oncologist and the clinical director of the Genitourinary Cancers Program at the Inova Schar Cancer Institute in Virginia. Today, we'll be discussing some key abstracts in GU oncology that will be featured at the 2023 ASCO Annual Meeting. Our full disclosures are available in the show notes and disclosures of all guests on the podcast can be found on our transcript at asco.orgDNpod. Jeanny, it's great to have you on the podcast today. Dr. Jeanny Aragon-Ching: Thank you so much, Dr. Agarwal, for having me. Dr. Neeraj Agarwal: Jeanny, let's begin with Abstract 4502 regarding long-term updated results on the CLEAR study. The abstract reports the final, prespecified overall survival analysis of the CLEAR trial, a four-year follow-up of lenvatinib plus pembrolizumab versus sunitinib in patients with advanced renal cell carcinoma. Dr. Jeanny Aragon-Ching: Yes, I would be happy to. So, just as a reminder, the combination of lenvatinib and pembrolizumab was initially approved by the FDA in August 2021 for first-line treatment of adult patients with advanced renal cell carcinoma. So, this was based on significant benefits that were seen in progression-free survival, which was a primary endpoint, but also showed improvement in the overall response rates compared with sunitinib in first-line advanced renal cell carcinoma. So this abstract reports on longer-term follow-up now at a median of 49.8 months, and PFS favored the combination lenvatinib and pembrolizumab compared to sunitinib across all MSKCC risk groups, and PFS benefit versus lenvatinib and pembro compared to sunitinib was maintained with a hazard ratio of 0.47. And even overall survival was also maintained with the combination with a hazard ratio of 0.79, and the overall survival favored the combination across all risk groups. If we look at the CR rate, it was 18.3% for the combination compared to 4.8% with sunitinib, unless patients in the combination arm received subsequent anticancer therapies, and that's intuitive. And the PFS2 was also longer with the combination at 43 months compared to 26 months. Now, it is important to note that grade III or more treatment-related adverse events did occur in about 74% of the patients in the combination of lenvatinib and pembro, compared to 60.3% in patients with sunitinib. Dr. Neeraj Agarwal: Jeanny, this is good news. So the main message from the abstract is that sustained results from this combination of lenvatinib plus pembrolizumab are being seen even after a longer follow-up of more than four years. Dr. Jeanny Aragon-Ching: Yes, I agree. So now, moving on, Neeraj, to a different setting in the RCC space, let's look at Abstract 4519, which is titled “Efficacy of First-line Immunotherapy-based Regimens in Patients with Sarcomatoid and/or Rhabdoid Metastatic Non-Clear Cell RCC: Results from the IMDC,” which will be discussed by Dr. Chris Labaki. So, Neeraj, based on this abstract, can you tell us a little bit more about the impact of these adverse pathologic risk features in non-clear cell RCC? Dr. Neeraj Agarwal: Of course. So, using real-world patient data, the IMDC investigators compared the outcomes of patients with metastatic non-clear cell RCC who were treated with immunotherapy-based combination regimens versus those who were treated with VEGF-TKIs alone. They also assessed the impact of sarcomatoid and rhabdoid features on response to IO-based combinations versus VEGF-TKIs. Of 103 patients with metastatic non-clear cell RCC who had rhabdoid or sarcomatoid features, 32% of patients were treated with immunotherapy-based combinations. After adjusting for confounding factors, the authors show that those treated with a combination of two immune checkpoint inhibitors or an immune checkpoint inhibitor with a VEGF-TKI combination had significantly improved overall survival, which was not reached in the immunotherapy combination group versus seven months within the VEGF-TKI group. Time to treatment failure and objective responses were also prolonged, significantly higher, and better in the immunotherapy groups compared with patients who were treated with VEGF-TKIs alone. Interestingly, if you look at those 430 patients with metastatic non-clear cell RCC who did not have sarcomatoid or rhabdoid features, they didn't seem to benefit with immunotherapy-based combinations. Dr. Jeanny Aragon-Ching: This is an exciting update, Neeraj. What are the key takeaways from this abstract? Dr. Neeraj Agarwal: So the main takeaway is if you see a patient with advanced non-clear cell RCC who has sarcomatoid and rhabdoid features, there appears to be a rather substantial and selective benefit with IO-based combinations. And in this context, I would like to highlight the ongoing SWOG 2200 trial also known as PAPMET2 trial, which is comparing the combination of cabozantinib plus atezolizumab. So immuno-therapy-based combinations versus cabozantinib alone in advanced papillary renal cell carcinoma setting. So this trial is being led by Dr. Benjamin Maughan and Dr. Monty Pal. And I like to encourage our listeners to consider referring their patients for involvement in this federally funded trial so that we can validate the data from this retrospective study in a prospective way. So, Jeanny, let's now move on to another important disease type which is urothelial carcinoma. There is a very recent accelerated FDA approval of the drug combination of enfortumab vedotin and pembrolizumab for cisplatin-ineligible metastatic urothelial carcinoma patients. This is Abstract 4505, which is being presented by Dr. Shilpa Gupta and colleagues. Can you please tell us more about this update? Dr. Jeanny Aragon-Ching: Yeah, absolutely. So, as you mentioned, Neeraj, the FDA just granted accelerated approval in April 2023 for this combination of enfortumab vedotin or EV, which is and ADC, antibody drug conjugate against nectin-4 and the PD-1 inhibitor pembroluzimab. So it's a combination for patients with locally advanced or metastatic urothelial carcinoma who are considered cisplatin ineligible. So this is nearly a four-year follow-up. So as a reminder, this was a phase 1b/2 trial that included 45 patients and it had a primary endpoint of safety and tolerability although the key secondary endpoints included confirmed overall responses, duration of response, progression-free survival, and the resist criteria was investigated via investigator and BICRs which is in a blinded independent central review. Even overall survival was a key secondary endpoint. So, the bottom line was the confirmed overall response by BICR was 73.3%, the disease control rate was about 84%, and the CR rate was 15.6% with a PFS of close to 13 months, and a 12-month overall survival rate of 83%. However, it is important to cite that there were treatment-related adverse events including skin reactions in 66%, neuropathy occurred in 62%, and ocular disorders in 40%. And there was a little bit of pneumonitis in close to 9%, colitis, and hypothyroidism, so there are side effects to watch out for. Dr. Neeraj Agarwal: So, Jeanny this is great. What is the key takeaway from this trial? Dr. Jeanny Aragon-Ching: So I think the most important thing is we now have a new combination of EV and pembro which shows very promising responses and survival in part which led to the FDA accelerated approval in the cisplatin-ineligible population of patients. However, we must note that the phase 3 trial of EV302 will ultimately establish which approach is really beneficial for all of our cisplatin-ineligible patients, either a carboplatin-based chemotherapy regimen or a non-platinum-based regimen such as EV and pembro. Dr. Neeraj Agarwal: Thanks Jeanny, would you like to discuss any other study in the bladder cancer space? Dr. Jeanny Aragon-Ching: Absolutely. I think Abstract 4508 from Dr. Seth Lerner and colleagues will be very relevant to our colleagues. This abstract is SWOG S1011, which is a phase 3 surgical trial to evaluate the benefit of a standard versus an extended lymphadenectomy performed at the time of radical cystectomy for muscle-invasive bladder cancer. Dr. Neeraj Agarwal: Yes. So this trial, as you said, is an important trial which randomized in a one-on-one fashion 618 patients with muscle-invasive bladder cancer undergoing radical cystectomy, and these patients were randomized to either standard lymph node dissection or an extended lymph node dissection. And standard lymph node dissection included, as we know, external and internal iliac and operative lymph node. The extended lymph node dissection included lymph nodes up to aortic bifurcation which included common iliac, presciatic, and presacral lymph nodes. At a median follow-up of approximately 6 years, there was no disease-free survival or overall survival benefit in patients undergoing an extended lymph node dissection compared to standard lymph node dissection. And extended lymph node dissection was also associated with greater morbidity and preoperative mortality. Dr. Jeanny Aragon-Ching: Very interesting data, Neeraj. So these results, I think, will be very useful for a lot of our surgical colleagues in both academia and the community who may still be inclined to perform extended lymphadenectomy during cystectomy. This study shows that it's actually not necessary. Dr. Neeraj Agarwal: Absolutely. So now let's move on to another disease type, which is very important - prostate cancer. There are several practice-informing abstracts that are worthwhile discussing. The first of these involves Abstract 5002, which looks at the impact of the PSA nadir as a prognostic factor after radiation therapy for localized prostate cancer, which will be presented by Dr. Praful Ravi and colleagues. Jeannie, can you please tell us more about this abstract? Dr. Jeanny Aragon-Ching: Yeah, definitely. So this abstract, as you mentioned, Neeraj, is a prognostic impact of PSA nadir of more than or equal to 0.1 nanogram per ml within six months after completion of radiotherapy for localized prostate cancer - an individual patient data analysis of randomized trials from the ICECaP Collaborative. Basically, it refers to an attempt to evaluate early surrogate measures to predict for long term outcomes such as prostate cancer-specific survival, metastases-free survival, and overall survival. So they looked at a big registry from the ICECaP collaboration that included 10,415 patients across 16 randomized controlled trials. And those men underwent treatment for intermediate risk and high risk prostate cancer treated with either radiation therapy alone in about a quarter of patients, or they got RT with short-term ADT in about 58% of patients, and 17% of them got RT with long-term ADT. So, after a median follow-up of ten years, what they found was, if you had a PSA nadir that is over or equal to 0.1 nanogram per ml within six months after completion of radiation therapy, it was associated with worse prostate cancer-specific survival, metastases-free survival, and overall survival. For instance, the five-year metastases-free survival for those who achieved a PSA nadir of less than 0.1 was 91% compared to those who did not, which was 79%. Therefore, they concluded that if you achieve a bad PSA of 0.1 or above within six months after you completed radiation, you had worse outcomes. Dr. Neeraj Agarwal: Jeanny, what is the key takeaway message from this study? Dr. Jeanny Aragon-Ching: The key takeaway from this ICECaP analysis is that this information would be very important to augment a signal-seeking endpoint, especially for clinical trial development, so that we can develop further strategies to de-escalate for those who don't need systemic intensification or therapy intensification versus escalation for those who really do. Dr. Neeraj Agarwal: So, my radiation oncology colleagues need to watch out for those patients who do not achieve a PSA of less than 0.1 nanogram per ml within the first six months of finishing radiation therapy. Very interesting data. Dr. Jeanny Aragon-Ching: Yes, absolutely. So. Neeraj another important abstract for our fellow clinicians, switching gears a little bit now, is Abstract 5011, which is titled “Do Bone Scans Overstage Disease Compared to PSMA PET?” This was an international, multicenter retrospective study with blinded, independent readers. Can you tell us more about this abstract? Dr. Neeraj Agarwal: Yes, a relatively small retrospective study, but still pertinent to our practice. So I'll summarize it. This study by Dr. Wolfgang Fendler and colleagues evaluated the ability of bone scans to detect osseous metastasis using PSMA PET scan as a reference standard. So in this multicenter retrospective study, 167 patients were included, of which 77 patients were at the initial staging of prostate cancer, 60 had biochemical recurrence after definitive therapy, and 30 patients had CRPC or castor-resistant disease. These patients had been imaged with a bone scan and a PSMA PET scan within 100 days. And in all patients, the positive predictive value, negative predictive value and specificity for bone scan were evaluated at different time points. They had bone scan and PSMA PET scan and both were compared. And what they found was interesting. All these three values - positive predictive value, negative predictive value, and specificity for bone scan were 0.73, 0.82 and 0.82 in all patients, and in initial staging, it was even lower at 0.43 and 0.94 and 0.80. So, without getting into too much detail regarding these numbers, I want to highlight the most important part of the study, that at the initial staging, 57% patients who had a positive bone scan had false positive bone scans. The interreader agreement for bone disease was actually moderate for bone scans and quite substantial for the PSMA PET scan. Dr. Jeanny Aragon-Ching: So, Neeraj, what do you think is the key takeaway message here for our audience? Dr. Neeraj Agarwal: The key takeaway message is that positive predictive value of bone scan was low in prostate cancer patients at initial staging, with the majority of positive bone scans being false positive. This suggests that a large proportion of patients which we consider to have low-volume metastatic disease by bone scan actually have localized disease. So in the newly diagnosed patients with prostate cancer, patients should ideally have a PSMA PET scan to rule out metastatic disease. So, let's move on to another abstract I would like to discuss, which has important implications in treatment, especially now that lutetium 177 is approved, but frankly not available widely. Dr. Jeanny Aragon-Ching: Yeah, that's actually very timely. So the abstract you're referring to is 5045, which is being presented by Dr. Yu Yang Sun and colleagues entitled “Effects of Lutetium PSMA 617 on Overall Survival in TheraP Versus VISION Randomized Trials: An Exploratory Analysis.” So, Neeraj, can you tell us more about the relevance of this exploratory analysis? Dr. Neeraj Agarwal: Definitely. In this abstract, Dr. Yang Sun and colleagues assess the effect of lutetium PSMA on overall survival in two different trials, TheraP and VISION trials. So, just for our listeners' recollection, the phase 2 TheraP trial compared lutetium PSMA and cabazitaxel in patients with mCRPC who had progression on docetaxel and had significant PSMA avidity on gallium PSMA pet scan, which was defined as a minimum uptake of SUV max of 20 at least one site of disease and SUV max of more than 10 at all sites of measurable disease. In this trial, 20 of 101 patients in the cabazitaxel arm crossed over to lutetium PSMA, and 32 of 99 patients in the lutetium PSMA arm crossed over to cabazitaxel. In the VISION trial, patients with mCRPC who previously progressed on at least one ARPI and one taxane-based therapy and had a positive gallium PSMA scan, and here, positivity was not stringently pre-specified as it was done in the context of TheraP trial. So, positive gallium pet scans were randomly assigned in two to one fashion to receive either lutetium PSMA plus best supportive care or standard of care versus standard of care. And I'd like to highlight that the standard of care comprised ARPIs and bone protecting agents and these patients were not allowed to have cytotoxic chemotherapy such as cabazitaxel in the standard of care arm. Now, overall survival was similar in the lutetium PSMA group regardless of whether they got lutetium PSMA in the VISION trial or TheraP trial. There was no difference in overall survival with lutetium in the lutetium arms of VISION and TheraP trial with a hazard ratio of 0.92. And there was no difference in the overall survival between the lutetium PSMA and the cabazitaxel group in the TheraP trial if you use counterfactual analysis, assuming crossover had not occurred. So, quite interesting in my view. Dr. Jeanny Aragon-Ching: Yeah, thanks Neeraj for that wonderful synopsis and discussion. So, what is the key take home message then? Dr. Neeraj Agarwal: The main message in this new exploratory analysis, which combined both the TheraP and VISION trials, is that lutetium PSMA and cabazitaxel seem to be associated with similar overall survival benefit in these highly selected patients with PSMA positivity. Additionally, the difference in the observed effect of lutetium PSMA and overall survival in the TheraP and VISION trials may be actually better explained by the use of different treatments in the respective control arms of these trials. And these results, in my view, are quite pertinent for those patients and providers who do not have access to lutetium-177 therapy. Let's go to another abstract that is currently relevant to our practice, given many patients with advanced prostate cancer who have concurrent diabetes; I'm talking about Abstract 5066. Jeanny, can you please tell us more about this abstract? Dr. Jeanny Aragon-Ching: Certainly, Neeraj. So this abstract will be presented by Dr. Amy Shaver and colleagues. So it's also very relevant, since many men who are diagnosed with prostate cancer frequently also have a concomitant diagnosis of type 2 diabetes mellitus. So, this was a SEER-Medicare population database analysis that looked at men who were treated with either abiraterone or enzalutamide and also had concomitant diagnosis of type 2 diabetes mellitus (DM). And they were identified using ICD-9 and ICD-10 codes and they were all tied in to acute care utilization. So they looked at CMS research data codes and ER hospitalization visits six months after treatment initiation was recorded. So all in all, they took a sample of 11,163 men, of whom close to 62% were treated with abiraterone and about 38% were treated with enzalutamide. So, of these, about 27% of them had type 2 DM, of whom 59% received abiraterone and about 41% had enzalutamide. So, the bottom line is, compared to those without diabetes mellitus, those who had type 2 diabetes had worse acute care utilization, which was 43% higher than those who got abiraterone compared to enzalutamide, and also had higher overall mortality. Therefore, the bottom line is, having type 2 diabetes mellitus, unfortunately, portends worse outcomes in men with prostate cancer, so careful attention needs to be paid to those who are starting out already with such comorbidities. So Neeraj, any final thoughts you have regarding this abstract and overall before we wrap up on the podcast today? Dr. Neeraj Agarwal: Absolutely. So it looks like, based on this very important pertinent Abstract 5066, which talks about the impact of diabetes on our patients, I think we need to be very watchful regarding the impact of diabetes on our patients who are being treated with abiraterone or enzalutamide, especially drugs which are known to make the metabolic syndrome and diabetes worse. I think close monitoring and close attention to control of diabetes is very important. So with that, I would urge the listeners to come and join us at the Annual Meeting, not only to celebrate these successes but also to help disseminate this cutting-edge data to practitioners and maximize the benefit to our patients across the globe. And thank you to our listeners for joining us today. You will find links to the abstracts we discussed today on the transcript of this episode. Finally, if you value the insights that you hear on our ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcast. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers: Dr. Neeraj Agarwal @neerajaiims Dr. Jeanny Aragon-Ching Follow ASCO on social media: @ASCO on Twitter ASCO on Facebook ASCO on LinkedIn Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, Crispr Therapeutics, Arvinas Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc., Pfizer/EMD Serono Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis, Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb, Astellas/Seattle Genetics.

university time vision speaker er dm patients clear effects consulting fda pfizer psa ev gu io astrazeneca suv rt pd bayer cms abstract merck efficacy prostate cancer annual meetings janssen novartis agarwal sanofi immunotherapy asco genentech amgen disclosures icd bristol myers squibb adt takeda adc rcc pfs gilead sciences bladder cancer nektar crpc novel approaches eisai asco annual meeting psma icecap emd serono foundation medicine jeanny aveo crispr therapeutics mskcc arpi psma pet medimmune swog therap seattle genetics dendreon neeraj agarwal arvinas pharmacyclics janssen oncology transcript dr mei pharma

Falco – "Falco 3"

Play Episode Listen Later May 22, 2023 33:30

Mit "Rock Me Amadeus" und "Jeanny" sind auf dem Album "Falco 3" zwei der größten Hits des österreichischen Megastars Falco gelandet. Für einen deutschsprachigen und auf deutsch-singenden Künstler ist es schon sehr ungewöhnlich, auch international erfolgreich zu sein. Hans Hölzel alias Falco hat es aber gleich mehrfach geschafft. Am international erfolgreichsten war sein Song "Rock Me Amadeus" von seinem Album "Falco 3". In dem Song singt der österreichische Sänger vordergründig über Wolfgang Amadeus Mozart, feiert hintergründig aber auch sich selbst ein wenig, denn er zieht durchaus einige Parallelen zwischen sich und dem Wunderkind aus Salzburg. Da wären zum Beispiel die Provokation, der Erfolg und vielleicht auch ein paar Damengeschichten. Aber auch das musikalische Talent wurde bei Falco ähnlich früh erkannt wie bei Mozart. Was die Musik von Falco so unsterblich gemacht hat, ist auch sein ganz besonderer Stil zu singen und auch zu texten. Eine Mischung aus Deutsch, Englisch und dem berühmten "Wiener Schmäh". Textlich hat Falco es geliebt zu polarisieren und auch zu provozieren, wie zum Beispiel bei dem Song "Jeanny". Viele Radiostationen weigerten sich nach Aufkommen des Skandals den Song "Jeanny" weiter in ihrem Programm zu spielen. Trotzdem hielt sich der Song durch die enorme Anzahl der Plattenverkäufe Wochenlang an der Spitze der deutschen Charts. Frauen, Geld und Drogen – in Songs wie "Munich Girls" oder "Vienna Calling" geht es auch immer wieder um den exzessiven Luxus. Themen, die auch den Lebensstil von Falco selbst widerspiegelten, der sich selbst gerne sehr luxuriös inszenierte. Unter seinem eigenen Namen Hans Hölzel wollte Falco schon vor seiner großen Karriere nicht mehr auftreten. Der Name war zu gewöhnlich, zu wenig international. Als er an einer Hotelbar den Skispringer Falko Weißpflog traf, war der Sänger so fasziniert von dem Namen, dass er ab da nur noch als Falco aufgetreten ist. Den Unterschied im Namen machte beim Sänger das "C" anstelle des "K" in dem Namen. __________ Über diese Songs vom Album “Falco 3” wird im Podcast gesprochen 03:36 Mins – “Rock Me Amadeus” 14:52 Mins – “America” 18:52 Mins – “Munich Girls” 23:11 Mins – “Vienna Calling” 24:56 Mins – “Jeanny” 31:00 Mins – “It's All Over Now, Baby Blue” __________ Über diese Songs wird außerdem im Podcast gesprochen 08:39 Mins – “Der Kommissar” von Falco 11:38 Mins – “Wann ma geh'n muss” von der EAV 12:44 Mins – “Mope” von der Bloodhound Gang 13:13 Mins – “Geil” von Bruce & Bongo 13:52 Mins – “Nikki war nie weg” von den Fantastischen Vier 21:06 Mins – “Looking for Love” von The Cars __________ Shownotes: Jetzt Abstimmen! Die SWR1 Meilensteine sind für den “Deutschen Podcastpreis” nominiert: https://www.deutscher-podcastpreis.de/podcasts/swr1-meilensteine-alben-die-geschichte-machten/ Review zu “Falco 3” bei laut.de: https://www.laut.de/Falco/Alben/Falco-3-26201 Youtube-Kanal von Falco mit Original Videos, Interviews uvm.: https://www.youtube.com/channel/UCMU63WkFaKXxg3I7uG-TDUg ZDF-Online-Artikel zu Falcos 25. Todestag: https://www.zdf.de/nachrichten/panorama/falco-25-jahre-tot-100.html Filmtipp: ORF-Online-Artikel zum Falco-Biopic „Falco – Verdammt, wir leben noch!“: https://tvthek.orf.at/profile/Additional-Content/1670/Falco-Verdammt-wir-leben-noch/14124564?meta=suggestion&query=Falco&pos=1 __________ Ihr wollt mehr Podcasts wie diesen? Abonniert die SWR1 Meilensteine! Fragen, Kritik, Anregungen? Schreibt uns an: meilensteine@swr.de

Alles über das Jahr 1986

Disko 80

Play Episode Listen Later Mar 26, 2023 64:48

Episode 43: Alles über das Jahr 1986- Wir klären in dieser Folge ein für alle Mal:Welches Raumschiff ist 1986 explodiert?Was war das größte Live-Konzert des Jahres mit 1,3 Millionen Zuschauern?Welchen Song hat Thomas 1986 aufgenommen und wieso klingt der so nach Garage?Wie hat die deutsche Atomindustrie nach Tschernobyl auch das letzte Restvertrauen verspielt?Wieso hat Ronald Reagan den Kokainschmuggel in die USA protegiert?Welche berühmte Mannschaft hat im Finale des Europapokals der Landesmeister 1986 alle Elfmeter verschossen? - Fun facts, hard facts & Nerd FactsSilent Circle Keyboarder Axel Breitung wurde später einer der bekanntesten deutschen Musikproduzenten, der u.a. mit Udo Lindenberg, Wolfsheim, Rednex, DJ Bobo, Andrea Berg und den Wildecker Herzbuben erfolgreich war. Das kann man wohl nur einen breitgefächerten Musikgeschmack nennen.Being boiled von Human League wurde sogar drei mal veröffentlicht, erst 1978 als B Seite auf deren ersten Single "Circus of Death", dann 1981, wobei der Song in UK auf Platz 6 kam und in Deutschland auf 57 und schließlich kam der Song 1986 dann in Deutschland auf Platz 6.Cancel Culture gab es auch schon 1985, so nahmen der Norddeutsche Rundfunk, der Sender Freies Berlin sowie der Bayerische Rundfunk das Lied „aus ethischen Gründen“ aus dem Programm; andere Sender spielten Jeanny nur noch in Hitparaden. Auch im DDR-Rundfunk wurde das Lied nicht mehr gesendet.- Purwien & Kowa LivePodcast Disko 80 goes live! Mit Special Guest, Podcast-Show, Live-performance und erstmalig ein DJ Set von Purwien & Kowa. Das alles findet statt am: Samstag, 24.06. 19:00 Uhr Im Kulturhof LemgrabeEintritt KollekteReservation unter info@kulturhof-Lemgrabe.dewww.Kulturhof-Lemgrabe.deKulturhof LemgrabeDorfstr.221368 Lemgrabe/DahlenburgKommt alle und macht uns und euch glücklich! - LinksPodcasts: https://disko80.buzzsprout.comRSS-Feed: https://feeds.buzzsprout.com/1754816.rssHomepage: http://www.purwienundkowa.comAktuelle CD von Purwien & Kowa: https://ffm.to/puk5Musik von Purwien & Kowa: https://purwienkowa.bandcamp.comBücher von Purwien & Kowa: https://amzn.to/2W9Ftj8Spotify Playlist Episode 43: https://spoti.fi/40msZRP

Mörderisches Kopfkino: „Jeanny“ von Falco

Sprechen wir über Mord?! Der SWR2 True Crime Podcast

Play Episode Listen Later Mar 13, 2023 30:28

Als „Jeanny“ von Falco 1985 die Charts stürmte, löste der Song einen der größten Skandale in der Geschichte der deutschsprachigen Popmusik-Geschichte aus. Wurde da etwa ein Sexualmord verherrlicht? Auch wenn davon im Text gar nicht ausdrücklich die Rede ist? Wie weit darf Kunst gehen? Und wie weit Zensur? Darüber diskutieren der ehemalige Bundesrichter Thomas Fischer und SWR2 Host Holger Schmidt mit der Musikredakteurin Christiane Falk.

song geschichte dar kunst rede charts wurde falco skandale zensur kopfkino jeanny

#2 - De Vriendin met het Groeiende Geheim (S03)

Op Zoek Naar

Play Episode Listen Later Feb 19, 2023 16:34

Henk is stapelverliefd op Jeanny, zij wordt met spoed opgenomen in het ziekenhuis. Als Henk daar aankomt ziet hij tot zijn grote verbazing naast haar bed een wiegje staan.

henk geheim jeanny

Happy Birthday to Us - Episode 43 - AYTO - IBES

Promicore Premium

Play Episode Listen Later Feb 17, 2023 84:13

Rosa macht Torben ein Geburtstagsgeschenk in Falco-Gestalt und so reden die beiden über Österreichs größten Österreicher, besprechen geschmacklosen Grabschmuck und checken die Kandidaten der neuen Staffel "Prominent Getrennt". Außerdem: Was ist dran an den Gerüchten um Torben und Jolina? Premium Content zu "Ich bin ein Star, holt mich hier raus!" Staffel 16, "Are You The One?" Staffel 4 Prominente Person der Woche: Falco Falcos erste Single "Einzelhaft" bei youtube: https://www.youtube.com/watch?v=d7VdiF5YuxU ZDF-Doku über Falco: https://youtu.be/becsvAvapO8 Falcos Grabstein auf dem Wiener Zentralfriedhof: https://de.wikipedia.org/wiki/Falco#/media/Datei:Falco_Grab.jpg Udo Jürgens Grab nebenan: https://de.wikipedia.org/wiki/Udo_Jürgens#/media/Datei:Udo_Jürgens.jpg Interview mit Falco bei youtube: https://youtu.be/g9zASAI5TYs Über Falcos Tod im Rolling Stone: https://www.rollingstone.de/falco-so-starb-der-groesste-oesterreichische-popstar-aller-zeiten-2039611/ "Jeanny" im "heute journal" vom 14.01.1986 bei youtube: https://www.youtube.com/watch?v=mo_R0B0Hqqw

rolling stones staffel kandidaten falco torben happy birthday to us premium content are you the one udo j ayto ibes jeanny jolina wiener zentralfriedhof

ARASENS, TRITON3, and Other Key Advances at GU23

Die Spur der Täter - Der True Crime Podcast des MDR

Play Episode Listen Later Feb 13, 2023 26:09

Guest host Dr. Neeraj Agarwal and Dr. Jeanny Aragon-Ching discuss several crucial studies that will be presented at the 2023 ASCO Genitourinary Cancers Symposium, including ARASENS, TRITON3, and others in prostate cancer, as well as novel therapies in mRCC and urothelial carcinoma. TRANSCRIPT Dr. Neeraj Agarwal: Hello, and welcome to the ASCO Daily News Podcast. I'm Dr. Neeraj Agarwal, your guest host of the ASCO Daily News Podcast today. I'm the director of the Genitourinary Oncology Program, a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. I'm delighted to welcome Dr. Jeanny Aragon-Ching, a medical oncologist and the clinical program director of the Genitourinary Cancers Program at the Inova Schar Cancer Institute in Virginia. Today we will be discussing key abstracts in genitourinary oncology that will be featured at the 2023 ASCO Genitourinary Cancers Symposium. Our full disclosures are available in the show notes, and disclosures for all guests on the podcast can be found on our transcripts at asco.org/podcasts. Jeanny, it is great to have you on the podcast today. Dr. Jeanny Aragon-Ching: Thank you so much, Dr. Agarwal, for having me. Dr. Neeraj Agarwal: So Jeanny, let's begin with Abstract 15 on the update on the ARASENS trial, which Dr. Maha Hussain will present [at the meeting]. In March ‘22, as we know, almost a year ago, the results of the ARASENS trials were published in the New England Journal of Medicine. Darolutamide, which is an AR signaling inhibitor plus androgen deprivation therapy plus docetaxel chemotherapy, significantly reduced the risk of death by 32.5% versus placebo plus ADT plus docetaxel. The effect of triplet therapy, including darolutamide on overall survival, was consistent across prespecified subgroups. However, survival outcomes by disease volume were not reported at the time. Can you please tell us about Abstract 15? Dr. Jeanny Aragon-Ching: Yeah, thank you so much, Neeraj, I would be happy to. So, this new data is actually very crucial for all clinicians. The title of this abstract is “Efficacy and Safety of Darolutamide in Combination with ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study.” So, as a quick reminder, in this trial, patients were randomized 1:1 to the standard dose of darolutamide 600 milligrams twice daily or placebo with ADT and docetaxel in the metastatic hormone-sensitive prostate cancer setting. Now remember, too, high volume disease was defined per the charted criteria, which is visceral metastases and/or four or more bone lesions, of which at least one or more has to be beyond the vertebral column or pelvis. 8And high-risk disease was actually defined per the LATITUDE criteria, which is any two or more of the following three factors: Gleason scores eight or more, bone lesions that are three or more, and the presence of measurable visceral metastases. Of all the 1,305 patients, 77% of them were actually classified as having high-volume disease, and 70% of them had high-risk disease. So, in both of these high-volume and low-volume disease patients, the triplet therapy darolutamide, ADT, and docetaxel actually improved overall survival and hazard ratio was 0.69 and 0.68, respectively. Compared to the placebo and ADT, and docetaxel arm. So overall survival improvement was also significant in patients across all risk, high-risk, or low-risk disease. Dr. Neeraj Agarwal: So, Jeanny, this is great news. So, the main message from this abstract for our audience is that triplet therapy of darolutamide plus docetaxel plus ADT is more efficacious than the doublet of ADT plus docetaxel chemotherapy, regardless of disease volume or risk status. One important caveat I would like to note is that triplet therapy with the darolutamide was not compared with the doublet therapy of ADT plus darolutamide or any androgen receptor signaling inhibitor such as abiraterone or apalutamide or enzalutamide, all of which have shown benefit consistently, regardless of volume status, and in the case of abiraterone, also in the context of high-risk disease setting, as we saw in the LATITUDE trial. Dr. Jeanny Aragon-Ching: Absolutely. I agree with that, Neeraj. Those are important points to consider. Now, moving on to a different setting in prostate cancer across the disease continuum, let's discuss Abstract 18, titled “Rucaparib for Metastatic Castrate-Resistant Prostate Cancer.” This is TRITON3 entering overall survival and efficacy of rucaparib versus docetaxel or second-generation engine pathway inhibitor therapy, which will provide us with some additional data regarding overall survival. Neeraj, based on this new abstract, can you tell us more about TRITON3, which will be presented by Dr. Alan Bryce and colleagues from the Mayo Clinic Arizona? Dr. Neeraj Agarwal: Of course. So TRITON3 is a randomized multicenter open-label phase 3 trial where rucaparib was compared with the physician choice of docetaxel chemotherapy or abiraterone or enzalutamide in those patients who had not received chemotherapy in the metastatic castration-resistant prostate cancer setting, and they had to be progressing on a prior androgen receptor signaling inhibitor in any setting prior. So, they just had to have disease progression either in the hormone-sensitive setting or CRPC setting on one of the AR inhibitors, and they had to have a BRCA1, BRCA2, or ATM alteration. So, in this context, these patients were randomized to rucaparib versus physician's choice of agent, which could again be docetaxel chemotherapy, abiraterone, or enzalutamide. So, OS maturity is 54% in BRCA group and 59% in the intention to treat population. In BRCA1 and BRCA2 populations, radiographic PFS, which was the primary endpoint, was 11.2 months in rucaparib group and 6.4 months in the physician choice arm. In the intention to treat population where you include all patients BRCA plus ATM patients, ATM positive patients. Radiographic PFS was 10 months almost versus 6.4 months with standard of care. And both were statistically significant as well as clinically meaningful improvement in the radiographic progression-free survival with rucaparib over physician's choice of either docetaxel or enzalutamide, or abiraterone. I would like to note that most frequent toxicity which we see with this group of agents is most frequent grade III or more toxicity was anemia, which was present in approximately 24% patients treated with rucaparib. Dr. Jeanny Aragon-Ching: Yeah. This is a really exciting update, Neeraj. What do you think is the key takeaway from this abstract? Dr. Neeraj Agarwal: The key takeaway is that TRITON3 trial met its primary endpoint, and rucaparib significantly improves radiographic progression-free survival in BRCA mutation-positive patients or BRCA ATM-positive patients. Overall survival is still immature, and these results further establish rucaparib as one of the standard of care options in those patients who have metastatic CRPC with prior treatment with the AR signaling inhibitor and who harbor one of the BRCA mutations or BRCA NAT mutations. So, Jeanny, before moving on to the renal cell carcinoma section in this podcast, there is an Abstract in prostate cancer talking about correlation between the source of funding and disparities among patients with advanced prostate cancer. So, I'm referring to that Abstract 40, titled “Source of Funding and Enrollment Disparity in Prostate Cancer Clinical Trials.” I thought this was an interesting abstract. Could you please tell us more about this abstract? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, in Abstract 40, Dr. Riaz and Dr. Bryce, and colleagues actually looked at phase II and III clinical trials that involved prostate cancer patients that reported on patients with age by 65 years, and they got the data from the MEDLINE and Embase databases. Trials recruiting from the United States were considered eligible for analysis by race and ethnicity. So, in terms of race and ethnic enrollment, they found that black patients were significantly underrepresented in the industry's funded trials. Notably, no significant disparity was observed in the US government-funded trials, but Hispanics were also significantly underrepresented in industry-funded clinical trials. However, no significant disparity was seen in terms of older adults overall and by funding sources. Remarkably, Black patients' representation in industry-funded prostate cancer trials has actually decreased over the last three decades. Dr. Neeraj Agarwal: That's concerning. So, what is your key takeaway from this trial, Jeanny? Dr. Jeanny Aragon-Ching: The key message here is that Black and Hispanic men with prostate cancer are significantly less likely to be included in industry-sponsored clinical trials. A bigger concern is that black patients' representation actually continues to decline over time. So these results warrant a really more proactive role by regulatory bodies to ensure that a proportional representation of minorities in the industry trials, which in turn will make these results more applicable to a wider entire population of men with prostate cancer. Dr. Neeraj Agarwal: Thanks, Jeanny. Let's move on to renal cell carcinoma. I saw some innovative research correlating the efficacy of immune checkpoint inhibitors with the time of the day these checkpoint inhibitors were administered. So, interestingly, there were two studies from two different groups of investigators showing very similar results. Please tell us about this innovative research correlating outcomes with immune checkpoint inhibitors with the time of the day these medicines or these drugs were infused into the patients. Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. I think they're very exciting and interesting. So there's actually two abstracts, so Abstract 681 and 678, which we, of course, can discuss separately. So, let's probably start first with Abstract 678. Neeraj, do you want to explain to us further about this abstract? Dr. Neeraj Agarwal: Yes. When our center participated in that abstract, which was led by Dr. Nazli Dizman from Yale University, Dr. Dizman and colleagues examined the relationship between the time of the administration of immune checkpoint inhibitors, or ICIs, as we call them, during the time of the day, and outcomes in patients with metastatic renal cell carcinoma. So, I'd like to point out that previously Dr. Qian and colleagues reported an association between the time of day of immunotherapy infusion and survival outcomes in patients with metastatic melanoma. In this study, Dr. Dizman and colleagues, which included our center also, patients with metastatic RCC who received nivolumab with or without ipilimumab– so these patients all received either nivolumab alone or without ipilimumab. And patients who received less than 25% of infusion after 4:30 pm. were assigned to the early-time of infusion group. So, if they have received less than 25% infusion of these immunotherapies after 04:30 pm in the evening, they belong to the early infusion group, and the rest were assigned to the late infusion group. In the univariate analysis, numerically higher objective responses and time to treatment failure were observed in the early infusion group compared to the late infusion group. So, differences were 33% versus 25% in objective responses in early versus late infusion group. If you look at time to treatment failure, 8.3 months versus 4.4 months in early versus late infusion group. In the multivariate models, which took into account the clinical characteristics such as age, gender, line of treatment, IMDC risk category, histological subtypes, there was a trend towards improved outcomes in those who received these infusions with ICIs early in the day. So, Dr. Dizman concluded that larger randomized and controlled investigations are warranted to examine the impact of this chronal modulation, if you will, on the efficacy of immune checkpoint inhibitors in metastatic RCC sets. Dr. Jeanny Aragon-Ching: Yeah, this is very interesting data, Neeraj. And that actually resonates closely with this other abstract by Fernandez Manias and colleagues in Abstract 681. So, in this abstract, the primary outcome was overall survival, but they did look at other secondary endpoints like time on treatment, time to the next treatment, and overall response rates. Now, because of the small number of events, the authors actually focused on just patients who received second-line immune checkpoint inhibitors. And what they did was they looked at patients who received overall more than 20% of their infusions after 04:30 pm, and they found that those who did receive actually fewer infusions had a significantly shorter time on treatment and had a worse overall survival. And similar results were seen when they looked at those who got more than 50% of their dose of checkpoint inhibitors that were administered after 04:30 pm, so interestingly enough, there was a 16% increase in the risk of death for each 10% increment of checkpoint infusion after 04:30 pm. So the key message here is that administration of checkpoint inhibitors after 04:30 pm is associated, unfortunately, with inferior outcomes. Now, these results should, of course, be further considered in the organization overall of the outpatient clinic as it can impact patient survival and outcomes. Dr. Neeraj Agarwal: Very interesting. So similar results from two independent groups of investigators from two different continents obviously made this research area very appealing and pertinent. Ideally, I think these results should be validated prospectively, but that will take time. But investigators who have already lagged multiple phase III trials should explore validating these results in the last phase 3 trials which have already been reported and where the data on the timing of infusion is available. Once validated, I think these results may profoundly influence how we organize, as you said, Jeanny, the outpatient scheduling of these checkpoint therapy infusions compared to those who are not checkpoint inhibitors. I think this is going to have very interesting data overall, no doubt. Before moving onto bladder cancer, I would like to discuss an important abstract related to testicular cancer patients titled “Longitudinal Evaluation of Plasma MicroRNA-371 to Detect Minimal Residual Disease and Early Relapse of Germ Cell Tumors.” Could you please tell us more about this abstract? Dr. Jeanny Aragon-Ching: Yeah, absolutely, Neeraj. So this is a very interesting up-and-coming Abstract, it's number 407, which will be presented by Dr. Lucia Nappi and colleagues. In this study, clinical patients with stage I germ cell tumor with available plasma samples after they underwent radical orchiectomy were all included. So, they looked at sensitivity, specificity, negative, positive predictive values, an area under the curve in predicting tumor recurrence, and they evaluated the microRNA-371, I'll just call it and truncate it as miR-371, and compared the same operating characteristics of current gold standard diagnostic tests. Relapse-free survival was correlated to post-orchiectomy miR-371 status, which could be either positive or negative. So, at a median follow-up of 41 months, 101 patients with clinical stage one germ cell tumor were included. About 35% of them experienced a disease relapse during that time of follow-up. Now, what they found was miR-371 was positive in about 63% of the relapsed patients, and the miR-371 positivity preceded clinically evident disease by a median of about three months. The specificity and positive predictive values were 100%, sensitivity was like 63%, and negative predictive value was 83.5%, so very high. No false positive results were seen. And, the authors reported that the recurrence-free survival of the patients who had positive post-orchiectomy miR-371 was significantly shorter compared to those patients who had a negative biomarker for the miR-371. So, they concluded that the miR-371 sensitivity correlated with the tumor burden, time between tumor relapse, the microRNA testing, and histology. It was notably a little bit more sensitive in non-seminomas compared to those who had seminoma. Dr. Neeraj Agarwal: Interesting findings, indeed. So, Jeanny, what is the take-home message from this abstract? Dr. Jeanny Aragon-Ching: Yeah, so I think the key takeaway is that microRNA-371 seems to be a good test, like a biomarker for predicting disease relapse in patients with early-stage germ cell tumor. So, additionally, its high specificity and positive predictive value in predicting relapse could really be used and utilized to guide adjuvant therapy, selections, and decisions after orchiectomy. Further validation in other studies, such as swab 1823, are currently ongoing or planned to validate its clinical utility. So Neeraj, moving on to bladder cancer, the last abstract I'd like to mention before we wrap up the podcast is Abstract 563, titled “Utility of ctDNA in Predicting Outcome and Pathological Complete Response in Patients with Bladder Cancer as a Guide for Selective Bladder Preservation Strategies.” Neeraj, can you tell us more about this abstract? Dr. Neeraj Agarwal: Sure. So, this study was led by Dr. Lars Dyrskjøt. He and colleagues evaluated the prognostic value of circulating tumor DNA, or ctDNA, in predicting recurrence in a cohort of 68 patients with muscle-invasive bladder cancer who received new adjuvant chemotherapy prior to cystectomy. So ctDNA was analyzed two times at baseline before new adjuvant chemotherapy and then before surgery or before cystectomy. So, patients had ctDNA assessed before neoadjuvant chemotherapy and then before cystectomy after completion of new adjuvant chemotherapy. At baseline, of the 64 patients, around 60% were ctDNA negative, and 40% were positive for ctDNA. So of those patients who were ctDNA negative, 84% achieved pathologic complete response, while in those who tested ctDNA positive, only 35% achieved their pathologic complete response after surgery. Prior to surgery, 84% of patients were ctDNA negative, and 81% achieved pathologic complete response. While none of the ctDNA-positive patients who were positive before surgery and after neoadjuvant chemotherapy, none of them achieved pathologic complete response, which translates into a positive predictive value of 100% and a negative predictive value of 81% for this test. So based on both ctDNA time points, the probability of ctDNA negative patients to achieve a pathologic complete response was significantly higher than ctDNA positive patients. At a median follow-up of 59 months, ctDNA-positive patients without pathologic complete response demonstrated significantly lower recurrence-free survival and overall survival compared to those who were ctDNA negative. So, I want to repeat that, at a longer follow-up, which Dr. Dyrskjøt will be presenting, ctDNA positive patients without pathologic complete response had significantly lower recurrence-free survival and overall survival compared to ctDNA negative patients. Furthermore, ctDNA status at baseline, which is before neoadjuvant chemotherapy and before cystectomy, was a better predictor of recurrence-free survival compared to pathologic complete response, which is a remarkable finding here, although it's a smaller data set. Dr. Jeanny Aragon-Ching: Agree completely, Neeraj. So, I think the importance here, too, is upon prospective validation in larger data sets, we will find that a negative ctDNA test would help in identifying patients who can benefit more from bladder-sparing strategies. Neeraj, any final thoughts before we wrap up the podcast today? Dr. Neeraj Agarwal: Before I share my final thoughts, Jeanny, I would like to thank you for joining us and sharing your insights. I always find them very valuable. So, thank you so much for taking the time. I would like to wrap up the podcast by saying we are seeing an explosion in the development of novel therapeutic approaches for our patients with genitourinary cancers. At the 2023 ASCO GU meeting, we will have multiple studies with practice-impacting data presented by investigators from around the world. I urge our listeners to come and join us in the meeting not only to celebrate these successes but also to help disseminate these cutting-edge data to practitioners and maximize the benefit for our patients across the globe. I would like to thank our listeners for joining us today. You will find links to the abstracts which we discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review and subscribe wherever you get your podcasts. Thank you so much. Disclaimer:  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  Find out more about today's speakers:  Dr. Neeraj Agarwal @neerajaimms Dr. Jeanny Aragon-Ching Follow ASCO on social media:   @ASCO on Twitter   ASCO on Facebook   ASCO on LinkedIn   Disclosures:  Dr. Neeraj Agarwal:   Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences  Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas  Dr. Jeanny Aragon-Ching:   Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc  Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, AstraZeneca/MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis  Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb , Astellas/Seattle Genetics  Travel, Accommodations, Expenses: Dendreon, Algeta/Bayer, Bristol Myers Squibb, EMD Serono, Astellas Pharma 

united states university black guide dna medicine safety patients os trials phase funding pfizer hispanic yale university advances astrazeneca mir atm notably utility bayer abstract oncology combination merck efficacy relapse prostate cancer hispanics janssen new england journal novartis gleason accommodations latitude agarwal sanofi precision medicine asco genentech amgen brca bristol myers squibb adt takeda rcc brca1 pfs riaz qian nektar bladder cancer brca2 crpc microrna medline eisai icis ctdna emd serono foundation medicine jeanny aveo docetaxel asco gu mayo clinic arizona mrcc seattle genetics neeraj agarwal dendreon embase pharmacyclics janssen oncology transcript dr mei pharma astrazeneca medimmune

Sie mussten sterben – Femizid an Jeanny

Play Episode Listen Later Nov 18, 2022 49:43

Nach jahrelangem Stalking wird Jeanny von ihrem Ex-Partner umgebracht – weil sie eine Frau ist. Ein Femizid, der exemplarisch für ein Problem steht, welches in Deutschland noch zu häufig verkannt wird.

partner radio deutschland frauen beziehung spur polizei stalking mord sterben ermittler ex partner crime time femizid mussten jeanny mdr aktuell nachrichtenradio

Key Posters on Advances in GU Cancers at ASCO22

Social Marketing Nerds – Facebook Ads und Social Advertising Podcast

Play Episode Listen Later May 26, 2022 19:50

Guest host Dr. Neeraj Agarwal, of the University of Utah Huntsman Cancer Institute and the ASCO Daily News editor-in-chief, discusses key therapeutic advances in mRCC and mUC, as well as new research that proposes periodic scans to monitor patients with mCSPC for disease progression, with Dr. Jeanny-Aragon-Ching of the Inova Schar Cancer Institute. Transcript: Dr. Neeraj Agarwal: Hello and welcome to the ASCO Daily News podcast. I'm Dr. Neeraj Agarwal, the director of the Genitourinary Oncology Program, a professor of medicine at the University of Utah Huntsman Cancer Institute, and editor-in-chief of the ASCO Daily News. My guest today is Dr. Jeanny Aragon-Ching, who is a medical oncologist and the Clinical Program Director of Genitourinary Cancers at the Inova Schar Cancer Institute in Virginia. Today, we will be discussing key posters in genitourinary (GU) oncology that will be featured at the 2022 ASCO Annual Meeting. Our full disclosures are available in the show notes and disclosures of all guests on the podcast can be found on our transcripts at asco.org/podcast. Jeanny, it is great to have you on the podcast today. Dr. Jeanny Aragon-Ching: Thanks, Neeraj. It's a pleasure for me to be here as well. Dr. Neeraj Agarwal: Jeanny, let's begin with Abstract 4510. This is a trial that represents a growing interest among researchers worldwide in the microbiome and how it is impacted by antibiotics and how it modulates immune checkpoint inhibitor response. Can you tell us about this study? Dr. Jeanny Aragon-Ching: Thanks, Neeraj, I would be happy to. So, the title of the abstract is, “Characterization of the Microbial Resistome in a Prospective Trial of CBM 588 in Metastatic Renal Cell Carcinoma Offers Mechanism for Interplay Between Antibiotic Use and Immune Checkpoint Inhibitor Activity.” So, this is an interesting abstract that originated likely from the observation that getting antibiotics while on checkpoint inhibitors typically results in worse outcomes, perhaps because antibiotics can clear the normal gut flora and thereby increase these pathogenic antibiotic-resistant bacteria. Now, on the other hand, there were some retrospective studies using a live microbial product called CBM 588, which seems to improve outcomes in patients on checkpoint inhibitors and getting antibiotics. So, the idea, therefore, is that shifting the genes encoding antimicrobial resistance could result in a better checkpoint inhibitor response. So, this Abstract 4510 is a small study conducted by Dr. Nazli Dizman and Dr. Sumanta (Monty) Kumar Pal, and colleagues, and enrolled 29 metastatic clear cell RCC patients with intermediate or poorest disease. And they were stratified into receiving either nivolumab or ipilimumab compared to nivo/IPI with CBM 588. Now stool samples were collected at baseline in week 12. And they did this whole metagenome sequencing to analyze a stool microbiome composition, and they also looked at the antibiotic resistance genes for the most common classes of antibiotics. The results showed an astounding improvement in objective responses. So, 58%, for instance, in nivo/IPI and the CBM 588 arm compared to only 20% in the nivo/IPI arm. And it seems like also the antibiotics resistance genes were also decreased in those getting the CBM 588 alongside nivo/IPI. Therefore, responses were improved by shifting the gut microbiome alone. So, these findings were published actually recently by these authors in Nature Medicine. So, in case anyone wants to take a deep dive, it would be a good interesting read for this dataset. Dr. Neeraj Agarwal: Very interesting, indeed. Jeanny, what is the main message here for our colleagues? Dr. Jeanny Aragon-Ching: I think, Neeraj, the key takeaway message is that this is a very provocative proof of concept trial that suggests shifting the gut microbiome has the potential to improve responses to checkpoint inhibitors and outcomes. So, this is a very up-and-coming trial and is seen also across the board in other cancers. Dr. Neeraj Agarwal: Thanks, Jeanny. Moving on to urothelial cancer, there is a poster that I think is a must-see for our colleagues. This is Abstract 4577 titled, “Defining Platinum Ineligible Patients with Metastatic Urothelial Carcinoma.” Dr. Jeanny Aragon-Ching: So, Neeraj, what can you tell us about this abstract? Dr. Neeraj Agarwal: So, over the past few years, there has been a tremendous evolution in the treatment landscape for patients with metastatic urothelial carcinoma. For over 40 years the standard of care for these patients has been cisplatin-based chemotherapy. However, approximately 50% of patients are cisplatin-ineligible, due to underlying comorbidities, and are offered carboplatin as an alternative. So, although the checkpoint inhibitors pembrolizumab and atezolizumab were approved as first-line therapy for these patients in 2017, the U.S. Food and Drug Administration (FDA) has now restricted the use of first-line pembrolizumab to platinum ineligible patients with metastatic urothelial carcinoma. The challenge we face as oncologists since the FDA restriction is the absence of a formal definition of platinum ineligibility and the inclusion of this definition in the guidelines. So, in Abstract 4577, Drs. Shilpa Gupta and Jonathan Rosenberg, along with the team present an updated consensus definition for platinum ineligibility based on an online survey of 60 genitourinary oncologists in the United States. Based on the results from this survey, any patient with metastatic urothelial carcinoma, meeting 1 of the following 5 clinical and or laboratory parameters should be considered platinum ineligible, and these are 1 of the following: an ECOG performance status of 3 or more, creatinine clearance of fewer than 30 mils per minute, or peripheral neuropathy of grade 2 or more, or heart failure class of 3 or more—so, this is NYHA heart failure class of 3 or more—and lastly, the combination of performance status of 2 or more, plus a creatinine clearance of less than 30 mils per minute. Dr. Jeanny Aragon-Ching: Well, this is a timely update, Neeraj. So, what do you think is a key takeaway from this abstract? Dr. Neeraj Agarwal: These criteria based on simple and easily available clinical and or laboratory parameters will now allow us to readily define platinum ineligibility in our patients with metastatic urothelial carcinoma, which is a need in busy clinics, both in academic and community settings. So, I think once published and obviously once endorsed by guidelines, we really would like to be able to use this criterion to quickly define platinum ineligibility in our clinics. Dr. Jeanny Aragon-Ching: Agree. Yeah. Dr. Neeraj Agarwal: So, Jeanny, let me switch the gears. PSMA testing is a hot topic this year. And there is an abstract that could potentially have an impact on future guidelines, and how we will practice further down the road. So, I'm referring to the Abstract 5088 titled, “Predictive Value of Extra Prostatic Disease Detection by Preoperative PSMAPET for Biochemical Recurrence-free Survival in Patients with Otherwise Localized Prostate Cancer and Who are Treated with Radical Prostatectomy.” So, this is a follow-up analysis of a multicenter prospective phase 3 imaging trial. So, could you please tell us more about this abstract where they are using PSMA PET scan in the preoperative localized prostate cancer setting? Dr. Jeanny Aragon-Ching: Absolutely, Neeraj. So, you may recall that the multicenter prospective phase 3 imaging trial that garnered gallium PSMA approval by the FDA was actually based on this study that looked at the intermediate and high-risk patients with prostate cancer undergoing radical prostatectomy and lymph node dissection, and they underwent prior gallium PSMA PET scanning for pelvic nodal metastases prior to surgery. So, this was actually previously reported by Dr. Calais and group. Now they are reporting on Abstract 5088 as a post hoc analysis of the same population and group of patients looking for extraprostatic disease. And the final pathology was also correlated to look at nodal disease in these patients in order to predict biochemical recurrence, so they follow these patients for biochemical recurrence occurrence. So, of the 36% of patients who did undergo radical prostatectomy after they underwent PSMA PET scan, about 41% of them recurred with biochemical recurrence, and 40% of them underwent some kind of salvage therapy or some treatment. What was very interesting was when they looked at the biochemical recurrence-free survival. It was better in those who were PSMA negative, and that recurrence-free survival was easily about 33 months, compared to only about 7.3 months in those who were PSMA-positive scans. Furthermore, the ones who had the longest and the highest biochemical recurrence-free survival, intuitively, were those who were node-negative and PSMA PET-negative, so probably not surprisingly. And that rate was about 46 months—close to 4 years. Whereas those who are node-positive on final pathology and their PSMA PET was also positive, they only had about 3 months of biochemical recurrence-free survival. Dr. Neeraj Agarwal: Very interesting. So, it looks like the PSMA PET scan is predicting biochemical recurrence-free survival in localized prostate cancer settings. So, Jeanny, what is the key takeaway from this trial? Dr. Jeanny Aragon-Ching: I think, Neeraj, the bottom line is that patients with extraprostatic disease that is detected by their preoperative PSMA PET scan does predict strongly a high risk of biochemical relapse, and this can really be an additional tool that clinicians can use to help inform and guide future therapy. Dr. Neeraj Agarwal: Thanks, Jeanny. The research on preoperative PSMA testing and its implications on future treatment strategies in the setting is going to be really interesting to watch in the very near future. Dr. Jeanny Aragon-Ching: Yes, absolutely. I really think we should also discuss Abstract 5072, along those lines, the importance really of radiographic monitoring for disease progression in patients with metastatic hormone-sensitive prostate cancer. Dr. Neeraj Agarwal: Yes, thanks for reminding and this is Abstract 5072. This is a post hoc analysis of the ARCHES trial, titled, “Radiographic Progression in the Absence of PSA Progression in Patients with Metastatic Hormone-sensitive Prostate Cancer.” During the last several years, we have seen many of these agents typically given for gastric resistant prostate cancer moving upfront to the castration-sensitive prostate cancer setting. This is especially true for androgen receptor access targeting agents such as abiraterone, enzalutamide, and apalutamide, all being now approved for patients with metastatic castration-sensitive prostate cancer. What is noteworthy from all these trials, and is reported in Abstract 5072, is the use of imaging studies to evaluate disease progression. So, in Abstract 5072, Dr. Andrew Armstrong and Dr. Arun Azad performed a post hoc analysis of the ARCHES trial to investigate the concordance between radiographic progression and the PSA Progression as defined by PCWG2 criteria, or between radiographic progression and any rise in the PSA above nadir, in patients who were being treated with this novel hormonal therapies, in this case, enzalutamide for metastatic castration sensitive prostate cancer. And as a quick reminder, ARCHES was a phase 3 trial that showed a significant reduction and radiographic progression-free survival and improved overall survival for patients with metastatic castration sensitive prostate cancer treated with enzalutamide plus androgen deprivation therapy (ADT) versus those treated with placebo plus androgen deprivation therapy. So, very interestingly, the findings from this study indicate that 67% of patients on the enzalutamide plus ADT arm did not have [Prostate Cancer Clinical Trials Working Group 2 criteria] PCWG2-defined prostate-specific antigen (PSA) progression at the time of radiographic progression. And discordance was present in the ADT-only arm as well, where they found 42% of patients on the ADT-only arm had radiographic progression but did not have PCWG2-defined PSA progression. Interestingly, this discordance of radiographic disease progression was also seen with any rise in the PSA above nadir. And I personally found this information to be very clinically relevant when we are seeing the majority of patients actually experiencing radiographic disease progression, not experiencing PSA progression at the same time. Dr. Jeanny Aragon-Ching: Yeah, absolutely. I agree with that, Neeraj. So, very interesting data. So, what do you think is the key takeaway message for the clinicians listening to us? Dr. Neeraj Agarwal: I'll make the message very simple. I think the message is that patients with metastatic castration-sensitive prostate cancer need to be monitored for disease progression with periodic scans, and PSA monitoring alone is not sufficient in the majority of these patients. Again, we cannot undervalue the role of periodic imaging studies in these patients so that we can timely diagnose them to have disease progression. Dr. Jeanny Aragon-Ching: I agree with that. Dr. Neeraj Agarwal: Jeanny, the last abstract I would like to mention before we wrap up the podcast is Abstract 4509, the results from the phase1 live SPARC 001 study. So, can you please tell us more about this study titled, “Phase-1 Live SPARC 001: The Study of Belzutifan in Advanced Solid Tumors,” which is an update of the renal cell carcinoma cohort with more than 3 years of total follow up? Dr. Jeanny Aragon-Ching: Thanks, Neeraj. So, while the current therapeutic landscape for patients with metastatic clear cell renal cell carcinoma (RCC) has changed dramatically over the past several years, with significant improvement in patient outcomes. Most patients unfortunately still experience disease progression on current treatments. So, in-depth molecular profiling of clear cell RCC has revealed recurrent loss of function mutations in VHL in actually greater than 90% of patients. So, the VHL protein, as you will recall, is part of the oxygen-sensing pathway, regulating levels of HIF which is hypoxia-inducible factor protein, it's a transcriptional activator that mediates the response to hypoxic conditions. So, HIF-2α is a key oncogenic driver in RCC. So, previous data you may recall from the phase-1 Live SPARC 001 trial was designed to evaluate belzutifan so, this was a novel HIF-2α inhibitor which showed durable anti-tumor activity and acceptable safety profile in patients with metastatic clear cell RCC. So, in Abstract 4509, Drs. Jonasch and Toni Choueiri presented updated results from this trial after more than 3 years of follow-up. Of the 55 patients enrolled 16% of patients remained in treatment. And 62% of patients had discontinued treatment because of, unfortunately, disease progression. The median progression-free survival (PFS) for the total cohort was 14.5 months. And the overall disease control rate was 80%. Forty percent of patients experienced grade 3 treatment-related adverse events with the most frequent ones being anemia and hypoxia. There were no great 4 or 5 treatment-related adverse events. And these results, therefore, show that belzutifan monotherapy continues to show a high rate of disease control and a safety profile in a heavily treated population of patients with metastatic RCC. So, it is great to see that there were no new safety signals. Dr. Neeraj Agarwal: Very nice data indeed. So, Jeanny, what is the key takeaway message here for our listeners? Dr. Jeanny Aragon-Ching: Yeah, I think the message here is that the use of belzutifan monotherapy continues to show efficacy and safety in patients with metastatic clear cell RCC, which have progressed on multiple prior contemporary therapies, and there are phase 3 trials currently underway. Dr. Neeraj Agarwal: Jeanny, any final thoughts before we wrap up the podcast today? Dr. Jeanny Aragon-Ching: Thanks, Neeraj. I think it's a really exciting time to be in genitourinary (GU) oncology, and I'm truly looking forward to seeing some great sessions at the 2022 ASCO Annual Meeting. Dr. Neeraj Agarwal: Thank you, Jeanny, for sharing your insight with us today. It was a great conversation. And thank you to our listeners for joining us today. You will find links to the abstracts discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcast. Disclosures: Dr. Neeraj Agarwal: Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb, AstraZeneca, Nektar, Lilly, Bayer, Pharmacyclics, Foundation Medicine, Astellas Pharma, Lilly, Exelixis, AstraZeneca, Pfizer, Merck, Novartis, Eisai, Seattle Genetics, EMD Serono, Janssen Oncology, AVEO, Calithera Biosciences, MEI Pharma, Genentech, Astellas Pharma, Foundation Medicine, and Gilead Sciences Research Funding (Institution): Bayer, Bristol-Myers Squibb, Takeda, Pfizer, Exelixis, Amgen, AstraZeneca, Calithera Biosciences, Celldex, Eisai, Genentech, Immunomedics, Janssen, Merck, Lilly, Nektar, ORIC Pharmaceuticals, crispr therapeutics, Arvinas Dr. Jeanny Aragon-Ching: Honoraria: Bristol-Myers Squibb, EMD Serono, Astellas Scientific and Medical Affairs Inc Consulting or Advisory Role: Algeta/Bayer, Dendreon, AstraZeneca, Janssen Biotech, Sanofi, EMD Serono, AstraZeneca/MedImmune, Bayer, Merck, Seattle Genetics, Pfizer, Immunomedics, Amgen, AVEO, Pfizer/Myovant, Exelixis Speakers' Bureau: Astellas Pharma, Janssen-Ortho, Bristol-Myers Squibb , Astellas/Seattle Genetics Travel, Accommodations, Expenses: Dendreon, Algeta/Bayer, Bristol Myers Squibb, EMD Serono, Astellas Pharma Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast expressed their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

united states university moving travel food speaker study cancer patients phase survival consulting fda pfizer psa forty drs absence gu advances astrazeneca bayer treated abstract oncology merck prostate cancer janssen calais novartis posters accommodations cancer care sanofi asco genentech amgen disclosures drug administration fda arches bristol myers squibb adt takeda characterization rcc pfs gilead sciences nature medicine ipi sparc nektar cbm hif eisai asco annual meeting jonathan rosenberg muc psma emd serono foundation medicine jeanny aveo andrew armstrong vhl psma pet ecog mrcc seattle genetics nyha neeraj agarwal arvinas dendreon pharmacyclics clinical program director janssen oncology mcspc toni choueiri mei pharma astrazeneca medimmune

🚀 Serverseitiges Tracking - Metas CAPI als Lösung in der Datenkrise?

Play Episode Listen Later May 19, 2022 52:10

Datenverlust, wohin das Auge reicht; alle Kampagnen auf Blindflug, Retargeting is dead - das apokalyptische Szenario für alle Marketer*innen seit dem sagenumwobenen iOS Update. Wie das Licht am Ende des Tunnels erscheint das serverseitige Tracking und Metas CAPI. Doch was genau können diese beiden Stichworte überhaupt leisten? Können sie Deine Kampagnen retten? Nerd Premiere! Jeanny, Nerd seit 3 Jahren, ist zum ersten Mal im Nerds Podcast! Juhu! Jeanny und Alexander besprechen im Detail, was die Datenkrise mit sich bringt und was für Lösungen sich anbieten. 💡

nerds tracking licht detail marketers auge sung metas tunnels szenario kampagnen retargeting capi juhu stichworte ios updates als l nerds podcast blindflug datenverlust jeanny

Social Marketing Nerds

Play Episode Listen Later May 19, 2022 52:10

nerds tracking licht detail marketers auge sung metas tunnels szenario kampagnen retargeting capi juhu stichworte ios updates als l nerds podcast blindflug datenverlust jeanny

🚀 Serverseitiges Tracking - Metas CAPI als Lösung in der Datenkrise?

Termfrequenz: Online Marketing Podcasts zum Thema SEO / SEA / Affiliate Marketing / Social Marketing / Google Analytics / Goo

Play Episode Listen Later May 19, 2022 52:10

nerds tracking licht detail marketers auge sung metas tunnels szenario kampagnen retargeting capi juhu stichworte ios updates als l nerds podcast blindflug datenverlust jeanny

Hillsong: A Megachurch Exposed... a Call to Truth

Play Episode Listen Later Mar 31, 2022 70:48

Hilary, Rachel, and Jeanny sit down to talk about the 3 episode docu-series "Hillsong: A Megachurch Exposed". After watching the docu-series together, they debrief and talk through the impact that Hillsong has had on christian culture, the current condition of the church, and the hope and redemption that could come out of this situation.

god jesus christ church truth documentary exposed fresh start hillsong docuseries megachurch biblical teaching hillsong church jeanny hillsong a megachurch exposed redeption

Romans 8 - Part 2 with Special Guest Jeanny Alexander

god jesus christ bible holy spirit romans new testament apostle paul romans 8 romans 6 christian living understanding the bible jeanny

Play Episode Listen Later Mar 23, 2022 42:07

In the second episode on Romans 8, Rachel and Hilary with special guest Jeanny Alexandre walk through the second half of Romans 8. In this authentic conversation, Rachel, Hilary, and Jeanny cover a range of topics including salvation, judgment vs. accountability, and predestination. Here is to another day of bringing God into culturally relevant conversations, and making sure the gospel is never boring.

The Scratch Cast - The Alternative Music Podcast - Episode 20: “Smell Ya Later”

The Scratch Cast: The Alternative Music Podcast

Play Episode Listen Later Mar 17, 2022 102:37

The Scratch Cast - The Alternative Music Podcast - Episode 20“Smell Ya Later”18th March 2022Perhaps we're pushing it calling this a monthly podcast now, but after what feels like ages (time for Snedds to watch all five seasons of The Wire), Episode 20 of The Scratch Cast - The Alternative Music Podcast is finally here. Grant and Snedds discuss their drunken experience of Kneecap live at The Barrowlands Ballroom, Snedds reviews the Foo Fighters' new slasher comedy Studio 666 and it's back to business (after the submission special) as we see the return of the metaphysical pinboard and the rest of our usual segments. On our singles swap this month we review “Working All The Time” by experimental hip-hop, r & b and pop artist Xenia Rubinos and “I Know I'm Not Easy To Like” by indie pop-rockers Pip Blom. On the next episode, we'll be discussing “Everything Is Going To Be Alright” by Princess Chelsea and “Circles” by Basement Revolver.On submission corner, we review the eponymous debut album from Austrian Post/Indie/Punk outfit Jeanny and discuss the singles Hate Mail and False Faces from Edinburgh's outspoken funk-punk band Radio Fury.And finally, on our album reviews, we discuss “Animorphs” the sixth album from Norwegian hardcore/indie-punk outfit Honningnbarna and “The Lightness Of The Dread” from East Kilbride singer-songwriter Michael Timmons.Check out the episode below or via any of the links at the bottom of the page. Sit back, relax and listen to Episode 20: ”Smell Ya Later”.If you want to support the show, you can buy us a coffee here: https://www.buymeacoffee.com/headscratcherIf you're wondering what our review scores relate to, check out our rating system below:1/10 - Destroy without listening2/10 - Rancid bin juice (bathe afterwards)3/10 - Hot garbage (avoid)4/10 - Meh (not worth going back to)5/10 - Forgettable (one or two good songs)6/10 - Just OK (for fans of the genre)7/10 - Good (quite like it)8/10 - Very good (must listen)9/10 - Exceptional (absolutely love it)10/10 - Practically flawless (unmissable)Don't forget to subscribe to The Scratch Cast on your favourite streaming/podcast service so you never miss an episode. Please leave a nice review :)Spotify: https://spoti.fi/2KYNkI2Apple Podcasts: https://apple.co/3082hBjGoogle Podcasts: http://bit.ly/2QXCohyYouTube: http://bit.ly/2QXtlxoDeezer: http://bit.ly/34sjqDACastbox: http://bit.ly/34sEJoHTuneIn Radio: http://bit.ly/2QVt8ur& more: https://podfollow.com/the-scratch-cast-podcastAll music clips are used as a teaser only and remain the property of the respective artists.Peace.

Romans 8 - Part 1 with Special Guest Jeanny Alexander

god jesus christ conversations bible prayer holy spirit romans holy romans 8 condemnation one verse jeanny

Play Episode Listen Later Mar 16, 2022 33:37

Hilary and Rachel talk through Part 1 Romans 8 this week with special guest Jeanny Alexandre . This conversations is all about life with the Holy Spirit. A life free of condemenation and shame. We dive deep into what life in the spirit tangibly looks like and how we can live differently. Here is to another day of bringing God into culturally relevant conversations, and making sure the gospel is never boring. To learn more about Jeanny's podcast One Verse go to: https://open.spotify.com/show/49jUfqADX37mMT1IPCoTPr?si=428e232b41084da4

Patricia Aulitzky über Freuden und Hürden des Schauspielens

Kunst und Klischee

Play Episode Listen Later Feb 24, 2022 58:32

Patricia Aulitzky ist eine österreichisch-schweizerische Schauspielerin, bekannt aus Film und Fernsehen: "Falco - Verdammt wir leben noch" (2008), "SOKO Donau" (2009), "Lena Lorenz" (2015-2018), "Die beste aller Welten" (2017), "Das Mädchen aus dem Bergsee" (2020), "Jeanny - das 5. Mädchen2 (2022) sind nur einige wenige Auszüge ihrer Filmografie.Wir haben mit Patricia darüber gesprochen wie sie überhaupt zum Schauspiel kam, über Schubladen-Denken im TV-Business, über Ageism bei Schauspielerinnen ab 40, über Oxytronic -- und was es bedeutet wenn die Kamera ständig auf einen gerichtet ist. Diese Podcast Folge ist gefördert durch die Stadt Wien /MA7, sowie Audiamo+.

film kamera welten ageism schauspielerin diese podcastfolge schauspiel freuden und h schauspielerinnen schubladendenken das ma filmografie jeanny bergsee

Romans 6: Abounding Grace, Dying to Yourself, and the Role Sin Plays in our Lives with Special Guests Hannah Rosenfarb & Jeanny Alexandre

god jesus christ conversations bible gospel romans sin scripture dying righteousness plays special guests alexandre romans 6 bible readings reading scripture abounding grace one verse jeanny

Play Episode Listen Later Feb 23, 2022 53:42

Hilary and Rachel talk through Romans 6 this week with special guests Hannah Rosenfarb & Jeanny Alexandre . This highly engaging conversation ranges from addressing how do we sin but let grace abound, walking in authority, understanding the severity of sin, and dying to yourself. Here is to another day of bringing God into culturally relevant conversations, and making sure the gospel is never boring. To learn more about Jeanny's podcast One Verse go to: https://open.spotify.com/show/49jUfqADX37mMT1IPCoTPr?si=428e232b41084da4

Jeanny - das fünfte Mädchen #27

Series Talk mit Mona Litha und Jamal Braun

Play Episode Listen Later Feb 20, 2022 103:14

.... Jeanny,quit livin´on drams, Jeanny, life is not what it seems.... Wer kennt ihn nicht, den Dauerohrwurm von Falco - ein Klassiker, der jetzt zu Falco´s 65. Geburtstag verfilmt wurde, lasst euch überraschen, wie wir ihn finden... Unser Intro: Epic Theme No. 2 "Majestic/Epic" by Steven O'Brien https://soundcloud.com/stevenobrien Creative Commons — Attribution 3.0 Unported — CC BY 3.0 Free Download / Stream: https://bit.ly/epic-theme-no-2 Music promoted by Audio Library https://youtu.be/nD6_aQIJgW0 --- Send in a voice message: https://anchor.fm/monalithajamalbraun/message

music geburtstag klassiker audio library das f falco free download stream nfte jeanny

Falco, österreichischer Musiker (Geburtstag, 19.02.1957)

WDR ZeitZeichen

Play Episode Listen Later Feb 18, 2022 13:44

Er verkörperte den Sound der achtziger Jahre mit Hits wie "Der Kommissar" und "Jeanny": der österreichische Musiker "Falco". Seine Erfolgssingle "Rock me Amadeus" führte 1985 als erster deutschsprachiger Song die US-Charts an. Der als exzentrisch geltende Künstler, der zeitlebens umstritten war und an Alkoholsucht litt, starb im Winter 1998 im Alter von 40 Jahren bei einem Verkehrsunfall in der Dominikanischen Republik.

sound song er hits musik geburtstag musiker popstars amadeus falco kommissar verkehrsunfall alkoholsucht dominikanischen republik rock me amadeus der kommissar jeanny us charts

1985 - Falco startet durch mit "Falco 3"

1001 Musikgeschichten

Play Episode Listen Later Feb 16, 2022 24:58

Er war ein äußerst charismatischer Typ, ein Superstar - aber er hatte auch mit großen Dämonen zu kämpfen... In dieser Folge geht's um den österreichischen Popstar Falco. Mitte der 80er war er eigentlich schon abgemeldet, doch dann taucht er mit einem Album voller Hits wieder auf! "Rock Me Amadeus", "Jeanny", "Vienna Calling" etc. - mit seiner dritten Platte gibt Falco sein Meisterstück ab, driftet aber auch zunehmend in Exzesse ab. Lutz Stolberg und Carsten Richter unterhalten sich darüber und lassen auch Wegbegleiter von Falco zu Wort kommen.

er hits durch superstar wort kultur mitte wien 80s typ startet falco platte wegbegleiter meisterst 80er exzesse rock me amadeus jeanny austropop vienna calling

07 | Monika Linder. Thema: Falco

Soltis Studiocast

Play Episode Listen Later Feb 6, 2022 61:51

Am 6. Februar 1998 starb Falco; am 19. Februar wäre der österreichische Musiker 65 geworden. 24 Jahre nach seinem Tod gewinnnt der Musiker Jahr für Jahr an Kultstatus – und seine Songs («Der Kommissar», «Rock Me Amadeus», «Jeanny», «Out of The Dark») gelten mittlerweile als Evergreens. Christoph Soltmannowski und Monika Linder sprechen über Falco – und versuchen, das Mysteriums seines Lebens und Geheimnis seines Erfolgs zu ergründen. Soltis Studiocast gibt es als Videoversion https://www.youtube.com/playlist?list=PL7bPd-OGwljyV6SfqlfZv19vaQMvUJfAe und als Audiopodcast auf Spotify, Apple Podcast und weiteren Plattformen. Podcast produziert von Christoph Soltmannowski / Tablecast. Soltis Studiocast gibt es als Videoversion https://www.youtube.com/playlist?list=PL7bPd-OGwljyV6SfqlfZv19vaQMvUJfAe und als Audiopodcast auf Spotify, Apple Podcast und weiteren Plattformen. Podcast produziert von Christoph Soltmannowski / Tablecast.

spotify dark thema apple podcast lebens tod geheimnis musiker plattformen erfolgs falco linder kultstatus evergreens rock me amadeus jeanny mysteriums

Schweizer Hitparade vom 2. Februar 1986

Bestseller auf dem Plattenteller

Play Episode Listen Later Jan 30, 2022 59:47

«Jeanny», ein Name, ein Skandal! 1985 löste der österreichische Popstar Falco eine erbitterte Diskussion aus, wie weit man mit einem Song gehen kann, in dem es um Gewalt an Frauen geht. Dabei sei doch alles nur «Musik» relativiert unser Musikexperte Ralph Wicki.

song dabei musik frauen diskussion gewalt skandal ein name jeanny schweizer hitparade

Moving Abroad Podcast #33: een guesthouse in Valencia, met Jeanny Grevelink

The Moving Abroad Podcast

Play Episode Listen Later Jan 5, 2022 44:48

Je bent nooit te oud om het roer om te gooien en in het buitenland een bed & breakfast te beginnen. Geloof je me niet? Luister dan naar het verhaal van Jeanny Grevelink. Zij was vijftig, had leuk werk en een gezellig boerderijtje op een prachtige plek. En toch... knaagde er iets. Was dit het dan tot haar pensioen? Ze verruilde het Nederlandse platteland voor een huis met twee gastenverblijven in de buurt van Valencia. Twaalf jaar later voelt ze zich er nog steeds ontzettend thuis. Maar een nieuw avontuur sluit ze niet uit, ze is ten slotte pas 62. Hoe kwam ze in Valencia terecht? Waarom bleef ze, toen haar partner ermee stopte? En hoe is het om in je eentje in een ander land te wonen? Ik vroeg het Jeanny op de warmste oudjaarsdag ooit met op de achtergrond Spaanse mussen en al vroeg feestvierende Spanjaarden. Allemaal terug te luisteren in deze aflevering. Download het gratis e-book "Vijf redenen waarom wonen in het buitenland zo fantastisch is" -> www.movingabroadpodcast.nl/e-book Connect op instagram -> @movingabroadpodcast. Vragen en feedback -> mail naar hallo@movingabroadpodcast.nl of stuur een DM op instagram Gratis Kick-Start sessie -> www.movingabroadpodcast.nl

dm maar ze waarom ik luister nederlandse zij vragen allemaal geloof vijf spaanse guest house moving abroad twaalf spanjaarden jeanny

34 - Change-Management: Veränderungen sind die neue Normalität. So nutzt du diese als Chance. | Jeanny Gucher & Teresa Zimmermann

State of Process Automation

Play Episode Listen Later Dec 11, 2021 39:27

In dieser Episode spreche ich mit Jeanny Gucher & Teresa Zimmermann, CO-Founder & CEO, highest excitement GmbH (our patterns) Wir sprechen über folgende Themen: Wie kann man die Unternehmenskultur aktiv beeinflussen? Warum scheitern viele Veränderungen in Unternehmen? Wie geht man Widerständen von Mitarbeitern um? Wie kreiert man eine Unternehmensversion, die alle Führungskräfte und Mitarbeiter motiviert? Interviewgast: Jeanny Gucher LinkedIn: https://www.linkedin.com/in/jeanny-gucher-our-patterns/ Interviewgast: Teresa Zimmermann LinkedIn: https://www.linkedin.com/in/teresa-zimmermann-vienna/ Podcast-Moderator: Christoph Pacher LinkedIn: https://www.linkedin.com/in/pacherchristoph/

ceo co founders diese unternehmen mitarbeiter change management mitarbeitern die neue normalit gmbh widerst zimmermann unternehmenskultur nutzt du themen wie jeanny

Folge 37 "Falco 3 – Falco" / "Das Licht dieser Welt" – Gisbert zu Knyphausen / "Don’t know what I am" – Alien Boy

Familienalbum - der Musikpodcast

Play Episode Listen Later Oct 6, 2021 63:24

In unserer Folge 37 zeigen wir uns immer wieder begeistert! Ob das vor allem auch an der Neuerscheinung von Alien Boy, „Don‘t Know What I Am“ liegt, die Christoph in Folge 36 mit großer Vehemenz angepriesen hat, hört Ihr am Ende der Folge. Los geht's mit dem Klassiker Falco, der mit Falco 3 von Andreas auf die Agenda gesetzt wurde. Mit an Arroganz grenzendem Selbstbewusstsein war er 1985 der vielleicht erste deutschsprachige Rapper. Wie das dem bei dieser Musikrichtung notorisch nörgelnden Nesthäkchen Sebastian gefällt wird gleich zu Beginn der Folge aufgelöst. Im Sandwich der beiden Alben platzieren wir Sebastians Überraschung, die mit rheinhessischem und/oder friesischen Adel aus dem Hause „Knyphausen“ daherkommt! Der Singer/Songwriter Gisbert zu Knyphausen war 2017 mit „Das Licht dieser Welt“ mehrsprachig und auch musikalisch vielfältig unterwegs, ob das alle Familienmitglieder überzeugt gibt es mit vielen mehr in Folge 36.

#11 Vergeltung oder Vergebung: 'Long Way Down' vs. 'Wer ist Edward Moon?'

Das Goldene Vlies / Der Literaturpodcast

Play Episode Listen Later Sep 15, 2021 80:39

Gibt es so etwas wie Gerechtigkeit im Angesicht von Mord? Kann der Tod des Täters den Tod des Opfers wieder gut machen? Und wenn nicht, wieso sterben dann immer noch so viele in den Todestrakten durch die Spritze oder auf der Straße durch Selbstjustiz?Und falls doch, was ist es, dass am Tod des Mörders Genugtuung verschafft? Und ist es diese Genugtuung Wert in Kauf zu nehmen, nicht den Richtigen erwischt zu haben? Diese Fragen werfen Jason Reynolds in ‘Long Way Down' und Sarah Crossan in ‘Wer ist Edward Moon?' auf. Beide begleiten jeweils einen jüngeren Bruder, deren älterer Bruder in einen Mordfall verwickelt ist. Bei dem einen ist der Bruder das Opfer, bei dem anderen (vermeintlich) der Täter.Was diese Tragödie für sie und ihre Familien bedeutet, beleuchten beide in fast poetischer - und dabei vollkommen reduzierter - Sprache eindrücklich. Hier geht es zu der Musik von meinem Gast Jasmin aka Jeanny:https://open.spotify.com/artist/4ZjQ8ZZwne4Nfefu9vilRA Auf Instagram zu finden @jeannymusic oder mit ihrer Band @janko_music_Ihr könnt den Podcast auch bei Castbox finden:https://castbox.fm/channel/Das-Goldene-Vlies--Der%C2%A0Literaturpodcast-id3705436?country=us Zitate beziehen sich auf folgende Ausgaben: Reynolds, Jason, Long Way Down, Faber & Faber, London, 2018 Crossan, Sarah, Wer ist Edward Moon?, Mixtvision, München, 2020 04:57 Reynolds, Jason, Long Way Down, Vorwort05:17 Reynolds, Jason, Long Way Down, S. 32509:24 Crossan, Sarah, Wer ist Edward Moon?, S. 8f14:11 Reynolds, Jason, Long Way Down, S.Performance Theater Heidelberg & Jasmin16:40 Reynolds, Jason, Long Way Down, S. 34f22:24 Reynolds, Jason, Long Way Down, S. 4824:10 Crossan, Sarah, Wer ist Edward Moon?, S. 87-93Sprecher:innen: Jasmin; Kristina Kelbler; Adrian Beierbach; Christoph Fischer35:58 Reynolds, Jason, Long Way Down, S. 36f38:11 Reynolds, Jason, Long Way Down, S. 18539:44 Reynolds, Jason, Long Way Down, S. 14644:03 Crossan, Sarah, Wer ist Edward Moon?, S. 250f45:21 Crossan, Sarah, Wer ist Edward Moon?, S. 27547:58 Reynolds, Jason, Long Way Down, S. 228f49:26 Crossan, Sarah, Wer ist Edward Moon?, S. 185f51:42 Crossan, Sarah, Wer ist Edward Moon?, S. 30654:42 Crossan, Sarah, Wer ist Edward Moon?, S. 321f01:02:16 Crossan, Sarah, Wer ist Edward Moon?, S. 28901:08:48 Reynolds, Jason, Long Way Down, S. 4101:10:35 Reynolds, Jason, Long Way Down, S. 4401:12:06 Reynolds, Jason, Long Way Down, S. 2301:12:42 Reynolds, Jason, Long Way Down, S. 23 See acast.com/privacy for privacy and opt-out information.

Caso Jerry Westrom e Jeanny Childs

Café Crime e Chocolate

Play Episode Listen Later Aug 8, 2021 50:51

E de repente a máscara do pai perfeito, cidadão exemplar cai com o peso do DNA.Todas fontes utilizadas para pesquisa deste episodio, estão em nossa pagina www.crimesemisteriosbrasil.com

child dna todas caso ancestry teste mapa materia biologia provas genealogia genetica quimica jeanny pericia

Falco - Falco 3

Alben für die Ewigkeit

Play Episode Listen Later Aug 4, 2021 22:23

Mozart hat ihn reich und berühmt gemacht. Mit Falco 3 und dem Riesenhit Amadeus hat sich Falco an die Spitze der europäischen Popmusik geschossen. Aber das Album ist viel mehr, als der Charterfolg zeigt. Es ist nicht weniger als ein neuer Weg dorthin.

weg mozart spitze falco popmusik rock me amadeus jeanny

Le syndicaliste Jeanny Morard prend sa retraite après avoir passé 16 ans à la tête d'UNIA Valais

Podcasts Rhône FM

Play Episode Listen Later Jul 30, 2021

pass avoir prend retraite valais jeanny

Jeanny Morard, secrétaire régional d'UNIA Valais, prend sa retraite après 37 ans de lutte

Podcasts Rhône FM

Play Episode Listen Later Jul 29, 2021

lutte prend secr retraite taire valais jeanny

Vom Ende der Einsamkeit... und der Todesstrafe?

Das Goldene Vlies / Der Literaturpodcast

Play Episode Listen Later Jun 15, 2021 14:18

Um euch einen kleinen Einblick in meine Podcastproduktion und einen feinen Ausblick auf die neue Staffel zu geben, stelle ich euch während der Sommerpause immer eine Person vor, mit der ich gerade zu einer neuen Folge spreche und arbeite. Denn in der neuen Staffel, die im Herbst 2021 startet, werde ich regelmäßig Gäste haben, mit denen ich mich dann über ein Thema und zwei Bücher dazu unterhalte. In dieser Mini-Episode reden wir aber vor allem über Musik, Literatur und andere Podcasts - aber natürlich gibt's einen kleinen Ausblick auf unsere gemeinsame Folge im Herbst...Playlist zu Benedict Wells ‘Vom Ende der Einsamkeit': https://open.spotify.com/playlist/4sL8D77Ex8HLtOKMq3m6q1?si=iIZdWzDdR1WIZCF9p60RFA&nd=1‘Wach' von Jeanny: https://open.spotify.com/album/1lKHC3MBz01napJiXaduLL?highlight=spotify:track:3jMvQZRFwqVwq8lT9U2maNWells, Benedict, ‘Vom Ende der Einsamkeit':https://www.diogenes.ch/leser/titel/benedict-wells/vom-ende-der-einsamkeit-9783257244441.htmlMordlust - Der Podcast:https://open.spotify.com/show/6wPqbSlsvoi3Rgjjc2Sn4R See acast.com/privacy for privacy and opt-out information.

podcasts thema musik playlist einblick ausblick staffel herbst sommerpause literatur einsamkeit wach todesstrafe vom ende podcast produktion jeanny

22: Strawboscopic Join Her FREE DIY-With-Us Music Promo Challenge

Hustle - Industry Advice for Womxn in Music

Play Episode Listen Later May 13, 2021 31:30

LISTEN NOW to this week's Podcast with Jeanny Ricci Creative Director Strawboscopic 15+ year experienced art director, natural-born creative, and enthusiastic music lover. Jeanny is the founder and creative director of Stroboscopic an international creative studio dedicated to Making Music Visible. This free 5 Day Challenge reveals how Independent Music Artists can start to create an effective, bespoke and budget-friendly promotion strategy by taking advantage of our DIY-With-Us system. Find Out More here: https://strawboscopic.com/diy-with-us-music-promo-challenge

promo day challenge us music jeanny independent music artists

Learning Life lessons with Jeanny Alexandre: Part One

Fuel For Freedom

Play Episode Listen Later Apr 5, 2021 22:24

Join Tony as he interviews Jeanny Alexandre, she has a masters in psychology and is the Director Of Discipleship at Harborside Church. In this discussion we learn about some significant lessons she learned that has helped fuel her success and add to her life. Listen in to see if some of those lessons she learned can help you in your life. Connect with Tony:Aim your sights

family health culture society funny personality selfhelp life lessons alexandre life skills wealth building social skills hidden potential learning life jeanny

8 - Bedankt voor uw stem op Karin Ollongren

AAAlandje

Play Episode Play 60 sec Highlight Listen Later Mar 26, 2021 50:43

Functie elders voor Pieter Omtzigt, het CDA-Kamerlid uit Twente dat er geen doekjes om windt dat hij zich verraden voelt door het kabinet dat hij gesteund heeft. Liet minister Kajsa Ollongren dat expres zien? De avondklok is het andere onderwerp dat geknipt en geschoren wordt. Net als Anja. haar kapster blijkt een diplomaat te paard.In een kredietwaardig land, op zoek naar waardigheid. musical credits ccncabel kjartan (jingle)lena orsova (tune with the best govt in de world)joshua empyre – opening tuneOnder journalistieke verwijzing (art 15 Auteurswet) het epische Jeanny van Falco. Buymeacoffee.com/coronica of vriendvandeshow/aaalandje

stem voor anja falco cda politiek vvd twente bedankt d66 ministerie pieter omtzigt liet aivd ollongren jeanny kajsa ollongren

Un tour d'actualité avec Jeanny Lorgeoux

Ça se passe en Val de Loire

Play Episode Listen Later Feb 2, 2021 10:50

Crise sanitaire, vie économique, affaires scolaires et dossiers politiques : Jeanny Lorgeoux, réélu avec près de 40% des voix en juin dernier, répond aux questions d'actualité de Denis Deshayes dans sa mairie de Romorantin-Lanthenay.

crise un tour jeanny

Resumen de la visita de Jeanny Arreaza a lo mejor del podcast de Jeremías Martorell

Jeremias Martorell Podcast

Play Episode Listen Later Dec 31, 2020 10:54

Multimedia makeup artist, Jeanny Arreaza es especialista en maquillaje, bodypainting y diseño.Ha colaborado con importantes canales de televisión del mercado hispano como Telemundo y Venevision; y ha participado en decenas de videos musicales y comerciales. Su pasión por la belleza y el maquillaje la ha impulsado a estudiar y mantenerse al día con las últimas novedades y tendencias. Y su trayectoria familiar la motivó a abrir su propio emprendimiento, que ofrece actualmente más de 10 servicios en el área del maquillaje.Instagram: https://www.instagram.com/jeremiasmar...LinkedIn: https://www.linkedin.com/in/jeremiasm...Twitter: https://twitter.com/jeremartorellFacebook: https://www.facebook.com/Jeremias-Mar...TikTok: tiktok.com/@martorelljeremiasSnapchat: https://www.snapchat.com/add/jeremart...Sitio web: https://jeremiasmartorell.com/Arbol de enlaces: https://jeremiasmartorell.com/links/YouTube: http://www.youtube.com/c/JeremiasMart...

tiktok makeup visita resumen lo mejor multimedia telemundo sitio jerem arbol martorell jeanny

Falco - 3 (1985) - Part 2

Permanent Record Podcast

Play Episode Listen Later Dec 8, 2020 106:34

Episode 119: Falco - 3 (1985) - Part 2 Wilkommen! Brian and Sarah are back to talk more about Falco-- or, as Brian likes to call him, The Austrian Slick-Meister-- and his third album, 3, released in 1985. This episode covers the two remaining singles, "Jeanny" and "Rock Me Amadeus," along with the album track "Männer des Westerns - Any Kind of Land." The hosts explore the controversy surrounding the song "Jeanny" and talk about the many classic film references in the video. Brian even delves a little bit into the world of true crime, which he does warn listeners about at the start of the episode. "Männer des Westerns" understandably prompts a discussion about Western society and pop culture, and when the hosts turn their attention to "Rock Me Amadeus," they also mention the 1984 movie that may (or may not!) have inspired the song. Also during this section, the hosts mention The Simpsons, armadillos, and Frankie Goes to Hollywood. And it probably isn't too surprising for regular listeners to learn that Brian does find a way to slip into "James Bond podcast" mode for a brief time during this episode, but how in the world did Brian and Sarah end up having an animated discussion about baking soda? Jeanny Männer Des Westens - Any Kind of Land Rock Me Amadeus Extra Credit For extra credit, Brian and Sarah talk about the 2008 biopic, "Falco: Dammit, We’re Still Alive!" starring Austrian singer Manuel Rudy. They even briefly mention the fact that there have been two musicals about Falco, with a third allegedly in the works. Final Review and Rating Even though the hosts didn't cover every track on the album in these episodes, they provide final reviews of the entire album, along with a record-adapter rating. Does 3 end up getting more than 3 record adapters from the hosts? Listen and find out! Watch the videos discussed here: Jeanny Männer Des Westens (2007 release) Rock Me Amadeus Excerpt from The Simpsons episode "A Fish Called Selma" Watch Out Armadillos Read more at http://www.permanentrecordpodcast.com/ Visit us at https://www.facebook.com/permrecordpodcast Follow us at https://twitter.com/permrecordpod Check out some pictures at https://www.instagram.com/permanentrecordpodcast/ Leave a voicemail for Brian & Sarah at (724) 490-8324 or https://www.speakpipe.com/PermRecordPod - we're ready to believe you! Cool Stuff Alert: Visit our new PRP Shop at https://www.redbubble.com/people/bluezonenetwork/ Visit Chattanooga’s #1 Newsletter!!

hollywood land western james bond newsletter simpsons austrian still alive westerns falco frankie goes wilkommen rock me amadeus jeanny final review

Jeanny Pearson - Cudowna podróż Freddiego Yatesa (fragment) [Wyd. Akapit Press]

Czyta: #TataMariusz

Play Episode Listen Later Nov 16, 2020 7:57

KONKURS/ROZDANIE zwał jak zwał a może ktoś książeczkę by chciał? w komentarzu pod tym postem na FB: Napisz (zgodnie z filmikiem) odpowiedź na pytanie: Czy poradziłbyś sobie ze zjedzeniem CAŁEJ SUROWEJ CEBULI? 3 najbardziej odjechane odpowiedzi zostaną nagrodzone książką Jeanny Pearson - Cudowna podróż Freddiego Yatesa. Link do recenzji: https://tatamariusz.pl/jenny-pearson-cudowna-podroz-freddiego-yatesa/ Link do książki: https://www.akapit-press.pl/glowna/cudowna-podroz-freddiego-yatesa-583.html Treść, za zgodą Wydawnictwa Akapit Press dostępna tutaj: https://tatamariusz.pl/category/wydawnictwo-akapit-press/ Muzyka: https://www.looperman.com/loops?mid=MatthewForest . : . : . : . : . : . mama; tata; dziecko; bajka; bajkowy; baśnie; baśniowy; usypianki; zasypianki; słuchowisko; czytanki; dobranocka; audiobook; podcast; do snu; terapeutyczne; edukacyjne

press podr pearson czy fragment muzyka jeanny

Sonja Pohlmeier - hilft Dir - Deine Vergangenheit zu transformieren und Deine Zukunft zu kreieren

COACH to go

Play Episode Listen Later Oct 28, 2020 44:44

Sonja Pohlmeier begleitet seit 25 Jahren Menschen auf dem Weg in ihre wahre Größe. Sie biete verschiedene Seminare an wie zum Beispiel Schlüssel zu Selbstliebe, der Jeanny Effekt - Wie du in deine wahre Größe kommst, Akasha Healing und die Ausbildung zum Coach. Wann ihr neues Programm mit online Kurs erscheint und was dahinter steckt - erfährst Du in dieser Folge COACH to go!

Eps 110 - Sdri. Jeanny Manuputty - Hati-hati Memilih Tempat Berteduh

Sapu Tangan

Play Episode Listen Later Oct 22, 2020 3:38

Sapaan hari ini dilayani oleh Sdri Jeanny Manuputty, perwakilan Komisi Pemuda GKI Bintaro Utama yang berjudul "Hati-hati Memilih Tempat Berteduh". Renungan dibacakan dari buku renungan "Youth for Christ" terbitan YKB GKI. Kiranya firman Tuhan ini dapat menyapa setiap kita agar tetap berpengharapan di tengah kehidupan kita. Tuhan Memberkati.

jesus christ youth hati tuhan tempat memilih renungan jeanny kiranya tuhan memberkati

Folge 2 - VFX Fiesta

440Hz

Play Episode Listen Later Sep 27, 2020 55:06

Wer würde nicht gerne auf einer Insel Urlaub machen? Warum sind diese Menschen Kugeln? Wer ist eigentlich Jeanny und warum reden alle Leute über sie? Wo ist Jona hin? WIR WISSEN ES AUCH NICHT! Spotify Playlist zur Folge: https://open.spotify.com/playlist/6juT7lFBD256EXg1FZ0MUw Social Media: @440HzCast E-Mail: 440HzCast@gmail.com --- Send in a voice message: https://anchor.fm/440hz/message

wo leute fiesta spotify playlist jona jeanny

A Miracle but not what you think! With Special Guest Jeanny Davenport

Blessing and Cursing

Play Episode Listen Later Aug 23, 2020 82:56

A Miracle but not what you think! With Special Guest Jeanny Davenport. Dirt Track Racing, Power of Prayer. Isa.54"17, Deu.30:19, 1Cor.15:55, Heb 13:5, John 6:26, Ch9, 14:12, 15:20, Math ch9, 26:41, Rom 8:18, Psalms 46:10Support the show (https://www.paypal.me/PJClay)

power prayer psalms math rom heb power of prayer davenport 1cor deu jeanny dirt track racing ch9

213. Home with Kemah Bob and special guests Polly Neate and Jeanny Priebe

The Guilty Feminist

Play Episode Listen Later Aug 3, 2020 72:52

The Guilty FeministPresented by Deborah Frances-White and Kemah Bob Episode 213: Homewith special guests Polly Neate and Jeanny Priebe and music from Grace Petrie and Ben Moss Recorded 28 July 2020 via Zoom. Released 3 August 2020. The Guilty Feminist theme by Mark Hodge and produced by Nick Sheldon. This episode of The Guilty Feminist is brought to you by the satirical novel Fleishman is in Trouble by Taffy Brodesser-Akner, available now in paperback from Waterstones and all good bookshops. Please support us on Patreon so we can continue making this podcasthttps://www.patreon.com/guiltyfeminist More about Deborah Frances-White http://deborahfrances-white.com https://twitter.com/DeborahFW https://www.virago.co.uk/the-guilty-feminist-book More about Kemah Bob https://twitter.com/kemahbob https://quibi.com/shows/hello-america-658 More about Polly and Shelter https://twitter.com/pollyn1 https://twitter.com/Shelter https://www.instagram.com/sheltercharity/?hl=en https://www.instagram.com/pollyatshelter/ shelter.org.uk More about Grace Petrie https://twitter.com/gracepetrie https://gracepetrie.com For more information about this and other episodes… visit guiltyfeminist.com tweet us twitter.com/guiltfempod like our Facebook page facebook.com/guiltyfeminist check out our Instagram instagram.com/theguiltyfeminist or join our mailing list eepurl.com/bRfSPT Come to a live recording! 8 August at the New Normal Festival. Tickets on sale now. 24 March at The Eventim Apollo in London. Tickets on sale now. Thank you to our amazing Patreon supporters… A, A K, A. Michélsen, abbey gersten, Abbi Whitcombe, Abbie Jayawardene, Abi Ashton, Abi Moorcock, Abigail Michael, Adél Schofield, Adele Vorauer, Adie Delaney, Adrian Brown, Adrian Coveney, Adriana Durham, Adriana Helena, Afton Aitkenhead, Agnieszka Kaminska, Aidan Dunne, Ailbhe Leamy, Aimée Morris, Aimee Smith, Aine laverty, Áinín Uí Chaiside, Ainsley Camps, Ainslie Frank, Aisling Durkin, Aisling Morgan, Aislinn Kumar, Aiste Dackauskaite, Alan Yoon, Alanna Mihic, Albert, Alex, Alex French, Alex Hudson, Alex Minnigin, Alex Robertshaw, Alex Vail, Alexander Colle, Alexandra Fernández, Alexandra Grey, Alexandra Gubin, Alexandra Hardy, Alexandra Lewis, alexandra miruna, Alexandra Pinhorn, Alexanna Miles, Ali Fleabite, Alia Pike, Alice Bone, Alice Chinn, Alice Devenney, Alice Howe, Alice MacLachlan, Alice Mellor, Alice Pyper, Alice S, Alicia, Alicia Brooks, Alicia Hamber-Stott, Alisa Duncan, Alison Buchanan, Alison Christian, Alison Clifton, Alison Clince, Alison Sneddon, Alison Stuebe, Alison Wood, Allie Mitchell, Allison Cole, Allison Monat, Allison Walkowski, Alma Castillo, Alobear, Alyson Hayes, Alyssa Nelson, Amanda Allen, Amanda Cooper, Amanda MacKenzie, Amanda Mackey, Amanda Pettersen, Amber Bartlett, Amber Giesbrecht, Amelia Fraser-McKelvie, Amy Boyle, Amy Cunningham, amy dallison, Amy Nelson, Amy Pon, Amy Reilly, Amy Richards, Amy Rosa, Amy Worsfold, Ana Drago, Ana Nash, Anabela Lewis, Anastacia Walden, Anastasia Denisova, Anca Grijac, Andi Hayes, Andrea, Andrea Cowper Roggen, andrea garford-tull, Andrea Huszar, Andrea McNaughton, Andrea Prezzi, Andrea Richards, Andreas Oberreiter, Andrew Bernard, Andrew Hoffman, Andrew Seiler, Andy McLellan, Andy Sheppard, Andy Williams, Anesa Elgahmi, Angela, Angela Curtin, Angela Hillan, Angela Miles, Angela Morton, Angela Pietz, Angela Sheahan, Angela Shepherd, Angela Wynne, angelique welsh, Angharad Baber, Angharad Phippen, Angi Strafford, Anita Alexander, Anja Frey, anlenae, Ann Blake, Ann Danylkiw, Anna, anna beaumont, Anna Benner, Anna Bray Sharpin, Anna Braybrooke, Anna Cook, Anna Coombs, Anna Dagnall, Anna Elizabeth Rawles, Anna Flaxman, Anna Fowler, Anna Herrmann, Anna Jackson, Anna Kent, Anna Kotowska, Anna Little, Anna Logan, Anna Louise Latour, Anna Lunding, Anna Macintyre, ANNA MCLOUGHLIN, Anna Noble, Anna Pritchard, anna reilly, Anna Sophie Felser, Anna Stephens, Annabel, Annalisa Roberts, annalise engledow, Anna-Michelle Nolan, Anne Heins, Anne Jefferies, Anne John, Anne Markland, Anne Marsden, Anne Murray, Annelet, Anne-Marie Adams, Annemarie Miano, Annie Banducci, Annie Davies, Annie Wills, Annika Liljeberg, Annika Neukirch, AnnTo, Anthea Kirk, Antonia Bridal, Antonia Dheere, Antonio Pignone, Antony Carter, Aoife Buggy, Aoife Clifford, Aoife McGee, Aoileann Ní Mhurchú, Aphra, Ariana Musiol, Ashini Bruce, Ashita Sharma, Ashleigh, Ashley Ball, Ashley Pidal, Asset Olleiric, Audrey Pearsall, Azul Zorzoli, Barbara Poppe, Beatrice Gauthe, Beattie Slavin, Bec Cork, Becca Bryer, Becci Louise, Beck, Becky Gale, Becky Louise, Becky Phillips, Belen Zevallos, Belinda, Belinda, Belinda Murphy, Bella Hood, Ben Malone, Benedetta Basile, Bérengère Ariaudo De Castelli, Bessie, Beth Be, Beth Humphries, Beth Mills, Beth West, Beth Wiggan, Bethan, Bethan Axford, Bethan Thomas, Bethany Holt, Bethy Turton, Beverley Adam, Bex House, Blanaid O'Regan, Bogdana Huma, Book Witch, Bradyn Sloan, Breda Smith, Brenda Annerl, Brendan Walsh, Brian Masters, Briana Ewing, Bridget Noonan, Bridgett Harris, Brigid Buckley, Bronte Makepeace, Bronwen Chatman, Brooke Maddestra, Bryce Tucker, Bryony Rose Knight, Bur.ke, C, C Baldock, c3168014, Caitlin Emery, Caitlin Phillips, Caitlin Prendergast, Caitriona de Burca, Cali Calarco, Callie Foord, Callie Poehlein, Callum Baker, Camila, Caoimhe deBurca, Cara-Heleny Stripp, Careen Jackson, Carin Macintyre, Carina McNulty, Carlotta Sommer, Carly Dean, Carmen Makepeace, Carmen Rodriguez, Caroline Caldwell, Caroline Hagen, caroline Harper, Caroline Lallis, Caroline Lehmann, Caroline Littleworth, Caroline Rhodes, Caroline Ross, Carrie Brassley, Carrie Stewart-Wild, Casey James, Casey-Lee Baxter, Cassie Barton, Cassie Edwards, Cat Bagg, Cat Prestipino, Cat Smith, Cat Smith, Cath Breckell, Catherine Bradon, Catherine Flynn, Catherine Hardstaff, Catherine Peek, Cathrin Kolb, Cathryn Bridges, Cathryn Durie, Cathy Hodgson, Cathy Slarks, Catriona Lawlor, Catriona Windsor, Cecelia Gavigan, Cecilie Marie Ammitzbøll Dinh, Celia Sullivan, Cerys, Chanel ONeill, Chani McBain, Chantal Donaldson-Foyer, Chante Inglis, Charis Cassells, Charlea Harrison, Charlee Brown, charlie weasley, Charlie Williams, Charlotte C, Charlotte Cohen, Charlotte Cooper, Charlotte Earl, Charlotte Evans, Charlotte Higgins, Charlotte James, Charlotte Mcfarlan, Charlotte Morgan-Russell, Charlotte OKeefe, Charlotte Tait, Charlotte Williams, Charlotte Young, Chelsea Fewkes, Cherry Lippz, Cheryl Sauve, Cheryl Simmonds, Cheyenne Dunnett, Chihira, Chloe, Chloe Lemmon, Chloe Lim, Chloe Oades, Chloe Waugh, Chris Evans, Christian M. Christensen, Christina, Christina Blenkhorn, Christina Fitzharris, Christine, Christine Brodie, Christine Horstmann, Christopher Dudman, Christy Filipich, Ciara, Ciara Farrelly, Ciara Foley, Clair McClung, Clair Swindells, Claire, Claire Coveney, Claire Crossland Naujoks, Claire Frith, Claire Gorby, Claire Harrison, Claire Housego, Claire Humphreys, Claire Jones, Claire Nurc, Claire Pettigrew, Claire Veldmeijer, Claire Wheeler, Claire Zeidler, Claire Zita Savage, Clara Hesseler, Clara Kirchmeir, Clare, Clare Coatman, Clare Commerford, Clare Dunne, Clare Foster, Clare Keogh, Clare Leavenworth Bakali, Clare MacDonald, Clare Molle, Clare Raychaudhuri, Clare Sheehy Hutton, Clare Storrow, Clare White, Claudia, Claudia, claudia kelly, Colleen Teresa, Connie McGroarty, Conor Byrne, Conor Walsh, Coral Paphitis, Cordula Modest, Corinna Weigelt, Corinne Evans, Corinne Whiteley, Cory Laurence, Courtney Cox, Courtney Weir, Craig Francis, Cristina Da Silva, Cristina Patriche, Cristina Saiz, Dai Morgan, Daina Aspin, Daisy Parsons, Dalia Rassam, Damaris, Damaris Critchlow, Dan Barnes-Davies, Dan Burraway, Dan Peterson, Dan Spence, Daniél Hofmeyr, Daniel Taylor, Daniel Willis, Daniela da Palma, Danielle Anderson, Danielle Jones, Danika Ehlers, Dara Callanan, Daria Baskina, David Cohen, David DeLoveh, David Jackson, David McDonald, Deana Whalley, Debbie Charlett, Debbie Corcoran, debbie mcvitty, Debby Swayne, Debora, Deborah Amott, Deborah Huber, Deborah Hubscher, Deborah Williams, Debra Taylor, Delphine Chhoa-Wilson, Delyth Jones, Denee Hayes, Denise, Denise Foley, Denise Hodgins, derval harte, Des Cho, Devon Harland, diana, Diana Stefanescu, Diep Feeks, Donna Howard, Dori Kay Hjalmarson, Doris Gray, Dorothea Maleczek, Dr Laura Martin, Dunja westhoff, Duplojo, E Caplan, E. M. O'Leary, Eavan Brennan, EC Barwell, Edel Cardiff, Edith Galliers, Edwin Habicher-John, Eiluned Cutter, Eimear Ní Ghuaire, Ekaterina, Eki Teebi, El George, Elaine Fowler, Eleanor Fairweather, Eleanor Monk, Eleonora Bertsa, Eliana Jordan, Elina Reimche, Elinor Goodhead, Elinor Olson, Elisabeth, Elisabeth, Elisabeth Wimmesberger, Eliza Cussen, Eliza Spilnere, Elizabeth, Elizabeth, Elizabeth Carse, Elizabeth Delay, Elizabeth Fitzsimon, Elizabeth J Beavis, Elizabeth Kenyon, Elizabeth Reeves, Elizabeth Snape, Elizabeth Surrey, Elizabeth Warburton, Elizabeth Welch, Ella, Ella Cockerell, Ella Green, Ella Taylor, Ellen, Ellen Blakeney, Ellen Crow, Ellen Egan, Ellen Francis, Ellen O'Brien, Ellen Redmayne-Smith, Ellen Vizuete, Elli Bell, Ellie, Ellie Awford, Ellie Katsourides, Ellie Pate, Ellie Wilson, Elmira Kuznetsova, Eloise, Eloise Fraser-Hurley, Els, Elsa Nightingale, Elspeth Mackay, Elva Cullen, Elya Marie, Em Hawkins, emer, Emilene Seabra, Emilia, Emilie Faure, emily, Emily, Emily, Emily Bamford, Emily Blandford, Emily Brinham Pierce, Emily Carpenter, Emily Carter-Scofield, Emily Cook, Emily Dalton, Emily Edwards, Emily Fuller, Emily Huntridge, Emily Kieffer, Emily McLoughlin, Emily Peterson, Emily Raisin, Emily Shaw, Emily Tarrant, Emily Thornton, Emma, Emma Armitage, Emma Bingham, Emma Bounds, Emma Cockroft, Emma Colvill, Emma Daly, Emma Davies, Emma Gent, Emma Gingell, Emma Harrison, Emma Hundertmark, Emma Martin, Emma McQueen, Emma Miller, Emma Pedley, Emma Porter, Emma Richards, Emma Rigby, Emma Sanmogan, Emma Teodo, Emma Thompson, Emma-Kate Yates, EmmaLee Griffith, Emmie, Eric Bell, Erica Edsell, Erica Silva, Erika Ward, Erin Pugh, Erin Satchell, Erin Taylor, Erin Wilson, Esther, Esther de Boer, Esther de Lange, Esther Ladiges, Eszter Fazekas, Etain O'Shea, Euan Munro, Eunice Rodriguez, Eva Culhane, Eva Pola, Eva-Luise Schwarz, Eve Hadshar, Eve Molloy, Evelyn Adcroft, Evelyn Voaden, EvK, Excella Simmons, faaiza bashir, Fahmina, Fanny Nordberg, Fay Clarke, Fay Pisani, Faye Armstrong, Felicity Diehl, Fenja Schulz, Fern Bradley, Fi Kennedy, Fifi Monahan, fightorflight, Fiona Dennison, Fiona Elliott-Frew, Fiona Kerr, Fiona Purcell, Fiona Walsh, Fiono o, Flora Donald, Flora Stanley, Forrester, Fran Lawley, Frances Atkinson, Frances Carragher, Frances Helm, Frances Neilson, Frances Singer, Frances Staples, Frances Wilde, Francesca Morelli, Frankie Self, Franziska, Franziska Hafner, Franziska S, Freya Bushnell, fuechsin, Gabi van der Linden, Gabriella Aurora Ferrari, Gabriella Garcia, Gail Betts, Gail Hamilton, Gail Mort, Gavin Thompson, Gaylynne Fell, Gayna Eales, Gem Mantle, Gemma ARCHER, Gemma Donovan, Gemma Gould, Gemma Harben, Gemma Hodge, Gemma Howlett, Gemma Le Mesurier, Gemma Maconie, Gemma Stead, Gemma Van, Gemma Woods, Genevieve Ladd, Georgia Blackwell, Georgia Burt, Georgia Dempsey, Georgia Drake, Georgia McNamara, Georgia Pierce, Georgie, georgie whittome, Georgina Parker, Geraldine Morley, Gill Stewart, Gillian Davidson, Gillian O'Halloran, Gina Boon, Gina Collins, Gina Decio, Gina Stamm, Ginger Kathryn, Giorgia Anile, Giulia Evolvi, Godbers Travel, Grace, Grace Damasceno, Grace Harrison, Grace Johnson, Grace Marshall, Grace Waterman, Grace Williams, Graham Watson, Grainne Keogh, Gregg Alans, Gregory Ball, Guro McCrea, Hagit Berkovich, Hana Mackechnie, Hana Medwell, Hanna, Hanna Stansvik, Hannah, Hannah Beresford, Hannah Dietrich, Hannah Eastman, Hannah Frank, Hannah Glaeser, Hannah Hudson, Hannah May Crawford, Hannah McKee, Hannah merrin, Hannah Mullaney, Hannah Müller, Hannah Pugh, Hannah Russell, Hannah Sardar, Hannah Scott, Hannah Sheppard, Hannah Simpson, Hannah Simpson, Hannah Tucker-Bloom, Hannah Underwood, Hannahbear, Harmony Huffman, Harriet, Harriet Burnham, Harriet Pickles, Harriet Sansby, Harriet Stanford, Hayley, Hayley, Hayley Fountain, Hayley King, Hayley Poynton, Hayley Shields, Hazel Bashford, Heather Beamish, Heather Coppell, Heather Linsk, Heather McPherson, Heather Morgan, Heather Morrey, Heena, Heiðdís Halls, Heidi, Helen, Helen, Helen, Helen, Helen Arnold, Helen Cameron, Helen Clements, Helen Curtis, Helen Frewen, Helen Jackson, Helen Jeffrey-Bourne, Helen MacNaughton, Helen Mills, Helen Olawole-Scott, Helen Page, Helen Roberts, Helen Spicer, Helen Westhead, Helena Hewitt, Helena Nimmo, Henry Bushell, Het Phillips, Hillary Birchem, Hillary Green-Lerman, Hollie Grant, Holly, Holly, Holly beckett, Holly Metcalf, Holly Pike, Holly Robinson, Holly Smith, Holly Wells, Holstein Wong, I Fink ., Ian Thompson-Darkes, Ide Wise, Imke Pukall, Imma Chippendale, Imogen Binnian, Imogen Michel, Indi, India Laurencine, Indra Peachey, Ingalill Herstad, Ioanna Trikerioti Chatziioannou, Irene Graham, Irina Peltegova, Isabel, Isabel Palmer, Isabella T, Isabella Zanni, Isabelle Handley-Allen, Isabelle Johnson, Ishita Shukla, Isobel Mawby, Isobel Thomas, Izzy Hampson, J Dunn, Jack Faulkner, Jackie Keegan, Jacque Leigh, Jacqui Liveston, Jacquie Rowe, Jade Warren, James Buchanan, James Clarke, Jami Acworth, Jamie Clapperton, Jane, Jane Becker, Jane Brassington, Jane Bulpin, Jane Whild, Janet, Janet Crossley, Janice Friesen, Janine Scott, Jantira Raftery, Jasmine Medhora, Jasmine Seppänen, Jason Molenda, Jayna Parekh, Jayne Sewell, Jaz Cummins, Jean Innes, Jean L Riling, Jean Ryba, Jeanne Elven, Jeet Landa, Jelena Holodkova, Jemma Shafier, Jen Armson, Jen compton, Jen Rodz, Jenn Butterworth, Jenna Dutton, Jenna Fincken, Jenna Hubbard, Jennifer Betsworth, Jennifer Bousfield, Jennifer Dolan, Jennifer Drummond, Jennifer Green, Jennifer Mance, Jennifer Muscheidt, Jennifer Robinson, Jennifer Wolfendale, Jenny Blake, Jenny Blochberger, Jenny Durina, Jenny George, Jenny Howson, Jenny Richens, Jeremy Money, Jess, Jess, jess, Jess B, Jess Crees, Jess Drake, Jess Elizabeth, Jess McGinn, Jess O'Riordan, Jess Purcell, Jessica, Jessica, Jessica Barnes, Jessica Birch, Jessica Carroll, Jessica Corner, Jessica Crocker, Jessica Duxbury, Jessica Ellis, Jessica Evans, Jessica Falk, Jessica Friedrici, Jessica Gaskin, Jessica Jones, Jessica Lephene Lincoln, Jessica Richards, Jessica Turner, Jessica Worner, Jessie Marvell, Jessie's Whimsical Photography, Jill Cremer, Jillian Reid, jme, Jo Abram-Merchant, Jo Betterton, Jo Homan, Jo Schneider, Jo Wood, Joana Veiga, JoAnn, Joanna Fearnley, Joanna Gregory, Joanna Higlett, Joanna Nelson Rendon, Joanna Thomson, Joanne Blakey, Joanne Elliott, joanne lamb, Joanne Riddell, Jocelyn Chalmers, Jocelyn Stirling, Jodie Eckhardt, Jodie Owen, Jody Palmer, Jody Walshe, Johanna Jaschik, Johanna Lloyd, John Barker, John Beisley, John Gregson, Jo-Jo Ellison, Jonathan Stewart, Joni Di Placido, Jonquil Coy, Jordyn Schemenauer, Josephine Lerasle, Josh Lister, Judit Demjen, Judith Dean, Judith Hudson, Judith Williams, Julia Altenbuchner, Julia Burns, Julia Faber, Júlia Fargas Esteve, Julia Herrling, Julia Jungman, Julia Roebuck, Julia Rutherford, Juliane Johanna, Julie Christensen, Julie Dirksen, Julie Kondo, Julie Richards, Julie Snow, Justin Edwards, K Evans, Kahiwa Sebire, Kai Jones, Kaja R Anker-Rasch, Kalli Fox, Kamilla Stoelen, Kara Chadwick, Kara Halliday, Kara Kohlmann, Karen Alexander, Karen Alldred, Karen Lamb, Karen Lopez, Karen Morecroft, Karen Thacker, Karenina Anderson, Karin Blum, Karli D, Karoliina Lehtinen, Karthika Raghwan, Kasia Sikora-Sikorski, Kat Allen, Kat Bradburn, Kat Fry, Kat Macann, Kat Mace, Kat Q, Kat Rulach, Kata Bitowt, Kate, Kate, Kate Anson, Kate Argent-Tingle, Kate Brown, Kate Burns, Kate Byrne, Kate D’Arcy, Kate Davis, Kate Dold, Kate Fisher, Kate Gallon, Kate Hadley, Kate Harford, Kate Hargreaves, Kate Jackson, Kate Jones, Kate Jones, Kate Kirwan, Kate Laing, Kate Lynch, Kate Ormsby, Kate Osborne, Kate Rolfe, Kate Ross, Kate Scott-Gatty, Kate Simon, Kate Stavert, Kate Thomson-McDermott, Kate Wattus, Kate Weybret, Kate Williams, Katharine Durrant, Katherine, Katherine Anderson, Katherine Ashmead, Katherine Booth Jones, Katherine Coyl, Katherine Ellis, Katherine Reed, Katherine Savage, Katherine Wharton, Katherine Wijnsma, Kathleen Cunningham, Kathleen Elizabeth Smith Airey, Kathleen LT Abruzzino, Kathleen Lucy Dearden, Kathrin, Kathryn Alan, Kathryn Dalziel, Kathryn Jamieson-Sinclair, Kathryn Marr, Kathy Cox, Katie, Katie, Katie Bell, Katie Brandwood, Katie Crookes, Katie Emelianova, Katie Huggins, Katie Kita, Katie Lambert, Katie Longbottom, Katie Ralph, Katie Scott, Katie Shelley, Katie Ship, Katie Sweeney, Katie van Rijn, Katie Vincent, Katie Webster, Katja, Katrien Vine, Katrina Batchelor, Katrina Brown, Katriona Little, Katy Donahue, Katy Espie, Katy Hunt, Kaya, Kaye Coholan, Kayleigh Gilchrist, Kayleigh Sacco, KB Donovan, Kelin, Kelley Gissane, Kelly, Kelly H, Kelly Hayes, Kelly Teruko, Kelly Ye, Kelsey Lubbe, Kelsey Poole, Kerri Lambert-Flower, Kerrie McCabe, Kerry, Kerry Blackshaw, Kerry Roberts, Kerry Smith, Kevin Fidgeon, Ki rhymeswith Pie, Kiersten, Kim Donoghue, Kim Matthews, Kim mcmurdo, Kim Parry, Kim Ryan, Kimberley Smith, Kimberley Turner, Kimberley Walker, Kiri Goss, Kirsten Barrett, Kirsty Goodin, Kirsty Holden, Kirsty Lilleyman, Kirsty Mackay, Kittie-Wai Lee, Kivanya, Konstantina Georgiadou, Krista Klein, Kristin Lewis, Kristin Thormann, Kristin Webster, Kristina, Kristina De St. Maurice, Kristine, Kylie Turton, La Shea, Lacey England, Lachlan Slade, Lara, Lara Nicholas, Laura, Laura, Laura Bottelli, Laura Campbell Chuhan, Laura Denton, Laura Ferguson, Laura Firth, Laura Humphries, Laura Keating, Laura Knight, Laura Kölbel, Laura Lowenthal, Laura Lysenko, Laura M Heilbrun, Laura Munro, Laura O, Laura Parker, Laura Robinson, Laura Ruxandu, Laura Shaffer, Laura Stott, Laura&Matt Courtney-White, Laurel M., Lauren, Lauren Banks, Lauren Blackburn, Lauren Hitchman, Lauren Hobbs, Lauren Peel, Lauren Smith, Lauren Swanson, Layla Sawyer, Lea, Lea BECLU, Lea Wansbrough, Leah Cooksey, Leah Da Silva, Leah Doll, Leah Ireland, Leah Tollefson, Leana Islam, Leandra, Leanne Fitzgerald, Leanne Gordon, Leanne Marques, Ledicia Perez, Lee Carroll, Leeky, Lefre de Burgh, Leigh Collier, leigha, Lena ackered, Lena Lindell, Leona Josifidis, Lera Miles, Lesley Andrews, Leslie Stepanek, Lexi Harding, Lexy Page, Leyla Collins, Lianne Harrison, Libby Price, Liesel Senn, Lilinaz Rouhani, Lily, Lily and Harry French - Hunkered in the bunker, Lily Maryon, Linda Dawn, Linda Ford, Lindsay, Lindsay Capps, Lindsey Bochniak, Lindy McMahon, Lisa, Lisa, Lisa Bird, Lisa Chong, Lisa Crosbie, Lisa cummins, Lisa Curme, LISA DONOGHUE, Lisa Dücker, lisa francine, Lisa Frischemeier, Lisa Gillespie, Lisa Greenwood, Lisa James, Lisa Oudshoorn, Lisa Swift, Lisa Thrower, Lisa van Goff, Lisa Yu, Lisa-Marie, Lisbet, Liv, LivEllen Ensby, Livia Cruz, Liz Bowman, Liz Elliott, Liz Jones, Liz Rosenthal, Liz Seeber, Liz Terry, Lizzie, Lizzie Addison, Lizzie Davies, Lizzie Walsh, L-J Evans, Loes, Lois Kelly, Lorcoln Green, Lorena Fraser, Lori Frecker, Lorna Docherty, Lorna Lanshe, Lotte Hajema, Louis Ross, Louisa Kraitzick, Louisa Lorenz, Louisa Rainbird, Louise, Louise Agley, Louise Arnott, Louise Barlow, Louise Best, Louise Detain, Louise Glavey, Louise Kelly, Louise McIntosh, Louise Mortensen, Louise Noonan, Louise Oakley, Louise Roper, Louise Troest, Louise Woolsey, Lowri Howells, Lucia Delgado, Lucie Beatrice, Lucie McLean, lucky, Lucy, Lucy, Lucy Attrill, Lucy Chandhial, Lucy Cook, Lucy crockford, Lucy Davey, Lucy Davis, Lucy England, Lucy Fisher, Lucy Lee, Lucy Pickering, Lucy Stone, Lucy Straker, Lucy Sweetland, Lucy T, Lucy Vince, Lucy Waring, Lucy Watson, Lucy White, Luka Sturtewagen, Lydia Allain Chapman, Lydia Heilen, Lydia White, Lyn Faltin, Lyndsey Clarke, Lynne Wells, Lynn-Marie Dennehy, M.Ch., M.Maria Lewis, Mac Ince, Maddie Cassidy, Maddie Maddie Noakes, Maddy Bee, Madeline Colin, Madeline Linnell, Maegan Springman, Magdalena Lastdrager, Maha Komber, Mai-anh Peterson, Mair Roberts, Máiréad Dorney, Maisie Hermon, Mali Hill, Manasa, Mandy, Mandy gambino, Mandy Robinson, Manon Dolet, Manuela Twrsnick, Marc Peter Williams, Marco Morbidelli, Marcus James, Maren Lutterbach, Margaret Riach, Margarete, Maria, Maria Agra, Maria de Andres Marquiegui, Maria Frolova, Marian clements, Marian Cole, Mariana Moyano, Marianna Mulligan, Marianne Brown, Marie Andrieux, Marie Langtry, Marie-Rose Delauzun, Marina Goodyear, Mariska van der Horst, Marissa Anne, Marissa Green, Mark Charters, Markus Hueppauf, Marnie Byles, Marnie Rowan, Marta Kask, Marta Kutt, Martha Chiavetta, Martha Routen, Martina Bishop Lasovska, Marvel M, Mary Hutchison, Mary marvel, Mary McAuliffe, Mary Nelson, Mary Neylon, Mary Traynor, Mary Wright, Mathilde Pind, matt venn, Matthew Elfstrand, Maureen Putz, maxvnfan ., May Chu Chu Nagoya, Japan, Maya Green, Maya Khalife, Maya Ono, Meg G, Megan Brindley, Megan Fosha, Megan Hindes, Megan Kathleen, Megan Kirby, Megan Knight, Megan Long, Megan Marcus, Megan Sayers, Megan Yakeley, Meghann, Meila Roy, Mel, Melanie El-Abed, Melinda, Melinda Lau, Melissa Beaumont, Melissa Brown, Melissa Brown, Melissa Freed, Melissa Ill, Melissa Lebert, Melody Lord, MENNA V VAN PRAAG, Merie Candelario, Metika Claxton, Mica Brdar, Michael Edelstein, Michael J. McCarthy, Michaela McCollin, Michal Goren, Michele McKenzie, Michele Taylor, Michelle, Michelle B, Michelle Blake, Michelle Chauhan, Michelle Fox, Michelle Heartfield, Michelle Jamieson, Michelle Lake, Michelle Livock, Michelle Lowry, Michelle Sutcliffe, Michelle Tilley, Milena, Millie Gretton-Watson, Mio Ihashi, Miranda, Miriam Konert, Mirjam Hofer, Miryam Boston, Misato Sato, Mischa Rogers, Miss Grouchiegrrl, Missy Cryssie, Molly Campbell, Molly May Holland, Molly Usborne, Momo Sun, Monia DM, Monica Beletsky, Monica Bhandari, Monica Garcia Koewandhono, Monica Medina, Monika Kolbe, Monika Mair, Monika Rüegg, monmon, Monte, Moon Leith, Moran Aharoni, Morgan Brown, Morgan Perkins, Morgen Stevens-Garmon, Mrs Helen Marshall, Ms Elizabeth Hillary, Ms H Powell, Ms Taylor, N Snajder, Na'ama Oren, Nadia A Kelem, Nadia Hampton, Nadia Pascal, Nadri Boswell, Nakita Kitson, Nana Darby, Naomi, Naomi Addyman, Naomi Elliott, Naomi Willoughby, NAS10, Natalia Boolaky, Natalia Brodecka, Natalia Edwards, Natalia Ibanez, Natalie Arnold, Natalie Barnes, Natalie Brett, Natalie Davila, Natalie Grove, Natalie Lukies, Natalie Murphy, Natalie Namer-Waldenstrom, Natalie Silvey, Natasha Brissenden, Natasha D, Natasha Rohde, Natasha Trenchard-Turner, Neel Kar, neil redmond, Nell Burnham, Nell Glen, Nelly Rwezaura, Nema Hart, Niamh Costello, Niamh NicGhabhann, Niamh Rogan, Nicci Forshaw, Nici Reece, Nick Bain, Nicki Warne, Nicola, Nicola Coyle, Nicola Creaser, Nicola Monk, Nicola Penny, Nicola Vogler, Nicola Wissbrock, Nicole Bradley, Nicole Fletcher, Nicole Kroesche, Nicole Lambert, Nicolle Gate, Niki Cox, Niki Priest, Nikki Comiskey, Nina Ratavaara, Noah Hougland, Noelle Rum, Noora Jyvala, Nora Gotzmann, NR, Odd Magne Jordal, Olga Mishura, Oli Hadfield, Oliver Greenwood, Oliver Platts, Olivia, Olivia, Olivia Anderson, Olivia Brajterman, Olivia Buchan, Olivia Horner, Olivia Paige, Olivia Thomas, Orla Doyle, Orla Shortall, Orna Devine, Ornela Cianciarelli, P Reeder, Paige Robinson, Pallavi Ahluwalia, Pamela Thompson, Patrice Woodland, Patricia Exley, Patricia Terrer, Patricia Þormar, Patti Wachtman, Paula Byrne, Paula Ríos Araya, Paula Watson, Pauline Schubert, Peggy Nobes, Pema Wainwright, Pendragon Stuart, Perdita Edge-Partington, Peta Trussell, Pete Fullergreen, Petia Veleva, Petra Bright, Philip Engleheart, Philip Olbrich, Philippa Collie, Philippa Ford, Philippa Rowlands, Phillipa Guthrey, Phoebe Fox, pillenknick, Pilly Taylor, Polly Brewster, Polly Jackman, Polly Pope, Polly Senior, Poppy Hulse, poppy kraay, Poppy Priscilla, Princess Peach, Princess_in_Toyland, Puja Conway, Queenie Pradhan, Quita Harkess, R Walmsley, Rachael Cowan, Rachael Imam, Rachel, Rachel, Rachel, Rachel, Rachel Abbott, Rachel Barreca, Rachel Blanchard, Rachel Broadbent, Rachel Brooke, Rachel Clarke, Rachel Craven, rachel crookes, Rachel Harris, Rachel Jones, Rachel Jones, Rachel O'Connor, Rachel Peake, Rachel Pearson, Rachel Pickering, Rachel Pomeroy, Rachel Read, Rachel Turner, Rachel Twigg Boyce, Rachel Tyler Jones, Rachel V, Rachel Westworth, Rachel York, Radhika Jagtap, Raman Bains, Rayanne Ordette, RBramley, Rebecca, Rebecca Barnett, Rebecca Bourke, Rebecca Brady, Rebecca Catterall, Rebecca Chan, Rebecca Ellison, Rebecca Ford, Rebecca Fowell, Rebecca Hedditch, Rebecca Heywood, Rebecca Jarvis, Rebecca Joanne, Rebecca Linssen, Rebecca Prentice, Rebecca Schutzengel, Rebecca Sharp, rebecca spence, Rebecca Taylor, Rebecca Wilson, Rebekah Drake, Rebekah Miller, Rebekka Andreasen, Regina Ryan, Reidun Kjome, Renee Berkhout, Reubs Walsh, Rhian Evans, Rhiannon Birchley, Rhoda Perdition, Rhona Foulis, Rita, Rivka Benjamin, RM Clifford, Rob Ellis, Robert, Robert Freudenthal, Robin Smith, Robyn, Robyn, Robyn Parker, Rochelle Zats, Rohan Newton, Roisin Mc atamney, Rolf Ammitsbøll Karlsen, Rona McPherson, Ronnie P, Rory Gibson, Rory Johnson, Rosa Cooper-Davies, Rosa Gierens, Rosalind Griffin, Rosanna Hignett, Rosarii Harte, Rose Chorlton, Rose GAN, Rose Martin, Rosemary Iles, Rosemary Keogh, Rosey Lock, Rosie, Rosie Burnham, Rosie Coniglio, Rosie Jones, Rosie Kerr, Rosie White, Rowan brook-thompson, Roxanne Berg, Roxanne Steel, Roz Morton, Rozalind Holmes, Ruby DayBranch, RubyRose Thompson, Ruchi Gulati, Rufus McDufus, Ruth, Ruth, Ruth & Thomas, Ruth Doherty, Ruth Gibbons, Ruth Hunter, Ruth Kent-Rogers, Ruth McKenna, Ruth pearson, Ruth Watson, Ruth Weir, S, S Sand, Sabine Totemeyer, Sabrina, Sacha Dillon, Sakthi Norton, Salima Budhani, Sally Domingo-Jones, Sally Elliott, sally mcivor, Sally Singleton, Salonee Gadgil, Sam Ashford-Thomas, Sam Bouwer, Sam Cray, Sam Cutforth MSMA, Sam Juthani, Sam Osborn, Sam Vendittelli, Samantha Cook, Samantha hubbard, Samantha Littler, Samantha Mera, Sami smith, Sammia Poveda, Samrina Nanwani, Sandra Franz, Sandra Lix, Sandra Wiebe, Sanne Cottaar, Santi Agra, Sara bar haim, Sara Boom, Sara Harte, Sara Sahlin, Sara Tchoryk, sara tuck, Sarah, Sarah, Sarah, Sarah, Sarah Alam, Sarah Allen, Sarah Bircham, Sarah Booth, Sarah Boyall, Sarah Bracegirdle, Sarah brooks, Sarah Brown, Sarah Clibbens, Sarah Erben, Sarah F, Sarah Favager-Dalton, Sarah Finch, Sarah Fox, Sarah Graydon, Sarah Gregory, Sarah Guthrie, Sarah H, Sarah Hewitt, Sarah Joy Lewis, Sarah Kwok, Sarah Lortscher, Sarah Mcfadden, Sarah Mercer, Sarah Moore, Sarah Morey, sarah murray, Sarah Pearce, Sarah Percival, Sarah Purcell, Sarah Rooney, Sarah S. Alfadl, Sarah Slade, Sarah Steed, Sarah Travers, Sarah Warner, Sarah Waskom, Sarah Webb, Sarah Webb, Sarah-Anne Buckley, Sarisah Chaine, Sarith Dekker, sarya, Sasha Louise, Saskia, Savannah Vasco, Sayli Korgaonkar, Sebastian Palmer, Selin, Serena Lillingston, Shallan Beighton, Shane, Shane Bonfield, Shannon Patterson, Shantel Ehrenberg, Sharon Thomson, Sharonne Blum, Sharyn wise, Shauna Gogerly, Sheila Maclean, Shelley James, Shelley Wragg, Shelly Halfon, Shelly Lachish, Shelly Lowerison, Shireen Munday, Shirley Cheung, Shona Barnes-McC, Shona Thoma, Shonagh Crawford, Sian Duffield, SibirianBlue, Silvana Nunes, Silvia Amaduzzi, Simon Coates, Simon Field, Simon Hardy, Simon James, Simon Klemm, Simone Norris, Simone Sheridan, Sinead Crean, Sinead Cummings, Siobhan Cox, Siobhan Hind, Siobhán Neville, Siobhán O'Riordan, Skye Rae, SM, Sofia Ramsay, Sol Escobar, Sole, Sonya Morrissey, Sophia, Sophia Fox-Dichter, Sophia Harris, Sophie, Sophie Allerton, Sophie Cooper, Sophie Gott, Sophie Hedley, Sophie J Allen, Sophie Kunert, Sophie Smart, Sophie Woollen, Sorcha Versteeg, Sören Davy, Stacey Ingram, Stacey Wood, Stefanie Bialas, Stefanie Oepen, Stefanie Preston, Stella Moss, Steph Brown, Steph Dylan, Steph king, Steph Pippett, Stephanie, Stephanie, Stephanie Eller, Stephanie Feistner, Stephanie jordan, Stephen Andrews, Stephen Olsen-Landis, Stephen Plume, Stin K, Sue Min, Sue Pedder, Susan, Susan Fairfax, Susan Hutchison, Susan Lester, Susie Hamilton, Suzanne Busch, Suzanne Farg, Suzanne Long, Suzanne Weston, Suzi Jobe, Suzy, Svenja Ladwig, Sveta Mardar, Swathi Rangarajan, Syd, T, T Smith, Tami, Tammy Coxen, Tammy Hawks, tamsin cromwell, Tamzen Armer, Tania Cohen, Tania fraser, Tanya Davydova, Tara Hooper, Tasha Kvelde, Tasha Sofla, Tassia Agatowski, Taylor, Teodora Dinescu, Terri Lucas, Tess Connolly, Tess Flottmann, Tess Wallace, Tessa and Kasia, Tessa McKeown, The Friendship Bench, Theodora Oikonomidi, Therese Young, Thomai Papathanasiou, Tiffanni Garner, Tina Williams, Tine Boving Foster, Tine Ludwig, TJ Woody, Tom Proctor, Tom Pughe, Toni Cheatle, Toni Garden, Tony Eaglestone, Tori Hodierne, Tracy Bull, Tracy Manning, Trina Wallace, Trish, Trish McTighe, trottolina, Tugela Barnes, Úna Dowdall, Úna Ryan, Uta Nevermann, Valentina Nicol, valeria giulia, Valerie Mah, Vali Forrister, Vanessa Lloyd, Vanessa Martins, Vera Hounjet, verenka, Verity Craft, Verity Glendenning, Verity Hinde, Vic Keytee, Vicki Wolf, Vicky Church, Vicky Gall, Victoria Ashraff, Victoria Ferdinands, Victoria Lawrance, Victoria Richards, Victoria Robinson, Victoria Vasiliou, Victoria Wade-Matthews, Victoria Waldock, Vikki Baker, Virginia Blackman, Viv Hall, Vivian Bernau, Viviana Pinzon, Vladimir Stejskal, WaltzingKea, Wen Foo, Wendy Badger, Wendy Hari, Wiebke Müller, Will, William Law, William Ruth, Yasmine Kherraji, Your Friend, Yvette, Yvette Gaynor, Zara Keith, Zoe Coughlan, Zoe Dawson-Couper, Zoe Flint, Zoe Mildon, Zoe Sellers, Zoe Wearmouth, Zosia Staniaszek, Zsófia Demjén, Zuza S.

japan zoom tickets released morris trouble beck lange peterson mccarthy shelter special guests aim sm monte sami ciara chris evans pie sole palma hei christensen halls jessica jones neville katja goff kaya nr linden els saskia boer syd forrester horst franziska oren davy michael j emma thompson kathrin indi kasia schofield lisa marie courtney cox waterstones zs your friends bur andy williams sarahs araya burgh princess peach fleishman selin bethan toyland siobh aine aphra david cohen rijn lauren smith kate brown david jackson karlsen christian m james buchanan sharyn sarah brown dinh jenny blake anne murray laura martin kate williams loes sarah moore robin smith rachel jones rachel harris guilty feminist dunja rosie jones amy nelson kate jones deborah frances white taffy brodesser akner jonathan stewart sarah allen melissa brown caitriona kate davis jessica turner daniel taylor james clarke priebe kai jones dan peterson justin edwards david mcdonald laura k cerys lisa d alex french john barker sarah h brendan walsh kate jackson rebecca taylor rebecca wilson erin taylor sarah fox heather morgan jennifer robinson morgan brown lucy davis laura robinson holly smith sarah webb lee carroll claire jones jennifer green dorney rebecca jarvis katherine ellis heena katie scott eric bell danielle jones rachel clarke rob ellis simon james liz jones charlie williams emily cook emily edwards lisbet burca jeanny katie bell maria lewis lucy fisher judith williams helen marshall laura parker casey james michelle b jo wood kemah bob kelin neate holly wells grace williams grace petrie emily peterson emily shaw lucy stone holly robinson sarah f danielle anderson grace marshall adrian brown victoria robinson tina williams erin wilson hofmeyr kelly hayes mary mcauliffe jessica evans william law andrew hoffman julie dirksen demj deborah williams andy sheppard emma davies friendship bench mary wright amanda allen rachel turner charlotte cooper jessica ellis lucy watson karen alexander laura knight charlotte higgins el george helen roberts gail hamilton rachel pearson katie webster anna cook emma miller conor byrne amy cunningham kate fisher donna howard kate ross amanda cooper emily carpenter pamela thompson paula r alex hudson emma martin jessica richards grace johnson julie christensen jessica carroll claire harrison michael edelstein eventim apollo rachel v lisa james rachel abbott carmen rodriguez karen lopez steph brown sarah gregory cat smith fiona kerr alexandra grey anna stephens rachel brooke mark hodge daniel willis linda ford stephen andrews hannah simpson lucy white kate burns rachel blanchard rosie white sarah mercer kristin lewis rachel york rebecca ford monica medina graham watson emma rigby hollie grant jennifer drummond julie richards victoria richards emma harrison rhian evans tom proctor brian masters katherine reed ruth hunter erika ward ruth watson lisa crosbie natalie barnes stacey wood molly campbell amanda mackenzie jenn butterworth olivia thomas kimberley smith john gregson book witch natalie murphy clare foster lois kelly jenny george anastasia denisova emma porter lisa gillespie kate simon megan kirby lucy cook sol escobar hannah frank kate hargreaves nicole lambert hannah hudson olivia anderson rachel read alexandra fern janine scott rebecca chan lisa swift francesca morelli kathy cox helen cameron tara hooper georgia burt wendy badger jackie keegan alison stuebe liz terry t smith tammy coxen cassie edwards elizabeth warburton mark charters kathleen cunningham claire humphreys heather beamish helen mills sarah slade eunice rodriguez mary traynor gina collins gregory ball chloe lim sarah rooney clare keogh zoe coughlan clare white kirsty holden laurel m rachel pickering caroline rhodes virginia blackman rachel craven zoe flint aidan dunne libby price alison clifton ellen o'brien joanne elliott allison cole sebastian palmer bethany holt viv hall kelsey lubbe wendy hari kimberley walker cory laurence alison sneddon sara boom emma pedley anna braybrooke

Interrupted ~ Jeanny Novita Ali

NBC Singapore

Play Episode Listen Later Jul 26, 2020 21:00

Interruptions do not always means an obstacle, they can also become opportunity for God to stretch us. Sometimes God uses these interruptions to change us to be more like Christ. Through this sermon, we will see from the scripture that often interruptions in life are divine appointments that are set up for divine assignments.

god jesus christ interrupted interruptions sometimes god novita' jeanny

Jeanny Arreaza, makeup artist, comparte Halloween en el podcast en vivo de Jeremías Martorell - #72

Jeremias Martorell Podcast

Play Episode Listen Later Jul 23, 2020 36:04

Multimedia makeup artist, Jeanny Arreaza es especialista en maquillaje, bodypainting y diseño.Ha colaborado con importantes canales de televisión del mercado hispano como Telemundo y Venevision; y ha participado en decenas de videos musicales y comerciales. Su pasión por la belleza y el maquillaje la ha impulsado a estudiar y mantenerse al día con las últimas novedades y tendencias. Y su trayectoria familiar la motivó a abrir su propio emprendimiento, que ofrece actualmente más de 10 servicios en el área del maquillaje.Si desean conocer más sobre los temas tratados en este podcast o si quieren comunicarse con Jeremías Martorell, les dejamos sus contactos directos:-Instagram: https://www.instagram.com/jeremiasmar...LinkedIn: https://www.linkedin.com/in/jeremiasm...Twitter: https://twitter.com/jeremartorellFacebook: https://www.facebook.com/Jeremias-Mar...TickTok: ticktok.com/@martorelljeremiasSnapchat: https://www.snapchat.com/add/jeremart...Sitio web: https://jeremiasmartorell.com/Arbol de enlaces: https://jeremiasmartorell.com/links/YouTube: http://www.youtube.com/c/JeremiasMart...

halloween makeup podcasten comparte en vivo el podcast multimedia emprendedores makeup artists telemundo sitio jerem arbol martorell ticktok jeanny

Dark 201 - Beginnings and Endings

Lit After Dark

Play Episode Listen Later Jul 16, 2020 92:09

Tommy, Josh, and Jenn dig into the season 2 opener of the incredible German language Netflix series Dark! In our spoiler-free (up to this episode) discussion, we discuss young Jonas’ struggles in his new situation, examine our evolving feelings towards Hannah as she grapples with harmful thoughts, and break down the introduction of a new investigator for the missing persons cases in Winden. Family Tree S2E1 -https://rb.gy/l14bxa Time Map S2E1 - https://rb.gy/jibev3 Links to items discussed in this episode: Wiki on free will - https://rb.gy/l0muxi || Stanford Encyclopedia of Philosophy on free will - https://rb.gy/8v6kg3 || The Kybalion by The Three Initiates - https://rb.gy/b30l5a || "The Fall of the Damned" by Peter Paul Rubens - https://rb.gy/dk5pkt || Wave Particle Duality - https://rb.gy/pn0b7n || Allegory of the Cave by Plato - https://rb.gy/li7j6z || Blind men and the elephant - https://rb.gy/ql0bqb || Higgs-Boson Video: https://rb.gy/lpwgic || “Jeanny” by Falco - https://rb.gy/jpnvkz || “It’s Happening Again” by Agnes Obel - https://rb.gy/wdqpuq ||

Dark 103 - Past & Present

Lit After Dark

Play Episode Listen Later Jun 14, 2020 67:50

Tommy, Josh, and Jenn explore the third episode of the incredible German language Netflix series Dark! In our spoiler-free discussion, we talk about the previous generation of the denizens of Winden, and note the different ways in which history is already repeating itself. We talk about poor Mikkel's fruitless quest and the dramatic irony of his interactions with his young parents, the trials and tribulations of being a powerful woman in the 80s like Claudia, and explore the beginnings of Hannah's relationship with Ulrich. Our analysis digs into the symbolic significance of Raider Bars (Raider is now Twix!), possible important connections that relate to the number 33, and Tears for Fears' "Shout" as a protest song. Family Tree for Season 1 Episode 3: https://rb.gy/hbezvb Links for Items discussed: A Roomful of Teeth Full Song - https://rb.gy/bvslh9 || (part used in episode) - https://rb.gy/eh95pl || "Jeanny" by Falco - https://rb.gy/jpnvkz || "Rock me Amadeus" by Falco - https://rb.gy/l4ufrv || "Dr. Zaius" by The Simpsons - https://rb.gy/s1twew || Nino D'Angelo - https://rb.gy/xmvdal || How to solve a rubik's cube - https://rb.gy/dmw6gn || The Plagues of Egypt (Tommy references #5, death of livestock) - https://rb.gy/3rx5vw || "Pleasure to Kill" by Kreator - https://rb.gy/4oebvp || "Familiar" by Agnes Obel - https://rb.gy/qjowou Wikipedia page for the number 33 - https://rb.gy/r6lkgr || "Shout" by Tears for Fears - https://rb.gy/onhg1j ||

fear netflix rock german dark tears pleasure wikipedia simpsons past present plagues family tree ulrich amadeus falco mikkel twix kreator winden zaius roomful agnes obel jeanny

RUN YOUR OWN RACE with Jeanny Rodríguez

FUSE LIFE

Play Episode Listen Later Feb 20, 2020 65:08

Jeanny Rodríguez had an alcoholic father, worship leader, she grew up in church, physically abused as a child, Rheumatoid arthritis since 11yrs, she was married at 20yrs old, battling sickness, couldn't have a baby for 5 years... Has a miracle son, then has a daughter, but her daughter dies. The arthritis requires 50 hrs+ of surgery all over my body. She runs a successful business, has survived cancer - TWICE! Was divorced after 27 years of marriage which included a lot of infidelities... Gets into new age, gets re-married, Abusive.. A month later her identical twin sister get diagnosed with lung cancer 2011 (last drop) On her knees... all in for Jesus!! Arrival!! 2015 Baptized again, miracle, divorced again. If you know people going through tough stuff.. they need to be on here.. All this led to her starting an awesome initiative that we will talk about... LEARN HOW TO RENEW YOUR MIND IN THIS FREE TRAINING THAT WE WANT TO GIFT YOU: fusebornformore.com/gift

god jesus christ church healing religion christianity overcoming cancer miracles arrival new age rodr guez baptized abusive powerful women rheumatoid run your own race jeanny

Am Gespréich: Jeanny Kratochwil, 13/02/2020 19:45

Play Episode Listen Later Feb 13, 2020

Et ass net dee Beruff, deen engem direkt an de Kapp kënnt, wann een un Theater denkt, mä et ass deen, deen engem direkt an d’A spréngt, wann een am Publikum sëtzt: Zeenograf oder Bühnenbildner, deen deen derfir suergt, datt e Stéck säi Kader huet. Dee raimlechen oder deen zäitlechen an deem sech alles ofspillt. D’Jeanny Kratochwil schafft schon zënter laange Joren als fräi Zeenografin op lëtzebuergeschen an auslännesche Bünen, den Ament kann ee vun hir d’Bünebild beim Pir-Kremer-Owend zu Miersch gesinn a Kostümer bei der Oper "Le Nozze di Figaro" zu Tréier. Wéi passionant dee Beruff ass a wéi se dozou koum, huet se de Mëtteg am Gespréich verroden.

news radio theater publikum luxembourg kost rtl kader figaro kapp ament joren jeanny beruff

Am Gespréich: Jeanny Kratochwil , 13/02/2020 19:45

Play Episode Listen Later Feb 13, 2020

news radio theater publikum kost rtl kader figaro kapp ament joren jeanny beruff

Am Gespréich: Jeanny Kratochwil , 13/02/2020 12:10

Play Episode Listen Later Feb 13, 2020

Et ass net dee Beruff, deen engem direkt an de Kapp kënnt, wann een un Theater denkt, mä et ass deen, deen engem direkt an d’A spréngt, wann een am Publikum sëtzt: Zeenograf oder Bühnenbildner, deen deen derfir suergt, datt e Stéck säi Kader huet. Dee raimlechen oder deen zäitlechen an deem sech alles ofspillt. D’Jeanny Kratochwil schafft schon zënter Joren als fräi Zeenografin op lëtzebuergeschen an auslännesche Bünen, den Ament kann ee vun hir d’Bünebild beim Pir-Kremer-Owend zu Miersch gesinn. De Mëtteg ass d'Jeanny Kratochwil d'Invitée am Gespréich.

news radio theater dem publikum rtl kader kapp ament joren jeanny beruff

Jeanny Kratochwil: Zeenograph zu Lëtzebuerg, 13/02/2020 08:08

Play Episode Listen Later Feb 13, 2020

Den Ament kann ee vun hir d’Bünebild beim Pir-Kremer-Owend zu Miersch gesinn.

jeanny

Am Gespréich: Jeanny Kratochwil, 13/02/2020 12:10

Women's Wealth: The Middle Way

Play Episode Listen Later Feb 13, 2020

Et ass net dee Beruff, deen engem direkt an de Kapp kënnt, wann een un Theater denkt, mä et ass deen, deen engem direkt an d’A spréngt, wann een am Publikum sëtzt: Zeenograf oder Bühnenbildner, deen deen derfir suergt, datt e Stéck säi Kader huet. Dee raimlechen oder deen zäitlechen an deem sech alles ofspillt. D’Jeanny Kratochwil schafft schon zënter Joren als fräi Zeenografin op lëtzebuergeschen an auslännesche Bünen, den Ament kann ee vun hir d’Bünebild beim Pir-Kremer-Owend zu Miersch gesinn. De Mëtteg ass d'Jeanny Kratochwil d'Invitée am Gespréich.

news radio theater dem publikum luxembourg rtl kader kapp ament joren jeanny beruff

The Value of Recycling with Miranda Wang and Jeanny Yao

Play Episode Listen Later Jan 22, 2020 14:07

The Value of Recycling with Miranda Wang and Jeanny Yao Today, less than 10% of packaging plastics are recycled. The rest is sent to landfills or becomes pollution. Our special guests today are long-term friends who are working together to change that statistic. They are entrepreneurs, environmental advocates and inventors, Miranda Wang and Jeannie Yao, are co-founders of BioCellection, a company that turns unrecyclable plastic waste into valuable chemicals. Their work with BioCellection has earned them many accolades, including Rolex Awards for Enterprise Laureate, and the Forbes 30 under 30. Join us every other week on Women's Wealth: The Middle Way®, a radio show aimed at helping women navigate questions about work, money, and family. You can find us on your favorite podcast app, including , , , . See you in two weeks! Helpful Links: Women’s Wealth: The Middle Way® Glen Eagle BioCellection 2019 Rolex Awards Laureate Documentary: Miranda Wang Forbes: BioCellection cofounders named Forbes 30 Under 30 for Social Entrepreneurship Interview Transcript: Susan Michel: Welcome back to Women’s Wealth: The Middle Way®, the show that answers your questions about work, money, and family. My name is Susan McGlory Michel and I am the CEO and founder of Glen Eagle, a wealth management firm in New Jersey. Today, less than 10% of packaging plastics are recycled. The rest is sent to landfills or becomes pollution. Our special guests today are long term friends who are working together to change that statistic. They are entrepreneurs, environmental advocates and inventors, Miranda Wang and Jeanny Yao, are co-founders of BioCellection, a company that turns unrecyclable plastic waste into valuable chemicals. Their work with BioCellection has earned them many accolades, including Rolex Awards for Enterprise Laureate, and the Forbes 30 under 30. Welcome to the show, Miranda and Jeanny. Miranda Wang: Hi. Thanks for having us. Susan Michel: Miranda, I'll begin with you because you both have such an impressive career and it's very unique, that you're both close friends, which I think is probably a great goal to have when you're starting something and have similar goals and aspirations. Miranda, can you start by telling us a little more about your inspiration as co-founder of BioCellection? And what is your primary goal? What was the idea that launched this as friends and then as a career? Miranda Wang: Yeah, we founded BioCellection when we were still students in college. And Jeanny and I had met each other when we were still in high school. So we go way back for more than 10 years of working together and being friends with each other. And we first came across a plastic pollution problem and realized that less than 9% of plastics produced annually are actually getting recycled. That’s a really shocking statistic for lots of people. And so, so realizing this, when we were 15 years old, really shaped the way that we decided to pursue our education in college. And then in 2015, when we decided to talk about this problem again, we realized that this was really something we wanted to get back into and do something about. And we really believed in using mission-driven for profit-businesses to create market-driven solutions. What we identified is that there was a gap. There's a gap today in the world of recycling and that the reason so little plastic is getting recycled, is that we actually lack economical recycling technologies in the world. For most of the packaging that we produce, that packaging usually gets highly contaminated with food or dirt or grease by the time it gets to a recycling plant. And it's actually cheaper today to landfill those plastics than it is to recycle it. We came together and decided there has to be a technology solution that is embedded in a business that allows us to take in plastics that are not recyclable today and use these plastics as a resource so that we can actually build...

ceo women new jersey forbes recycling wang social entrepreneurship jeanny

#05 WHVSeries Part 1 : Introduction to the Work and Holiday Visa

Menuju Dewasa

Play Episode Listen Later Jan 21, 2020 23:08

And we are back with another episode about the things that change our lives. Dan di episode kali ini gw (@hathalicious) dan Jeanny (@jeannyfs) will be talking about Work and Holiday Visa Australia subclass 462, yang kita apply 3 tahun lalu. Kita akan bahas pengenalan tentang visa ini requirements, and step-by-step cara apply visa ini. Related links : Visa Application Checklist https://indonesia.embassy.gov.au/jakt/Checklist_WHol.html Overview https://immi.homeaffairs.gov.au/visas/getting-a-visa/visa-listing/work-holiday-462 Ditjen Imigrasi @ditjen_imigrasi Voice Message https://anchor.fm/suarahatha/message Music from https://filmmusic.io "4604 wallpaper" by Kevin MacLeod

music work holiday visa kevin macleod kita jeanny

Dr. Jeanny Aragon-Ching Highlights Key Research in Genitourinary Cancers